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MDM2, murine double minute 2, is a RING type-E3 ligase protein and also an oncogene. 
MDM2 plays a critical role in determining the steady levels and activity of p53 in cells using 
two mechanisms. The N-terminal domain of MDM2 binds to the transactivation domain of 
p53 and inhibits its transcriptional activity. The RING domain of MDM2 plays a role in the 
ubiquitination (and degradation) of p53. Several proteins are responsible for the 
ubiquitination mechanism including the ubiquitin-activating enzyme (E1), ubiquitin-
conjugating enzyme (E2) and ubiquitin ligase (E3). Since the E2-E3 interaction is essential 
for ubiquitination, the protein-protein recognition site is a potential drug target.  
 
Two different MDM2 RING constructs were expressed and purified: MDM2RING (residues 
386-491) and MDM2RING△C (residues 386-478). Both constructs were characterised 
using dynamic light scattering, size exclusion chromatography, mass spectrometry, NMR 
and electron microscopy. E3 ligase activity in vitro was also studied. Taken together these 
results showed that the MDM2RING construct formed a concentration-dependent oligomeric 
structure. In contrast, the MDM2RING△C construct formed a dimer at all concentrations. 
Both MDM2RING and MDM2RING △ C retain E3 ligase activity. However, the 
MDM2RING△C construct is less active. Full length E2 enzyme UbcH5a was also purified. 
Various biophysical techniques were used to study its interaction with MDM2 as well as 
with potential small molecule inhibitors as in principle, small molecules which disrupt the 
interaction between MDM2 and UbcH5a, could prevent/promote ubiquitination of p53.  
 
The dimerisation of MDM2 is important for its E3 activity and the C8-binding site 
potentially provides a second druggable site. In this work, peptide 9, which has the same 
sequence as the C-terminus of MDMX (an MDM2 homologue) was found to inhibit MDM2 
E3 activity. Various biological techniques including NMR, fluorescence anisotropy, and 
electrospray mass spectrometry were used to investigate the interaction between two 
inhibitory peptides and MDM2. A major part of project involved virtual screening (VS) to 
search for small molecules which can affect MDM2-dependent ubiquitination. Three 
potential targets were considered: (1) the C8-binding site of MDM2; (2) the UbcH5a-binding 
site of MDM2; and (3) the MDM2-binding site of UbcH5a. Several small molecules were 
identified using our virtual screening database-mining and docking programs that were 
shown to affect MDM2-dependent ubiquitination of p53.  
 ii 
In terms of understanding the complex biochemical mechanism of MDM2 this work 
provides two interesting and functionally relevant observations: (i) the MDM2 RING△C 
construct is a dimer as this would not be expected form the existing studies, and has less E3 
ligase activity than MDM2RING; (ii) small molecules that bind MDM2 on the E2 binding 
site enhanced E3 ligase activity. One model to explain these observations is that binding of 
small molecule activators family to the RING induces a change in the conformation of the C-
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The Ubiquitin Protease System (UPS) is vital in the determination of the fates of a wealth of 
proteins in cells. There are three proteins involved: E1 (ubiquitin activating enzyme), E2 
(ubiquitin conjugating enzyme) and E3 (ubiquitin protein ligase). A number of tumours have 
been found to be related to the UPS. One example is the observation that tumours which 
have wild type p53 are correlated with an upregulation of an E3 ligase protein, MDM2 
(murine double minute 2). In tumour therapies, several drugs are designed to inhibit the 
interaction of MDM2 to p53, such as Nutlin (Vassilev et al., 2004), and RITA (Issaeva et al., 
2004).  
 
This chapter is divided into two parts: (1) The biology of the UPS, and (2) Virtual screening 
(VS) strategy to design new ligands. In the first part, an overview of the UPS is provided 
including roles of many components of the UPS such as ubiquitin, E1s, E2s, and E3s. 
Ubiquitination plays an important role in regulation of the level of tumour suppressor p53 
through MDM2-mediated transcriptional inhibition and MDM2-mediated p53 proteolysis. 
Therefore, MDM2 is an appealing anticancer target to rescue p53-mediated apoptosis. To 
achieve the aim of developing MDM2 inhibitors, VS strategies were used to screen potential 
leads. In part II, information about protein-protein interactions and the challenges of 
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Part I MDM2 and the Ubiquitin Proteasome System 
1.1 Ubiquitin Proteasome System (UPS) 
The Ubiquitin Proteasome System (UPS) plays a number of key roles in controlling cell 
growth and proliferation, including progression of the cell cycle, tumour suppression, and 
induction of the inflammatory response (Glickman & Ciechanover, 2002; Hershko & 
Ciechanover, 1998; Koepp et al., 1999; Pickart, 2001b; Rock & Goldberg, 1999; Weissman, 
2001). UPS is a well-defined multistep pathway that processes the ubiquitin modification of 
proteins. The enzymes involved include ubiquitin (Ub), ubiquitin activating enzyme (E1), 
ubiquitin conjugating enzyme (E2), ubiquitin protein ligase (E3) and the 26S proteasome 
(Figure 1-1A) (Hershko et al., 1983; Peter et al., 1998; Pickart & Eddins, 2004). In the first 
step, E1 adenylates the C-terminus of Ub in an ATP-dependent process, forming the E1-
AMP~Ub intermediate. Subsequently, this activated ubiquitin is transferred to the catalytic 
domain of E1, forming the E1~Ub thioester intermediate. A second ubiquitin binds to the 
adenylation domain of E1, becoming the E1-AMP~Ub intermediate. This doubly loaded E1 
is now recognised by E2. The ubiquitin bound to the catalytic site of E1 is then transferred to 
the active site cysteine residue of E2 through transesterification and forms an E2~Ub 
thioester intermediate. In the third step, E3 binds with its substrate protein and interacts with 
ubiquitin-charged E2. Subsequently, the terminal glycine carboxylate group of ubiquitin is 
linked in an amide isopeptide linkage to an ε–amino group of a lysine residue on the 
substrate protein, or to a lysine residue of a ubiquitin already attached to the substrate protein 
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Ubiquitinated proteins have different cellular fates that depend on the topology or the 
number of the substrate-conjugated ubiquitins and the subcellular localisation of the 
substrate (Figure 1-1B) (Pickart, 2000). For instance, substrates marked with a Lys48-linked 
(K48-linked) polyubiquitin chain are targeted for proteolysis by the multisubunit ATP-
dependent 26S proteasome (Hershko & Ciechanover, 1998; Hochstrasser, 1996; Thrower et 
al., 2000). Substrates conjugated with a Lys63-linked (K63-linked) polyubiquitin chain are 
directed for non-proteolytic signalling, such as ribosomal function, DNA repair and 
inflammatory response (Deng et al., 2000; Hoege et al., 2002; Hofmann & Pickart, 1999; 
Spence et al., 1995; Spence et al., 2000). Some proteins bound with one or a few ubiquitins 
are directed for endocytosis (Kim et al., 2007; Hicke, 1999). It has been noted that 
disregulation in ubiquitination results in pathological syndromes, including tumour 
development, viral infection, inflammation and neurogenesis deficiency (Lam et al., 2000; 
Joazeiro et al., 1999; Matsuura et al., 1997; Petroski, 2008; Scheffner et al., 1990; Staub et 
al., 1997).  
 
Reviews show that there are few E1s, limited numbers of E2s and large numbers of E3s 
involved in ubiquitination pathways (Hershko & Ciechanover, 1998; Hochstrasser, 1996). 
Although the numbers of E2s are limited, each E2 interacts with several E3s. Similarly, each 
E3 interacts with one or more E2s (van Wijk & Timmers, 2010). Moreover, E3s play 
important roles in the determination of the substrate specificity. Those complicated 
combinations of E2-E3 complexes provide delicate cellular regulation to enable cells to deal 
with different conditions. Moreover, E3s play important roles in the determination of the 
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1.1.1 Ub: Ubiquitin 
As the name suggests ubiquitin or ubiquitin-like proteins (UBLs), such as Sumo and Nedd8, 
are ubiquitous in cells and play critical roles in the determination of the fate of cellular 
proteins (Herrmann et al., 2007; Kerscher et al., 2006). Ubiquitin (Ub) is a 76-amino-acid 
residue protein. Sumo and Nedd8 are 103- and 76-amino acid proteins, respectively. 
Ubiquitin has 57% identity to Nedd8 and 18% identity to Sumo (Figure 1-2A). Ubiquitin and 
UBLs share a common structural fold, called the β-grasp (Figure 1-2B) and have similar 
biochemical mechanisms to modify proteins. For instance, the last C-terminal residue of Ub 
and Nedd8 and the last third residue of Sumo is a glycine which is involved in the interaction 
of thioester bond formation between the carboxyl-terminal glycine (G76 in Ub and Nedd8, 
G99 in Sumo) attached to the active cysteine residue of the E1 or E2 upon the thioesteration 
(Lois & Lima, 2005; Wenzel et al., 2010). An isopeptide bond forms between the amino acid 
group of the lysine residue of target protein (or ubiquitin). The canonical ubiquitin-chain is 
the Lys48 linked-polyubiquitin chain that is recognised and degraded by the 26S proteasome 
(Hershko & Ciechanover, 1998). Furthermore, several topologies of ubiquitin chains have 
been characterised (Pickart, 2001a) and shown to play a number of roles in different cellular 
functions (Table 1-1). For example, the Lys48-linked or the Lys11-linked and Lys29-linked 
polyubiquitin chain attached target proteins are degraded by the 26S proteasome. In the 
nonproteolytic pathway, Lys6-linked and Lys63-linked mono-ubiquitin or polyubiquitin 
chains play distinct roles in regulatory modifications. 
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Figure 1-2: Sequences and structures of Ubiquitin and Ubiquitin-like proteins (Ubls). (A) 
Sequence alignments of Ubiquitin, Sumo, and Nedd8. Identical residues are shown in white 
letters and conservative substitutions are shown in red. Secondary structure elements within these 
proteins are denoted above the sequences (based on the structure of ubiquitin, PDB code: 1UBQ). 
Red cylinders represent α-helices and arrows represent β-sheets. Numbering refers to the 
ubiquitin sequence. (B) Structures are highly conserved, and are principally comprised of a β-
grasp fold (yellow). The structure of Ubiquitin, Sumo and Nedd8 are rendered of a using Pymol. 
α-helixes, β-sheets, and loops are coloured in red, yellow and green, respectively. Ubiquitin (left 
panel, PDB code: 1UBQ) (Vijay-Kumar et al., 1987), Sumo (middle panel, PDB code: 1A5R) 
(Bayer et al., 1998) and Nedd 8 (right panel, PDB code: 1NDD) (Whitby et al., 1998). 
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1.1.2 E1: Ubiquitin activating enzyme 
In most organisms, ubiquitin activating enzyme (E1) is an essential enzyme to activate 
ubiquitin or UBLs for the entire downstream ubiquitination/ sumolyation/ neddylation 
pathway (Haas & Rose, 1982; McGrath et al., 1991). Although there are several types of E1s 
(monomers, homodimers and heterodimers) (Table 1-2), the conserved E1 functions are to 
activate ubiquitin (UBLs) in an ATP-dependent mechanism and transfer activated ubiquitin 
to E2 proteins (Haas & Rose, 1982; Hershko et al., 1983). In general, the structures of the 
E1s can be dissected into several domains (Schulman & Harper, 2009): the adenylation 
domain, inactive adenylation domain, the ubiquitin fold, and the catalytic Cys domain 
(Figure 1-3). Fully loaded E1 contains two activated ubiquitins: an adenylate-linked 
ubiquitin (UBL(A)) and a thioester-linked ubiquitin (UBL(T)). Initially the adenylation 
domain of E1 is responsible for the adenylation of ubiquitin to generate an 
ubiquitin~adenylate intermediate (UBL(A)). The adenylate-linked ubiquitin (UBL(A)) acts 
as a donor to facilitate the thioester formation of the ubiquitin to a conserved active site 
cysteine of E1 (Haas & Rose, 1982; Schulman & Harper, 2009). Sequentially, a UBL(A) is 
transferred to the activated Cys in the catalytic domain to form a thioester bond, forming the 
activated ubiquitin~E1 complex (UBL(T) ~ E1). Once an E2 binds to the ubiquitin fold 
domain of a doubly loaded E1, it stimulates the transfer of UBL(T) to E2 and forms a E2~Ub 
complex via a thioester bond (Walden et al., 2003). 
 
Table 1-2: Ubiquitin activating enzyme (E1) family. There are several species in different 
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(PDB: 3CMM)  
 
Figure 1-3: The ubiquitin activating enzyme (E1). (A) General structural compositions of the 
E1s and the roles of the E1s: adenylation of ubiquitin, thioesterification, and binding to the E2. 
(B) One example of the structure of the E1 proteins: yeast, UBA1 (PDB code: 3CMM)(Lee & 
Schindelin, 2008). The structure on the left is presented in surface representation, that on the 
right is shown in cartoon representation. Distinct domains of UBA1 are coloured as follow: 
catalytic domain in magenta, adenylation domain in cyan and ubiquitin fold domain in green. The 
active cysteine residue on UBA1 is depicted as a yellow sphere.  
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1.1.3 E2: Ubiquitin conjugating enzyme 
The E2s act as carriers of Ub from E1 to the different E3-substrate complexes. An E2 protein 
interacts with an E1 and forms a thioester conjugate with the C-terminus of Ub (the E2~Ub 
intermediate). The charged E2 (E2~Ub) binds to an E3 and transfers the attached Ub to the 
E3 or the substrate. Recent studies reveal that the E2s also determine the types of mono-
ubiquitin chain and polyubiquitin chain of the lysine linkage (Christensen et al., 2007; 
Roderigo-Brenni & Morgan, 2007; Windheim et al., 2008). E2s are central to the UPS 
system, playing numerous roles including interaction with E1, ubiquitin/ UBLs, and different 
E3s, the diverse functions of E2s being reflected in their relative abundance. This relative 
abundance reveals why determining the mechanisms of E2-mediated interactions have been 
the focus of so much research activity with more than 35 E2 proteins identified in the human 
genome (van Wijk & Timmers, 2010). 
 
 Topology of E2 Ubc domain 
There are over 90 structures of E2s available to date in the PDB (Wenzel et al., 2011). All 
E2s have an evolutionarily conserved catalytic ubiquitin-conservation domain, Ubc domain, 
consisting of approximate 150 residues (Cook et al., 1993; Huang et al., 1999; Jiang & 
Basavappa, 1999; Miura et al., 1999; Worthylake et al., 1998; Zheng et al., 2000). The Ubc 
domain has a compact structure formed by α2, a short 310 helix and four antiparallel β–sheets, 
surrounded by α1 on one side and α3 and α4 on the other side (Figure1-4). The catalytically 
active cysteine, a highly conserved residue in all E2s for the catalysis of ubiquitin, is located 
in a shallow groove surrounded by residues in the long loop (L5) that connects β4 and the 
short 310 helix. Those residues surrounding the catalytically active cysteine of E2 are also 
highly conserved. For example, there is an HPN motif which usually is located about ten 
residues preceding the catalytically active cysteine residue (Wenzel et al., 2011). The HPN 





























Figure 1-4: Ubiquitin-conjugating enzyme (E2). An E2 Ubc domain consists of four α-helices, 
four antiparallel β–sheets, and a short 310 helix. An active cysteine residue (yellow sticks) is 
responsible for the interaction with Gly76 of Ub. The HPN motif is also depicted in magenta 
sticks. This E2 structure is UbcH5b protein (PDB code: 2C4O). 
 
 Four classes of E2s 
Although all E2s share a highly conserved topology of the Ubc domain, the sizes and 
specific biological functions of E2s are distinct (van Wijk & Timmers, 2010; Winn et al., 
2004). Some E2s have N- or C- terminal extensions to the Ubc domain, which play 
important roles in their specific interactions with partner proteins. There are four E2 families 
classified on the basis of the presence of the additional fragments. Class I E2s have only a 
Ubc domain, such as the UbcH5 family, UbcH7, UbcH9 and Ubc13 (Giraud et al., 1998; 
Houben et al., 2004; van Demark et al., 2001; Zheng et al., 2000); Class II E2s contain a Ubc 
domain plus a N-terminal extension, such as UbcH10 (Lin et al., 2002; Summers et al., 
2008). Class III E2s comprise an Ubc domain plus a C-terminal extension, such as cell 
division cycle 34 (CDC34) (Ceccarelli et al., 2011); and Class IV E2s have a Ubc domain 
plus both an N- and C-terminal extensions, such as E2–230K and BIRC6. 










(1FBV)                                   (1I7K)                 (3RZ3)                                (3CEG)  
 
Figure 1-5: Structures of four classes of E2s. Each representative E2 protein is as following: 
Class I-UbcH7 (PDB code: 1FBV); Class II- UbcH10 (PDB code: 1I7K); Class III- CDC34 
(PDB code: 3RZ3) and Class IV- BIRC6 (PDB code: 3CEG). All E2 proteins have a conserved 
Ubc domain (detail in the text). 
 
 
 Interaction surfaces of the E2s 
Functions and mechanism of E2s have been described (Wenzel et al., 2011) that suggest the 
entire surface of E2 is involved in protein-protein interactions (Figure 1-6). The canonical 
E2-mediated interactions include the following (Figure 1-6): the H1/L4/L6 motif of the E2 
Ubc domain is responsible for the E3 interaction (in region A) (Zhang et al., 2005), and the 
H1/L1/L2 motif is the E1-binding site (in region B) (Huang et al., 2005). The E1- and E3-
binding sites on the E2 surface overlap. The active site cysteine residue is responsible for the 
formation of a thioester bond with ubiquitin (in region C) (Sakata et al., 2010). Recently, 
many non-canonical E2-interactions have been observed, for example, the backside of an E2 
is found to interact with ubiquitin or sumo molecules (in region D) (Brzovic et al., 2006). 
The C-lobe of a sumo E2 (Ubc9) is found to bind the substrate RanGAP1 (in region E) 








































Figure 1-6: E2s and the E2-partners. Each motif on the E2 surface responsible for the 
interaction with a distinct binding partner is shown. Canonical E2-mediated interactions are 
presented as below: the E2-E3 complex is shown in the Ubc13-CHIP U-box complex (region A); 
the E1-E2 complex is seen in the Ubc12-E1 complex (region B); the E2-Ub covalent conjugate is 
seen in the UbcH5b-Ub complex (region C). Noncanonical E2-mediated interactions are seen in 
the noncovalent UbcH5c-Ub complex (region D) and the Ubc9-RanGAP1 (region E) complex. 
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1.1.4 E3: Ubiquitin protein ligase 
In the ubiquitination pathway, E3s coordinate the interactions of multiple proteins. The 
function of E3 ligase in the ubiquitination system involves in the binding of E2 protein to 
transfer the ubiquitin to its substrate. E3s can also ubiquitinate themselves 
(autoubiquitination) by adding ubiquitin to their own lysine residues. E3s are involved in the 
binding of charged E2 (Ub-E2), the binding of the substrate, the transfer of Ub to the 
substrate, and the covalent ligation of one or more Ub(s) to the lysine residue of the substrate 
(Deshaies, 1999; Deshaies & Joazeiro, 2009; Kamadurai et al., 2009).  
 
Productive ubiquitination depends on the efficient interactions of the E3 and its cognate E2 
in addition to those with substrate. Many studies have found that E2 or E3 are modified and 
regulated by additional factors before ubiquitination is induced (Deng et al., 2000; Hofmann 
& Pickart 1999; Lahav-Baratz et al., 1995; Rajapurohitam et al., 1999). For example, the 
binding of a small molecule can allosterically regulate E3 function (Worrall et al., 2009). 
One of the most common mechanisms is phosphorylation (Feldman et al., 1997; Skowyra et 
al., 1997; Yaron et al., 1998). The interaction of the E3-substrate regulated via 
phosphorylation is coupled with the activity of cyclin-dependent kinase (CDK), which 
mediates the cell cycle (Deshaies, 1999; Koepp et al., 1999; Page & Hieter, 1999).  
 
A large number of E3s have been found and have been grouped into distinct families 
dependent upon the characteristics of their domains, including HECT domain, PHD domain, 
U-box/RING domain and multisubunit SCF domain (Deshaies, 1999; Huibregtse et al., 1995; 
Loricke et al., 1999). Sequences or structures of those distinct E3s families are unrelated 
(Borden, 2000; Huang et al., 1999; Zheng et al., 2000). The mechanisms of E3-mediated 
ubiquitination are distinct (Figure 1-7): the HECT domain E3s mediate covalent catalysis for 
ubiquitin transfer (Huibregtse et al., 1995) and the RING/U-Box and SCF E3 acts as 











































Figure 1-7: Two types of E3-mediated ubiquitination mechanisms. (A) HECT domain E3-
mediated and (B) RING/U box domain or PHD domain E3s-mediated ubiquitination. 
 
1.1.4.1 HECT domain E3 
One family of the E3s is the HECT domain family (homologous to E6-AP carboxyl 
terminus), that consists of ~ 350 residues. There are many HECT domain E3s, such as E6-
AP, Ras5, Itch and Toml (Beaudenon et al., 1999; Huibregtse et al., 1997; Qui et al., 2000; 
Saleh et al., 1998; Scheffner et al., 1993). The HECT domain E3s often consist of several 
sub domains (Figure 1-8): the unique N-terminal domain (N-lobe) is for the binding of 
specific substrate(s), while the C-terminus (C-lobe) is for mediation of covalent catalysis 
with the Ub-E2 conjugate and processing the ubiquitination (Huibregtse et al., 1993; Kumar 
et al., 1999). One of the significant features of the HECT domain is that a strictly conserved 
cysteine residue is located ~35 residues upstream of the C-terminus (C-lobe) (Huibregtse et 
al., 1995; Kamadurai et al., 2009). The mechanism of HECT E3s-mediated ubiquitination is 
through covalent catalysis: the formation a thioester intermediate of the conserved cysteine 
residue on HECT E3s with the activated ubiquitin on E2 (Huibregtse et al., 1995) (Figure 1-
7A), followed by the ubiquitin being transferred to the substrate. Previous reports have 
shown that the cognate E2s of all HECT domain E3s are Ubc4, UbcH5, UbcH7 or UbcH8 
(Duncan et al., 2000; Huang et al., 1999; Huibregtse et al., 1997; Kumar et al., 1997; Nuber 
et al., 1996). 









Figure 1-8: The structure of the Ub-UbcH5a-HECT (NEDD4L) complex. Active residue, Cys 
922 (NEDD4L HECT domain), and active site Cys85 (UbcH5b) are coloured in yellow spheres. 
Both cysteine residues are responsible for the interaction with the glycine of ubiquitin. Ubiquitin 
Gly76 is depicted in gray spheres. (PDB code: 3JVZ) (Kamadurai et al., 2009). 
 
1.1.4.2 RING domain E3s 
One dominant family of the E3s are proteins with a RING finger domain (Really Interesting 
New Gene). RING finger domains have a set of cysteine and histidine residues which 
coordinate two zinc ions in a cross-brace structure and form a characteristic globular 
conformation (Borden, 2000; Loricke et al., 1999). Unlike the HECT domain E3s, the RING 
domain E3s act as scaffolds to interact with E2s and bring the ubiquitin closer to the 
substrate (Figure 1-7B) (Borden, 2000; Joazeiro & Weissman, 2000). Compared to the 
HECT domain E3s, the RING E3s can autoubiquitinate and this mechanism plays an 
important role in the down-regulation of E3 to maintain normal physiological function (Fang 
et al., 2000; Joazeiro & Weissman, 2000; Lorick et al., 1999). RING-type E3s are modular: 
the RING domain interacts with the E2 and facilitates the ubiquitination of the substrate, 
other subunits within the proteins are responsible for the binding of the substrate. Hundreds 
of RING finger proteins have been found and are implicated in different cellular functions 
(Deshaies, 1999; Joazeiro & Weissman, 2000). It is not clear whether all RING finger 
proteins have E3 ligase activity; however, a large number of RING finger proteins are E3 
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ligases, including single-subunit E3s such as c-Cbl-1, cIAP2, MDM2 (Mace et al., 2008; 
Kostic et al., 2006; Zheng et al., 2000) and multiple subunit E3s such as SCF E3 ligase, VCB 
E3s (Deshaies, 1999; Page & Hieter, 1999; Tyers & Jorgensen, 2000; Wei & Sun, 2010). 
The distinct features of these two types of the RING E3s are described as bellow. 
 
 Multiple-subunit E3s 
The multiple-subunit E3s, such as the SCF E3s (Skp1-Cullin-F-box protein), the VCB E3s 
and the APC E3s, consist of several proteins, including an essential small RING E3 protein 
Rbx1 (approximately 100 residues) (Deshaies, 1999; Page & Hieter, 1999; Tyers & 
Jorgensen, 2000). In the scaffold model of the SCF E3s or the VCB E3s, Rbx1 plays a 
critical role to coordinate the Fbox protein/Cul1/E2-Ub (in the SCF E3s) and 















VCB E3s  
Figure 1-9: Multi-subunit E3s architecture. SCF E3s contain an Fbox Protein, Skp1, Cul1 and 
Rbx1. VCB E3s including pVHL, Cul2, Elo C/B and Rbx1. Rbx1 plays a role in the co-
ordination with E2 proteins and other proteins to become active E3s. Fbox and pVHL are 
responsible for substrate-binding. 
 
 Single-subunit E3s: RING/U-box E3s 
Single-subunits E3s are modular: one subunit is the RING or U-Box domain, other subunits 
are responsible for substrate binding. The fold of a RING-type E3 ligase is a unique cross-
brace zinc-binding scheme (Figure 1-10), for example MDM2 (Linke et al., 2006; Kostic et 
al., 2006; Haupt et al., 1997), c-Cb1 (Zheng et al., 2000), IAPs (Mace et al., 2008). The U-
Box domain adopts a similar conformation to that of the RING domain (Figure 1-10), for 
example CHIP U-Box (Zhang et al., 2005). One significant difference is that stabilisation of 
the conformation of the U-box is provided by electrostatic and hydrophobic interactions 
(Zhang et al., 2005). Many single-subunit E3s often interact with a partner protein and form 
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a heterodimer or homodimer, such as MDM2 homodimer, MDM2/MDMX heterodimer 
(Kubbutat et al., 1997; Haupt et al., 1997; Stad et al., 2000), c-Cbl homodimer (Waterman et 
al., 1999), BARD1/BRCA1 (Brzovic et al., 2001), Bmi-Ring1b heterodimer (Buchwald et al., 
2006) and inhibitors of apoptosis (IAPs) homodimer (Mace et al., 2008). Dimerisation 
interactions of the MDM2/MDMX dimer (PDB: 2VJE) were contributed by β3 and the C-
terminal residues of one monomer with the β2 of the other monomer (Linke et al., 2008). 
Other RING-type E3 ligases, such BRCA1-BARD and Bmi-Ring1b, form heterodimers 
through their N-and/or C-terminal helices preceding the RING domains (Brzovic et al., 2001; 









(PDB code 2C2V)  
Figure 1-10: Single subunit RING/U-Box E3s. MDM2, cIAP2 and c-Cbl are RING E3s, and 
two zinc ions (gray spheres) play roles in stabilising the conformation of the RING domain. 
CHIP U-Box E3 has a similar architecture stabilised by hydrophobic interactions. 
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1.1.5 MDM2 E3 ligase is a oncoprotein 
1.1.5.1 Biological roles of MDM2 
 MDM2 –related diseases 
MDM2 (murine double minute 2) is a well characterised oncoprotein that regulates the level 
of p53 through transrepression and ubiquitination (Grier et al., 2006; Iwakuma & Lozano, 
2003; Ko & Prives, 1996; Momand et al., 1992; Oliner et al., 1993). MDM2 transrepresses 
p53 by binding to the transactivation domain of p53 and inhibits p53-mediated transcription, 
resulting in the disruption of cell cycle arrest or apoptosis (Shmueli & Oren, 2004; Stommel 
& Wahl, 2004; Yang et al., 2004). MDM2 also regulates p53 through its E3 ligase activity 
ubiquitinating p53 for further proteolysis (Brooks. & Gu, 2006; Honda & Yasuda, 2000). It 
has been demonstrated that amplification of the MDM2 gene is observed in human tumours 
that contain wild type p53 (Juven-Gershon & Oren, 1999; Momand et al., 1998), 
overexpression of MDM2 induces chromosome instability in tumors that contain wild type 
p53 (Carroll et al., 1999). It has been found that tumours containing a single nucleotide 
polymorphism (SNP309) in the MDM2 promotor accelerates SP1-dependent MDM2 
transcription, the increased concentration of MDM2 protein results in subsequent attenuation 
of p53-dependent transcription and apoptosis (Arva et al., 2005; Bond et al., 2004). It has 
been shown that the level of MDM2 increases in tumour cells, such as soft tissue sarcoma 
(Bartel et al., 2001; Toledo & Wahl, 2006). Furthermore, many tumours contain alternatively 
spliced MDM2 variants including human breast, ovarian, bladder and astrocytic neoplasms 
tumours, and those MDM2 variants lack the p53-binding domain (Dang et al., 2002; Hori et 
al., 2000; Matsumoto et al., 1998; Sigalas et al., 1996).  
 
 MDM2-binding partners 
MDM2 proteins also have a number of protein-protein interaction partners, distinct 
complexes each having their specific biological functions (Daujate et al., 2001; Ganguli & 
Wasylyk, 2003; Momand et al., 2000). Several reports have demonstrated that the ARF-
MDM2 complex promotes p53 stability (Honda & Yasuda, 1999; Sherr & Weber, 2000; 
Zhang et al., 1998). ARF, a tumor suppressor protein, binds to MDM2 and blocks the 
nucleo-cytoplasmic shuttling of MDM2 sequestering MDM2 in the nucleolus (Tao & Levine, 
1999; Zhang & Xiong, 2001). p300/CBP (CREB-binding protein) acetylates p53 and 
activates the transactivation function of p53 (Gu & Roeder, 1997). In contrast, it has been 
described that the MDM2-p300/CBP-p53 ternary complex inhibits p300-mediated 
acetylation of p53 (Ito et al., 2001; Kobet et al., 2000). In the Ras signaling pathway, Ras 
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promotes the transcriptional activation of MDM2 (Ries et al., 2000). L11 is also found to 
bind to MDM2 and sequester MDM2 in the nucleolus (Lohrum et al., 2003). It has been 
demonstrated that MDM2 is phosphorylated on Ser395 by ATM-mediated phosphorylation 
and the p53 function is rescued (Maya et al., 2001). Akt kinase can enhance the nuclear 
translocation of MDM2, and inhibit the interaction of MDM2 with ARF and also promote 
the MDM2 E3 activity upon the enhancement of the interaction of MDM2 with p300/CBP 
(Ashcroft et al., 2002; Ogawara et al., 2002; Zhou et al., 2001). It has been demonstrated that 
Numb (specifying cell fate during development) is degraded by MDM2 (Juven-Gershon et 
al., 1998; Yogosawa et al., 2003). Androgen receptor protein (AR), a transcription factor, 
interacts with MDM2RING domain and is ubiquitinated and degraded by MDM2 (Lin et al., 
2002). Furthermore, it has been shown that MDM2 also interacts with E2F1 to stimulate cell 
proliferation (Loughran & La, 2000). MDM2 may also play roles in ribosomal biogenesis 
and translation regulation in the cell via an interaction with the ribosomal protein, L5 
(Elenbaas et al., 1996; Marechal et al., 1994). MDMX (or MDM4), a MDM2 homologue, is 
also found to regulate p53 (Böttger et al., 1999; Shvarts et al., 1996) and it also has been 
shown that the MDM2-MDMX heterodimer has stronger E3 activity (Badciong & Hass, 
2002; Marine et al., 2007). Many tumours have been found to be related to the 
overexpression of MDM2, and some contain MDM2 variants and mutated p53. Therefore, 
MDM2 has become a very exciting and popular drug target in recent years (Shangary & 
Wang, 2009). 
 
 the flexibility of MDM2 
Structural studies show that the binding cleft of the MDM2 hydrophobic domain is flexible 
and can adapt to the different shapes of the peptides and small molecules with some 
significant changes seen upon ligand binding (Bowman et al., 2007; Dastidar et al., 2008; 
Stoll et al., 2001; Wallace et al., 2006; Vassilev et al., 2004). There is dynamic 
communication between each domain to determine its substrate binding and ubiquitination 
ability (Nicholson & Hupp, 2010; Schon et al., 2004). Recent studies also describe that 
MDM2-dependent transrepression activity can be mediated by RING-mediated allosteric 
modulation (Poyurovsky et al., 2003; Shimizu et al., 2002; Wawrzynow et al., 2009). 
Mutations in the RING domain of MDM2 that disrupt zinc coordination have a higher 
affinity for the BOX-I transactivation domain of p53 and transrepression of p53 function 
(Wawrzynow et al., 2009).  
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1.1.5.2 Composition of modular MDM2 
MDM2 is a RING-type E3 protein. Similar to the canonical RING-E3 ligase proteins, 
MDM2 is also a modular protein which interacts with its cognate E2 and binds to the 
substrate. MDM2 is 491 amino acids long and is a multi domain protein (Figure 1-11) 
composed of the following: a lid region (residues 16-23), a hydrophobic pocket (residues 29-
128); a nuclear localization signal (NLS) (residues 181-185), a nuclear export signal (NES) 
(residues 191-199), an acidic domain (200-299); a zinc-finger domain (300-332), a nucleolar 
localisation signal (NoLS) and the C-terminal RING domain (residues 438-478). Each 
domain has its own function and binding partners as shown in Figure 1-12. 
 
● ● ● ● ● ● ●
● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ●
●
10 20 30 40 50 60 70
80 90 100 110 120 130 140 150
160 170 180 190 200 210 220 230
240
● ● ● ● ● ●
● ●
250 260 270 280 290 300
310
● ● ● ● ● ●
● ●
320 330 340 350 360 370 380
390 400
● ● ● ● ●
● ● ● ●
410 420 430 440 450
460 470 480 491
 
 
Figure 1-11: Sequence alignments of MDM2 and its analogous protein, MDMX. Identical 
residues are shown in letters enclosed in filled red boxes. The numbering and distinct domains 
above the alignments correspond to the MDM2 sequence. Hydrophobic domain marked with 
green bar, lid motif (pink bar), the nuclear localization signal (black dashed bar), the nuclear 
export signal (green dashed bar), acidic domain (cyan bar), zinc finger domain (orange bar) and 
RING domain (red bar).  
  Chapter 1 
 21 
hydrophobic domain Acidic domain Zinc Finger RING






*Interacts with the BOX I-domain of p53  
(transactivation domain)
* Phosphorylated Ser 166 and Ser186 
enhance MDM2 to interact with 
p300/CBP, promote nuclear localisation, 
inhibit the interaction with ARF, and also 
increase p53 degredation.
Acidic domain
*Interacts with the BOX V-domain of p53  
(DNA-binding domain)
* Interacts with p300/CBP to become the 
ternary complex (MDM2-p300/CBP-p53) 
and inhibit p53-mediated functions
Tyr394 residue
* c-Ab1 phosphorylates Tyr394 and 
inhibits MDM2 E3 activity, and  promotes 
the accumulation of p53
* *
Ser395 residue
* ATM phosphorylates Ser395 and 
inhibits MDM2 E3 activity, and  promote 
p53 active
RING domain
*Interaction with its cognate E2 to      
promote MDM2 E3 active 
*Dimerisation (oligomerisation) through 
the C-tail 
*ATP binding motif (P loop/ Walker A)
*interacts with ribosomal protein L5
*interacts with androgen receptor (AR)
* *
NLS & NES motif
* Responsible for the shuttle of 




* ATR phosphorylates Ser407 and 
inhibits MDM2-mediated p53 
nuclear export
 
Figure 1-12: Schematic representations of modular MDM2. Each domain on MDM2 interacts 
with different binding partners and plays different roles in cellular regulation. 
 
 MDM2 hydrophobic domain 
The hydrophobic pocket at the N-terminus of MDM2 is formed by residues 25-109, there is 
a deep groove formed by 14 aromatic and hydrophobic residues (Kussie et al., 1996). This 
deep groove plays a critical role in interactions with the BOX-I transactivation domain of 
p53 (Chi et al., 2005; Kussie et al., 1996; Schon et al., 2002; Schon et al., 2004). 
Biochemical studies have confirmed that this MDM2-p53 interaction is essential for the 
transrepression of p53 and disruption of the p53-dependent transcriptional machinery (Oliner 
et al., 1993; Stommel & Wahl, 2005; Thut et al., 1997). Crystallography data shows that an 
amphiphatic p53 α-helix peptide (residues 17-29) binds into the deep cleft on the N-terminal 
hydrophobic domain of MDM2 (Figure 1-13) (Kussie et al., 1996). Especially, p53 residues 
(F19/W23/L26) provide significant interactions with MDM2. Site-directed mutagenesis 
experiments reveal that mutations of the above residues reduce the binding affinity of p53 to 
MDM2. Because the p53-MDM2 interaction shows a tight “lock and key” configuration (Kd 
from 50 to 500 nM) (Schon et al., 2002), a large number of anti-p53-dependent cancer drugs 
are designed to disrupt the p53-MDM2 interaction (Hu & Hu, 2008; Shangary & Wang, 
2009; Tovar et al., 2006; Vassilev et al., 2004). 
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MDM2 hydrophobic domain







Figure 1-13: The structure of the MDM2-p53 complex. The hydrophobic domain of MDM2 is 
shown in green and the transactivation domain of p53 is shown in yellow (PDB code: 1YCR). 
Three critical residues (F19/W23/L26), which provide major interactions to the residues around 
the cavity of MDM2 hydrophobic domain, are depicted in sticks.  
 
 MDM2 Lid motif, NLS, & NES 
There is a PI3-kinase-like phosphorylation site at Ser17 on the lid motif (or pseudosubstrate 
motif, aa 16~23) of MDM2 (Mayo et al., 1997). The MDM2 lid motif plays a critical role in 
the control of the “open-close switch” conformation to favour/inhibit the binding of the p53 
into the MDM2 hydrophobic groove in a phosphorylation-dependent manner (Uhrinova et al., 
2005; Worrall et al., 2010). Biochemical studies and a quantitative fluorescence-based dye 
binding assays show that MDM2 phosphomimetic mutant, S17D, opens the lid over the 
MDM2 hydrophobic groove, stabilising the p53-MDM2 interaction (McCoy et al., 2003; 
Worrall et al., 2009; Worrall et al., 2010).  The nuclear localisation signal (NLS) and nuclear 
export signal (NES) play roles in the transportation of MDM2 and MDM2-bound p53 in the 
cytoplasm or nucleus to regulate MDM2 and p53 functions (Freedman & Levine, 1998; Roth 
et al., 1998). 
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MDM2 aa 1-119










Figure 1-14: Structure of MDM2 flexible Lid motif. Left panel: NMR structure of MDM2 N-
terminal domain (PDB: 1Z1M) reveals that the flexibility of MDM2 lid motif (blue line). Right 
panel: Distinct MDM2 lid conformations (open/close) are shown presented in surface 
representations, the p53-binding site is highlighted by a black circle, the lid motif is coloured in 
blue and Ser17 is depicted in yellow. 
 
 
 MDM2 acidic domain  
The acidic domain of MDM2 interacts with the BOX-V peptide derived from the DNA 
binding domain of p53 (Wallace et al., 2006). MDM2 acidic domain is critical for the poly-
ubiquitination of p53 (Argentini et al., 2001; Meulmeester et al., 2003). MDM2 lacking the 
acidic domain that overlap that overlaps the p300/CBP-binding domain can monoubiquinate 
p53, but fail to degrade p53 (Zhu et al., 2001). This domain is quite flexible, and as yet no 
structure has been published. 
 
 MDM2 C4 zinc finger domain 
The X-ray structure of MDM2 C4 zinc-finger domain has been solved (PDB code: 2C6A) 
and it has been shown that this domain plays a critical role in the inhibition of cell growth 
and in the regulation of Gl cycle arrest (Brown et al., 1998; Yu, et al, 2006). This domain 
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adopts a compact globular zinc ribbon conformation, four residues (Cys305, Cys308, 
Cys319 and Cys322) interact with a single zinc ion to maintain the integrity of this domain 
(Figure 1-15). In follicular lymphomas and liposarcomas, missense mutations in the MDM2 
C4 zinc finger domain have been found to be Cys305Phe and Cys308Tyr, respectively 
(Schlott et al. 1997; Tamborini et al. 2001). These mutants may be responsible for effects 





(PDB code : 2C6A)
 
Figure 1-15: MDM2 C4 zinc finger domain (PDB: 2C6A). Four cysteine residues, Cys305, 
Cys308, Cys319, and Cys322 (shown as yellow sticks) co-ordinate with zinc. The single zinc ion 
is shown as a white sphere. 
 
 MDM2 RING domain 
MDM2 has a RING-type E3 ligase domain, of approximately 60 residues, which is found at 
the C-terminal zinc-binding domain (Boddy et al., 1994; Fang et al., 2000). Similar to other 
RING domain E3s, MDM2RING has a compact ββαβ fold, a small hydrophobic core, and 
contains two essential zinc ions (Figure 1-16). In recent years, structures of both the MDM2 
homodimer (PDB code: 2HDP) and MDM2-MDMX heterodimer (PDB code: 2VJE) have 
been published (Kostic et al., 2006; Linke et al., 2008). Both structures show that each 
subunit of the MDM2-MDM2 homodimer or MDM2-MDMX heterodimer coordinates two 
zinc ions in a sequential manner and in an anticooperative binding mode. The conformation 
of each MDM2 RING subunit is stabilised by the two zinc ions in a C2H2C4 cross-brace 
zinc binding topology: one C4 zinc binding site (C438C441C461C464) and one H2C2 zinc 
binding site (H452H457C475C478). The MDM2 RING domain also contains an RNA-
binding motif and it has been found that addition of RNA stimulates ubiquitination (Elenbaas 
et al., 1996; Lai et al., 1998). It has been noted that MDM2 contains an ATP binding motif 
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(448GCIVHGKT455), Walker A or P loop, which plays a role in intracellular localisation, 
and ATP-dependent chaperone activity and also mediates the tetramerisation of p53 
(Poyurovsky et al., 2003; Stevens et al., 2008; Wawrzynow et al., 2007). ATP-bound MDM2 
is preferentially localised in the nucleolus, and one MDM2 mutant (K454A) results in the 
upregulation E3 ligase actitivty promoting the degradation of p53 (Poyurovsky et al., 2003). 
The last eight residues at the MDM2 C-terminus (Figure 1-16) have been found to be 


















Residues coordinate with zinc
(PDB code: 2HDP)  
Figure 1-16: Crystal structure of dimeric MDM2 RING domain, residue 432-491, (PDB 
code: 2HDP). (A) Residues coordinate with zinc are highlighted in yellow sticks. (B) Residues 
located in the ATP-binding site are shown in orange sticks. (C) The C- terminal eight residues (in 
cyan) are responsible for the dimerisation.  (D) Residues located in the E2-binding site are 
highlighted in magenta. Zinc ions are shown as grey spheres.  
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1.1.6 Tumour suppressor protein: p53 
1.1.6.1 Biological roles of p53 
p53 is a tumour suppressor protein that functions to protect cells from malignant 
transformation (Lane, 1992; Levine, 1997; Vogelstein et al., 2000; Vousden & Prives, 2009). 
In more than 50% of human cancers, p53 is found to be mutated and inactivated (Hollstein et 
al., 1994). p53 regulates cell cycle arrest and apoptosis through post-translational 
modifications of p53 to induce p53-dependent gene expression (Krummel et al., 2005; Xu, 
2003). Those p53-responsive genes express proteins involved in numerous signal 
transduction pathways (Figure 1-17). A number of reports have noted that the mechanisms of 
p53 activation are regulated by several post-translational modifications: ubiquitination, 
phosphorylation, acetylation, sumolyation, neddylation, and methylation (Brooks & Gu, 
2003; Brooks & Gu, 2006; Chuikov et al., 2004; Fraser et al., 2010; Rodriguez et al., 1999; 
Xirodimas et al., 2004). Tumour suppressor protein, p53, behaves as a specific DNA-binding 
protein or transcription factor regulating those genes that mediate DNA amplification, cell 
cycle arrest, apoptosis, and cellular senescence when cells are damaged (Ashcroft et al., 2000; 


















Figure 1-17: Biological roles of p53. p53 is regulated by several modifications, for example 
ubiquitination, phosphorylation, acetylation, sumolyation, neddylation and methylation. p53 also 
is responsible for several tasks including cell cycle arrest, apoptosis, DNA damage and cellular 
amplification. 
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 p53-binding partners 
There are two core mechanisms to control the level and function of p53 in stressed cells 
(Table 1-3): positive regulation (stabilisation or stimulation of translation) and negative 
regulation (repression of the transcription or ubiquitination/ degradation) (Dornan & Hupp, 
2001; Lu, 2005; Toledo & Wahl, 2006; Lavin & Gueven, 2006). For DNA damage responses, 
positive regulation to mediate p53 is through its transcriptional coactivator, p300/CBP to 
stimulate DNA-dependent mediated acetylation (Brooks & Gu, 2003; Shimizu& Hupp, 2003) 
and activating gene expression by forming a complex with chromatin remodelling factors 
(Barlev et al., 2001; Dornan et al., 2003). Moreover, activation of p53-mediated 
transcriptional regulation of various genes involved in apoptosis or cell cycle arrest is 
controlled by an ATM-CHK2-depedent pathway (Banin et al., 1998; Ljungman & Lane, 
2004; Meek, 2004; Shieh et al., 2000). Numerous studies have showed that ARF (p14ARF in 
humans and p19ARF in mouse) can induce p53 upon the inhibition of MDM2 activity (Kamijo 
et al., 1998; Pomerantz et al., 1998; Sherr, 2001; Zhang et al., 1998; Zhang & Xiong, 2001). 
Furthermore, several ribosomal proteins, such as L11 and L23, stabilise p53 by inhibiting 
MDM2 activity (Dai et al., 2004; Zhang et al., 2003). Ribosomal protein, L26 stimulates the 
translational expression level of p53 upon binding to the 5’-untranslated region of p53 
(Takagi et al., 2005). HAUSP (the herpes virus-associated ubiquitin-specific protease), one 
of DUBs (deubiquitin enzymes), stabilises p53 and promotes p53-mediated apoptosis and 
cell cycle arrest (Li et al., 2002; Li et al., 2004; Hu et al., 2002). p53 function is negatively 
regulated by a number of E3 proteins, including MDM2, COP1, Pirh2, and ARF-BP1 
(Brooks & Gu, 2006; Chen et al., 2005; Dornan et al., 2004; Ghosh et al., 2003; Leng et al., 
2003). These complicated and delicate protein-protein interactions provide evidence for the 
hypothesis that cellular proteins can exist in distinct combinations under different 
environmental conditions. 
 
Table 1-3: Positive and negative regulators of p53. 












* Only some regulators of p53 are listed here.  
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1.1.6.2 The interactions between MDM2-p53 
MDM2 is the predominant oncogenic E3 ligase for p53. MDM2 mediates the abundance of 
p53 in the cell through several protein-protein interactions (Figure 1-18): (1) MDM2 acts a 
transrepressor to mediate p53-mediated transcription through the binding of the N-terminal 
hydrophobic domain (Hy) of MDM2 to the transactivation domain (BOX-I domain, Thr18-
Asp29) of p53 (Momand et al., 1992; Oliner et al., 1993; Shimizu and Hupp, 2003). It has 
been shown that disruption of the interaction between the hydrophobic domain of MDM2 
and the BOX-I activation domain of p53 can rescue p53 function (Dornan & Hupp, 2001; 
Lin et al., 1994; Liu et al., 2001). (2) The acidic domain interacts with the DNA binding 
domain (BOX-V) of p53 (Shimizu et al., 2002; Wallace, et al., 2006). A peptide derived 
from the S9-S10 linker region in the DNA-binding domain of p53 is able to inhibit the 
ubiquitination of p53 by MDM2 (Shimizu et al., 2002). (3) MDM2 is a RING–type E3-ligase 
that ubiquitinates p53 and induces degradation of p53 by the 26S proteasome (Arva et al., 
2005; Kubbutat et al., 1997; Haupt et al., 1997; Honda et al., 1997; Michael and Oren, 2003). 
Furthermore, recent reports indicate that MDM2 acts as an ATP-dependent molecular 
chaperone to regulate p53 (Burch et al., 2004; Wawrzynow et al., 2007). MDM2 has become 
an attractive drug target for p53-related cancer therapy by disruption of the p53-MDM2 












Figure 1-18: MDM2-p53 interactions. Hydrophobic domain (Hy) of MDM2 interacts with the 
transactivation domain (BOX-I) of p53. Acidic domain (Ac) of MDM2 interacts with the DNA-
binding domain (BOX-V) of p53. The MDM2 RING domain is responsible for the ubiquitination 
of p53. 
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Part II Antagonists/Agonists of Protein-Protein Interaction  
1.2.1 Protein-Protein Interaction (PPI): the challenges 
Protein-Protein interactions (PPI) play important roles in biological functions by regulating 
proteins, such as kinases (protein phosphorylation), proteases (proteolysis), or glycosylases 
(glycosylation). Recently, PPIs became attractive pharmaceutical targets, after the complete 
genome sequence became available. However, PPIs are challenging targets for the design of 
small-molecule inhibitors (Arkin & Wells, 2004; Cochran, 2000; Dömling, 2008; Ma et al., 
2003; Teague, 2003) because the majority of PPI interfaces are widely spread over the 
surfaces of proteins forming a flat interface (Nooren & Thornton, 2003). Historically, small 
molecules inhibitory for a number of enzymes were designed based upon known bioactive 
small molecules (neurotransmitters) or ligands. Because the structures of those small 
molecules are known, they provide a template for the design of new antagonists. However, 
this approach is not applicable in the case of the majority of PPIs. Drugs that can act as the 
starting template for the design of small molecules of PPI are rare. One of the few examples 
is Cyp A/ CsA and FKBP/ FK506, providing the templates for further drug design (Schreiber 
& Crabtree, 1992; Yang et al., 2007). A major problem is still the difficulty of identifying a 
druggable site in most PPIs. Numerous mutagenesis experiments and structural studies are 
used to define the binding interface and verify residues critical for binding in the PPIs, 
revealing that the binding residues are also often found in discontinuous parts in the protein 
sequence. For example, with the well characterised E2-E3 protein-protein interaction (Figure 
1-6), residues in H1/L4/L6 in E2 interact with residues in E3.  
 
Many reports have shown that a “typical” PPI interface has an approximate surface area of 
700 ~ 1600Å and includes approximately 170 atoms, which may be from both main chains 
and side chains (Lo et al., 1999; Stites, 1997; Jones & Thornton, 1996). At the interface, 
aromatic residues and arginine residue are often present, and hydrophobic surfaces promote 
complex formation (Clackson & Wells, 1995). Moreover, hydrogen bonds, salt bridges and 
van der Waals interactions are also frequently observed in PPIs. The PPI interface is large 
and it is unlikely that every part of the interface is an ideal site for small-molecule binding.  
 
Drug like molecules have been found to follow the so called “Lipinski’s rules of five” 
(Lipinski et al., 1997), suggesting that greater drug efficacy will be achieved if molecules 
have the following properties: (1) The molecular weight is less than 500 Daltons. (2) The 
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LogP value is less than 5. (3) The molecule has less than 5 hydrogen bond donor. (4)The 
molecule has less than 10 hydrogen bond acceptors. The ideal pharmaceutical agents would 
have the following characteristics: few side effects, in vivo efficacy, good bioavailability, 
solubility and no toxicity (Ajay et al., 1998; Bemis & Murcko, 1996; Bemis & Murcko, 1999; 
Lipinski et al., 1997). 
 
Although a number of PPI antagonists have been developed and are in clinical trials 
(Dömling, et al., 2000), identifying PPI antagonists is still a very challenging task. There are 
no universal principles governing the features of PPIs. Some PPI interfaces are more 
accessible and antagonists can readily bind to these interfaces whereas some PPIs contain 
surfaces which are buried and therefore not readily accessible. The PPI antagonists 
developed to date have diverse features (and modes of action) (Figure 1-19). Some 
antagonists are competitive antagonists which bind to the PPI binding site on the interfaces. 
For example, Nutlin, one of the best characterised molecules, binds to the hydrophobic 
domain of MDM2 to interfere with binding of the p53. In some cases, allosteric PPI 
antagonists bind to other areas remote from the interface, resulting in conformational 
changes of one protein, thus interfering with the interaction with the partner protein. For 
example, agonists act as modules to (de)polymerise the tubulin cytoskeleton (Luque & Freire, 
2000; Jordan, 2002). de novo prediction of a potential druggable site is very difficult and 
therefore that the design of small molecule inhibitor for PPI is very challenging. However, 
the study and discovery of small molecule inhibitors of PPIs is important as many PPIs are 
implicated in tumourognesis.  
 
There are numerous methods to identify the “consensus” characteristics of the “hotspot” (the 
potential binding site for small molecules), which is comprised of subset of the interface that 
may provide high binding abilities (Bogan & Thorn, 1998; DeLano, 2002; Ma et al., 2003). 
For example, crystallisation of proteins with various organic solvents is used to characterise 
the binding site (Mattos & Ringe, 1996), nuclear-magnetic resonance (NMR) analysis of 
proteins with a library of small molecules can be used to verify the potential binding motif 
(Fejzo et al., 1999; Shuker et al., 1996), or computational analysis can be performed to 
determine the anatomy of cavities in protein pockets in a potential binding site (Liang et al., 
1998). Recently, a number of PPI antagonists/agonists have been discovered by 
combinations of several techniques, including (1) Direct screening methods for PPI 
antagonists: phage display, and high-throughput screening (HTS) with libraries of small 
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molecules (Schaffer et al., 2003; Sidhu et al., 2003). (2) Virtual screening methods for PPI 
antagonists: utilising structural information of the PPI interface generated from structural 
studies (NMR, X-ray crystallography), and combinations of computational analysis to 
identify the hotspots on PPI or virtual screening (VS) strategies searching for the potential 
PPI antagonists (Ma et al., 2003).  
 
Figure 1-19: Developments and challenges of antagonists/agonists of PPI. Details introduced 
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1.2.2 Virtual screening (VS) and database mining approaches 
There are various strategies used to identify drug leads, including high throughput screening 
(HTS) and virtual screening (VS) in silico. Numerous studies showed that in vitro or in vivo 
HTS methods have a number of straightforward advantages to characterise the effects of 
small molecules on the target protein. However, HTS methods also have a number of 
disadvantages including cost and time taken to perform the experiments. VS is a technique 
which uses simulation methods to predict the characteristics of small molecules or to pre-
calculate (estimate) binding affinities between small molecules and the drug target. 
Compared to high-throughput screening, VS is economical and able to simulate the rational 
binding modes of selected small molecules from a large chemical database (in our project, 
millions of compounds) in a short time. VS therefore has many advantages as the first step of 
drug discovery for PPI antagonists/agonists, since most PPIs lack any template that could be 
used for the rational design of small molecule inhibitors. After new PPI antagonists/agonists 
have been selected by VS, their effects can be evaluated by in vitro or in vivo assays.  
 
The VS approach can be both protein structure-based and ligand-based. Protein structure-
based VS approach is based on the knowledge of the target receptor selecting potential 
ligands that have affinities to the receptor, such an approach is used in our in-house 
programme, LIDAEUS (Taylor et al., 2008). Ligand-based VS and database mining methods 
search for new small molecules which might have some of the characteristics required and 
this approach is used in our in-house programme, UFSRAT. 
 
To date, no known ligand to the MDM2 RING domain has been characterised. To achieve 
our aims of developing our MDM2/UbcH5a antagonists/agonists, we set up a VS pipeline 
which combines several programmes including EDULISS, UFSRAT, LIDAEUS, and 
AutoDock (Figure 1-20) (introduced in more detail in the following section). Several 
potential small molecules were selected by VS that can affect MDM2-mediated 
ubiquitination of p53, the first such methods are reported. Results of VS to find 
MDM2/UbcH5a antagonists/agonists are presented in Chapter 6. 
 





EDULISS: small molecule database
UFSRAT: molecular shape-based similarity search
AutoDock: virtual docking program
(1) Choose the target site (2) Potential binding residues (3) Site points
 
Figure 1-20: The selection process undertaken in virtual screening. Step 1 is to choose the 
target site of interest. Step 2 is to determine the starting molecule (potential binding residues) that 
was found to interact with the target site. Step 3 is to create the dots required for simulation on 
the basis of the distances or/ types of atoms using UFSRAT or LIDAEUS. Step 4 is to start the 
virtual screening runs, including the EDULISS, LIDAEUS, UFSRAT, AutoDock and 
biochemical assay. More detail is provided in the text. 
 
 EDULISS (EDinburgh University Ligand Selection System) 
EDULISS is a recently developed relational database (http://eduliss.bch.ed.ac.uk/) (Hsin et 
al., 2011). To date, in EDULISS, there are more than 5 million commercially available 
compounds sourced from 28 suppliers. Within the database, the following information is 
available on each compound, including structural, physiochemical, and pharmacophoric 
properties. EDULISS is a powerful data-mining program because each molecule is stored 
with its 3D structure along with over 1600 calculated descriptor values (molecular 
descriptors), such as topology, geometry, physicochemistry and toxicology. EDULISS also 
stores information on interatomic distances between various atoms in each molecule. This 
feature is useful for the Interatomic Pharmocophore Profiles (IPP) that defines the 
characteristics required for the interatomic distance of hydrogen bond donor and acceptor 
atoms, halogens, phosphorous and sulphur atoms (Hsin et al., 2011). These features are also 
useful to extract subgroups that have similarly shaped molecules or fit the specific 
pharmacophore properties required.  
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As shown in Figure 1-21, in our project those compounds selected conform to Lipinski’s rule 








Filtered by specific 
parameters:




(for next VS run)
 
Figure 1-21: The concept of EDULISS. Selections of molecular descriptors, such as Lipinski’s 
rule of 5 or suppliers, act as filters to sieve out potential molecules. One of advantages is to 
reduce the number of candidate molecules and therefore save computational time in the VS run.  
 
 UFSRAT (Ultra Fast Shape Recognition with Atom Types) 
UFSRAT is a ligand-based virtual screening program to search for small molecules on the 
basis of molecular similarity to known ligands (Developed by Dr. Shave et al., 
http://opus.bch.ed.ac.uk/ ufsrat/index.php). Molecular similarity is an important concept to 
biologists and chemists. The overall concept is that similar molecules are supposed to have 
similar properties and behave in a consistent manner. One significant application of 
molecular similarity is in rational drug design, especially in medicinal chemistry and in the 
pharmaceutical industry. Once there is a known binder/ligand, which can be used as a 
starting molecule, new potential binders may be synthesised by adding or removing chemical 
groups or atoms from the starting scaffold (Bender & Glen, 2004; Dimasi, 2001).  
 
The concept of UFSRAT is that consideration is given to both shape and atom type 
descriptors within a molecule (Figure 1-22). In UFSRAT- molecular similarity is important 
and atoms of certain type in a common position contribute to higher similarity scores. This is 
important to ensure that similar interactions occur in a candidate molecule as in a query 
molecule. Each descriptor is assigned a value. Similarity (0 < score < 1) between two 
molecules is that the values of the geometrical distribution of a candidate molecule against 
that of the query molecule. UFSRAT had been successfully used in our project (See Chapter 
6, the antagonists of MDM2-MDM2 dimerisation) and in addition to the study of inhibitors 
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of 11β –hydroxysteroid dehydrogenase (11βHSD1) and the immunophilin protein FKBP 













Figure 1-22: A query molecule (blue) and a candidate molecule (green) UFSRAT predicted 
similarity. Dash circles highlight some atom types in the common positions, presumably 
contributing to similar interactions with the target. Selected candidate molecules also keep the 
same atom types as the query molecule. Hydrogen bond donors are coloured in red, hydrogen 
bond acceptor are coloured in blue. 
 
 LIDAEUS (Ligand Discovery At Edinburgh University) 
LIDAEUS is our in-house simulation program which uses a structure-based VS program for 
the docking and mining of molecules into the target receptor (Dr, Taylor Paul; Shave et al., 
2008). LIDAEUS has been successfully used in the study of inhibitors of human cyclophilin-
A (CypA) and FKBP (Taylor et al., 2008; Wu et al., 2003). LIDAEUS is a user-oriented, 
highly adaptable and modular rigid body docking program. Prior to using LIDAEUS, a PDB 
file of a receptor-ligand complex is required to generate the virtual maps. This map is used to 
generate the binding pocket and define a set of site points (atoms of a known ligand) that act 
as a starting template for small molecule similarity screening. The pipeline of LIDAEUS 
includes the following four steps: Preen, Pose, Score, and Sort (Figure 1- 23). “Preen” 
defines site points, which are generated by LIDAEUS, and are coloured according to their 
molecular characteristics: hydrogen bond donors (red), hydrogen bond acceptors (blue) and 
hydrophobic atoms (white). The site points act as a starting template for the design of small 
molecules to the target site of interest. “Pose” is a procedure to fit the molecules onto the set 
of the site points generated in many ways. “Score” is used to estimate the energies of the 
molecules position that position over the site points in the binding pocket. “Sort” outputs the 
top scoring ligands on the basis of the simulated binding energies generated in the Score step. 
  Chapter 1 
 36 
The top scoring ligand candidates are presumed to have similar interactions with the target 
protein to that of the known ligands, and hence provide another level of selectivity prior to 
evaluation of the test ligands using biochemical or biophysical analysis. 
 
Preen Pose Score & Sort
 
 
Figure 1-23: Steps involved in LIDAEUS. LIDAEUS includes four steps: Preen, Pose Score & 
Sort (Taylor et al., 2008). The target is coloured in green surface representation. Sites points of a 
starting template are coloured on the basis of atom types: hydrogen bond donor (red), hydrogen 
bond acceptor (blue) and hydrophobic atom (white). A candidate molecule is shown in stick form.  
 
Further detail on UFSRAT and LIDAEUS are available in Steven R. Shave’s thesis (2009) 
“The development of high performance structure and ligand based virtual screening 
techniques, and also in Daphne Kan’s thesis (2007) “Studies of protein-ligand interactions 
and the discovery of new cyclophilin inhibitors.” (University of Edinburgh) 
 
 AutoDock 
The basic concept of AutoDock is to predict how a small molecule binds to the target 
receptor of known 3D structure (http://autodock.scripps.edu/). Major advantages of 
AutoDock are rapid grid-based energy evaluation and an efficient search of torsional 
freedom. AutoDock is a package of automated docking tools: AutoGrid, AutoDock and 
AutoDockTools (Goodsell et al., 1996; Morris et al., 2009; Norgan et al., 2011; Sotriffer et 
al., 2000). “AutoGrid” is designed to pre-calculate grids that describe the target protein. Four 
steps are required in an AutoDock calculation: (1) coordinate file preparation using 
“AutoDockTool”; (2) creating grid parameters and pre-calculation of atomic affinities and 
the torsional degree of freedom of side chains using “AutoGrid”; (3) docking the ligands to 
the receptor using “AutoDock” on the basis of free energy calculation; and (4) Analysis of  
the results using AutoDockTools which is a tool to analyse ligand-receptor docking 
calculations and visualisation of the atomic affinity grids (Morris et al., 2008). This feature is 
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important for synthetic chemistry to facilitate optimisation of small molecules resulting in 
higher binding affinity with the receptor. Application of AutoDock to our project is 
described in greater detail in Chapter 6.  
 
1.3 Aim of the project: Discovery of MDM2 Antagonists 
MDM2 plays a critical role in the regulation of the p53 level in cells. About 50% of human 
tumors are related to mutations or deletions in the p53 gene. Human cancers that have wild 
type p53 proteins overexpress MDM2, which inhibits p53-mediated transcription or 
degradates p53 by ubiquitination. Hence, inhibitors of p53-MDM2 or of MDM2-mediated 
ubiquitination are attractive strategies to rescue p53 function for potential cancer therapies 
(Lauria et al., 2010; Patel & Player, 2008).  
 
To date, only a few small molecules found to inhibit MDM2 E3 ligase activity have been 
identified (Lai, et al., 2002; Yang, et al., 2005). There are large numbers of inhibitors found 
to interrupt the MDM2-p53 interactions (Weber, 2010). One well characterised inhibitor is 
Nutlin. Nutlin, a BOX-I mimetic, has been proved to have high affinity with the hydrophobic 
domain of MDM2, and activates p53-dependent transcription in vitro and in vivo (Vassilev, 
2004; Vassilev et al., 2007; White et al., 2006). The mechanism of Nutlin resulting in the 
rescue of p53 function has been widely studied. An early hypothesis suggested that when 
Nutlin binds to the hydrophobic domain of MDM2 it would prevent interaction between p53 
and MDM2, and p53 would not be ubiquitinated. In fact, Nutlin does inhibit the interaction 
of p53 and MDM2, but does not block ubiquitination of p53 (Wallace et al., 2006). The 12.1 
peptide (MPRFMDYWEGLN) shows similar behaviour and is able to inhibit the p53-
MDM2 interaction but does not attenuate the MDM2-mediated ubiquitination to p53 
(Böttger et al., 1996; Wallace et al., 2006).  
 
Recently, the MDM2 RING domain has attracted significant effort in drug design due to its 
E3 ligase activity. The goal is to disrupt MDM2 E3 ligase activity directly. There are two 
alternative target sites on the MDM2RING domain: (1) the C8-binding site (for the 
dimerisation) and (2) the E2-binding site. It has been found the MDM2 RING domain 
proteins are more active as dimers rather than monomers. Therefore, if small molecules 
having higher affinities with the C8-binding site can be designed; MDM2 will exist as 
monomers and will have weaker E3 ligase activity. Interaction with the E2 protein is 
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essential to trigger E3-mediated ubiquitination. Therefore, if small molecules bind to the E2-
binding site of the E3 protein or the E3-binding site of E2, ubiquitination pathways are 
interrupted.  
 
In this project, we characterised the interactions between MDM2 and its partner UbcH5a. In 
an attempt to provide new therapies for MDM2-mediated tumours, a virtual screening 
strategy (VS) was applied to design new potential drugs that could affect MDM2 E3 ligase 
activity. The interaction between UbcH5a and MDM2 is essential for the ubiquitination 
mechanism. Therefore, the interaction between MDM2 and UbcH5a provides a potentially 
druggable site, providing opportunities to design small molecules that disrupt the interactions. 
Numerous reports indicate that dimerisation of MDM2 affects its E3 ligase activity. This 
provides an alternative druggable site (Figure 1-24): the C8-binding site. Overall, in this 
project, we will focus on three potential drug targets: (1) the UbcH5a-binding site of MDM2, 
(2) the MDM2-binding site of UbcH5a, and (3) The C8-binding site of MDM2. The aim is to 
screen potential MDM2 antagonists to inhibit MDM2 E3 activity.  
 




Figure 1-24: The aims of the project. (1) The study of UbcH5a-MDM2RING domain 
interaction (dashed red square). (2) Search for new small molecules to inhibit MDM2 E3 ligase 
activity upon the interruption the UbcH5a-MDM2 interaction or MDM2 dimerisation. Left figure 
is the model of the full length MDM2-p53 interaction through hydrophobic domain (Hy), and 
acidic domain (Ac) to allosterically regulate MDM2-mediated ubiquitination (more detail in 
Wallace et al., 2006). Right figure is the model of MDM2-UbcH5a interaction. MDM2RING-
MDM2RING is shown as a cartoon. UbcH5a is shown in surface representations. The arrows 
(red & blue) are the druggable sites of interest.  The MDM2-UbcH5a complex model was built 
based on the known crystal structure of the cIAP2UbcH5b complex (PDB: 3EB6). 
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This chapter described the strategies behind the expression and purification of MDM2RING 
(residues 386-491), MDM2RING△C (residues 386-478) and UbcH5a (residues 1-147). 
Following our optimisation of the purification procedures, the purity of each protein 
routinely was greater than 95%. These purified proteins were used for further biophysical 
and biochemical studies (Chapter 3) and structural studies (Chapter 4), and also as drug 
targets to study the effects of peptide 9 selected by K. Ball’s group and of small molecules 
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2.1 Introduction 
MDM2 is an E3 ligase protein which plays a critical role in determining the level of p53 in 
cells. It is a modular protein and its RING domain possesses E3 ligase activity. Here, we 
have produced and purified two constructs: MDM2RING (residue 386-491) and 
MDM2RING△C (residues 386-478). There are two published structures of MDM2RING 
proteins, MDM2/MDM2 homodimer (PDB ID: 2HDP) and MDM2/MDMX heterodimer 
(PDB_ID: 2VJE). However, there is no structure of a complex of MDM2 with a partner 
protein, for example UbcH5a. It has been proved that the interaction between E2-E3 is 
essential for the ubiquitination pathway. There are several structures of an E2-E3 complex 
available, which show that the E2-binding site of the E3 protein is quite expanded around the 
E3 surface. Previous studies have shown that the binding affinity between MDM2RING and 
its partner UbcH5 is too weak to be detected by ITC or pull-down methods: perhaps under 
these experimental condition, small MDM2 RING domain (residues 432-491), which may 
lack sufficient interaction for the UbcH5a-binding. One of our initial aims was to obtain the 
crystal structure of MDM2-UbcH5a, and the protein-protein interaction affinity is therefore a 
critical factor in determining if we can achieve this goal. A larger MDM2RING construct 
(residue 386-491) may have higher affinities with UbcH5a, therefore increasing the 
likelihood of obtaining the crystal structure of the MDM2-UbcH5a complex. In this project, 
we designed an MDM2RING construct, comprised of residues 386-491. MDM2 C-terminal 
tail fragment plays a critical role in oligomerisation of the protein and is also required for 
MDM2 E3 activity. A number of papers have shown that MDM2RING△C exists as a 
monomer and loses its E3 ligase activity. Therefore, we also made a construct, 
MDM2RING△C, consisting residues 386-478, as a negative control in our studies. 
MDM2RING, MDM2RING△C and UbcH5a were successfully produced and purified in 
this project. Amino acid sequences of those proteins are shown in the Figure 2-1 
(MDM2RING & MDM2RING△C) and Figure 6-11 (UbcH5a). Pure proteins are essential 
for crystallisation, NMR analysis and biophysical characterisation, such as dynamic light 
scattering (DLS), thermal denaturation assay (TDA), circular dichroism (CD), and 
fluorescence anisotropy (Chapter 3, 4, 5 & 6). We also carried out in vitro ubiquitination 
experiments to test if our purified proteins are active. 
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2.2 Cloning 
2.2.1 Cloning: MDM2RING & MDM2RING△C 
The principle of cloning is that the coding gene of the protein was inserted into the 
expression vector, pET15b, and then transformed into Escherichia coli BL21(DE3) 
expression system. pET15b (Novagen Co.) contains a T7 promoter upstream at the multiple 
cloning sites (as protein expression sites) (Figure 2-1B). pET15b has a lac operator, which 
strictly controls the T7 promoter. BL21(DE3) is a modified Escherichia coli, which can 
express T7 polymerase. To produce the target protein, isopropyl β-D-1- 
thiogalactopyranoside (IPTG) is used to induce the expression of T7 polymerase, which 
binds to T7 promoter and triggers the expression of the inserted gene and produces the target 
protein. Advantages of the pET15b vector are that it possesses an N-terminal His．Tag, 
following a thrombin cleavage site, both of which facilitate protein purification (Figure 2-2).  
 
2.2.2 Material and Methods: Cloning  
MDM2 (murine double mutant 2) (Accession number Q00987) residues 386-491 
(MDM2RING) and residues 386-478 (MDM2RING△C) were cloned into the expression 
vector pET15b (Novagen Co.) that carries a His．Tag and a thrombin cleavage site (Figure 
2-2). In PCR reactions, the templates were plasmids containing the full length mdm2 gene 
which were gifts provided by Kathryn Ball’s group. PCR reaction mixtures included the 
plasmid templates (5 ng), forward primer (1 nmole), reverse primer (1 nmole), ATP, reaction 
buffer, T7 polymerase (1 Unit, Sigma Co.) and ddH2O up to final volume of 30 μl. PCR 
reaction conditions were: 95℃, 5 minutes; 30 cycles of 95℃, 30 seconds, 72℃, 45 seconds, 
and 37℃, 60 seconds; 37℃, 5minutes. The PCR products were checked on a 1.2% agarose 
gel.  
 
To obtain the constructs containing the RING domain of MDM2, primers were designed to 






BamHI_478R 5’-CGCGGATCCTAACATACT GGGCAGGGCTTATT-3’  
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All the forward primers contained an NdeI restriction site and the reverse primers included a 
BamHI restriction site. For cloning, the PCR products and expression vectors pET15b were 
treated by NdeI and BamHI enzymes for 1 hour at 37℃. Those treated samples were loaded 
onto a 1.2% agarose gel to separate cleaved samples from the uncleaved samples. The bands 
of the expected sizes were cut out of the agarose gel and purified using a gel extraction kit 
(QIAGEN, Co.). Next, we used a Rapid DNA ligation Kit (Roche Co.). The ligation mixture 
included purified cleaved pET15b, cleaved PCR products, ligase, and ligation buffer. 
Ligation mixtures were incubated for 5 minutes at room temperature. Following ligation, 
mixtures were transformed to the competent cells used for cloning and plasmid production, 
DH5α. Competent cells were put on ice for 15 minutes, followed by heat shock at 42℃ for 
90 seconds, and the cells were put back on ice quickly for another 15 minutes. The 
transformed cells were incubated at 37℃ with shaking at 250 rpm for 1 hour and then spread 
on LB plates (+100 μg/ml carbenicillin) and incubated at 37℃ overnight. A single colony 












Figure 2-1: Cloning of MDM2 RING constructs. (A) Schematic diagram presenting the 
domain architecture of MDM2. The RING domain starts from C438 to C478. The secondary 
structure of MDM2 RING domain exists as β1β2α1β3. The zinc binding residues are labeled with 
red asterisks (*). The sequences (G448CIVHGKT G456) shown in green and underlined are the 
ATP binding motif, Walker A. In our project, two constructs were generated: MDM2RING 
(residues 386 ~ 491) and MDM2RING△C (residues 386 ~ 478). (B) The cloning vector used in 
this project is pET15b (Details available from Novagen Co.).  
  Chapter 2 
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2.2.3 Results and Discussion: Cloning 
In this work, we designed and constructed two MDM2 RING domain proteins, MDM2RING 
(residues 386-491), and MDM2RING △ C (residues 386-478). Specific primers were 
designed for the cloning. After optimisation of PCR conditions, the fragments of 
MDM2RING and MDM2RING△C were successfully amplified (Figure 2-2A). The sizes of 
the PCR products shown on the agarose gel were as expected the sizes of MDM2RING and 
MDM2RING△C, respectively, 387 and 346 bps. For cloning, those PCR products and the 
vectors, pET15b, were treated by these two restriction enzymes (NdeI / BamHI) following by 
separation of cleaved and uncleaved fragments on a 1.2 % agarose gel. Cleaved fragments of 
the PCR products were purified and inserted into the expression vector, pET15b.  
 
Those MDM2RING ligates (pET15b-MDM2RING or pET15b-MDM2RING △ C) were 
treated by two restriction enzymes (NdeI and BamHI) to confirm whether the molecular sizes 
of those clones were what we expected. The MDM2RING ligates were treated by NdeI / 
BamHI and analysed on 1.2 % agarose gel. The size of the smaller fragment was about 300 ~ 
400 bps and the size of the larger one was about 5000 ~ 6000 bps. The sizes of those two 
fragments were similar to the size of MDM2RING (372 bps) and pET15b (5708 bps). 
Constructs have been checked by sequencing and were the correct sequence. 
 











































Figure 2-2: Cloning of MDM2 RING domain: MDM2RING and MDM2RING△C. (A) PCR 
products are checked on the 1.2% agarose gel.  PCR reactions: 95℃, 5minuts; 30 cycles of 95℃, 
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30 seconds; 72℃, 45 seconds, and 37℃, 5 minutes. The sizes of those PCR products are 
respectively 387 bps (MDM2RING) and 346 bps (MDM2RING△C). (B) Constructs of pET15b-
MDM2RING are digested by the restriction enzymes NdeI/BamHI. The size of the smaller 
fragment is approximately 300 ~ 400 bps, similar to the expected size of 372 bps. The larger 
fragment (~ 5.7 kbps) is pET15b. Those constructs have been confirmed by sequencing.   
 
2.3 Protein expression 
High yields of pure proteins are required for protein crystallisation, NMR and biophysical 
experiments. We successfully cloned MDM2RING and MDM2RING △ C into the 
expression vector, pET15b. UbcH5a plasmid, a kind gift, from Professor Kathryn Ball, was 
cloned into pET15b. The pET expression system utilise IPTG-induced expression of the 
target protein. Recombinant protein expression is affected by various factors including: 
induction temperature, concentration of IPTG used, time post induction or the requirement 
for additives. Those factors can determine both the yield and quality of the over-expressed 
recombinant proteins. Therefore, a number of expression trials are required to determine 
optimal expression conditions. 
 
2.3.1 Materials and Methods: Protein Expression 
 Protein Expression 
A single colony was used to inoculate 5 ml LB (+ 100 μg/ml carbenicillin) followed by 
incubation at 37℃ overnight with agitation at 250 rpm. The overnight cell culture was 
transferred into fresh LB broth (+ 100 μg/ml carbenicillin) using a 1:40 inoculum ratio and 
was incubated at 37℃ for 1.5 ~ 2 hours until the O.D.600 reached 0.6 ~ 0.8. IPTG to a final 
concentration of 1 mM was added to the cell culture followed by incubation at 37℃ for 
another 5 hours to express the protein of interest. Cells were harvested by centrifugation at 
8,000 xg for 30 minutes. Cell pellets were frozen in liquid nitrogen and stored at -80 ℃. 
UbcH5a was expressed as above. Because MDM2RING and MDM2RING△C are zinc-
binding proteins, 100 μM ZnAcetate was added to cell cultures 15 minutes before the 
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 SDS-PAGE 
SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis, is a common 
technique to separate proteins based on their electrophoretic mobility. In this work, 15% 
SDS-PAGE was used to observe the purity of our target proteins. The recipes of each SDS-
PAGE we used were shown below: separation gel [4X Tris-SDS, pH8.0 (4.65 ml), 30% 
acrylamide (9.3 ml), sterile H2O (4.65 ml), 10% APS (15 μl) and TEMED (5 μl)] and 
stacking gel [8X Tris-SDS, pH6.8 (6.25 ml), 30% acrylamide (3.25 ml), sterile H2O (1.5 ml), 
10% APS (15 μl) and TEMED (5 μl)]. Sample (15 μl) was mixed with 2X loading dye (15μl) 
and heated at 95℃ for 5 minutes before loading into the gel. 
 
2.3.2 Results & Discussions: Protein expressions 
In this work, many expression trials were carried out to increase the level of expressions of 
the proteins, such as different expression cells, temperatures, and IPTG-induction times 
(Figure 2-3). MDM2RING, MDM2RING△C and UbcH5b, were expressed by 1 mM IPTG 
at 18℃ and 37℃, respectively, for different induction times. The level of the expression of 
the protein was detected using 15% SDS-PAGE. Results showed that, at an induction 
temperature of 18℃, MDM2RING was not expressed even after inducing for 3 ~ 5 hours, 
but only started to be over-expressed after being induced overnight (Figure 2-3B). Because 
MDM2RING is a zinc-binding protein, the addition of zinc metals should be beneficial to 
allow the protein to adopt the correct structure while it is expressed. However, for some cells, 
the addition of zinc metals may damage cell growth and reduce protein expression. Here, our 
results show that addition of zinc metals did not affect the protein expression (Figure 2-3B). 
MDM2RING was induced after 3 hours at 37℃. The expression levels of the cells induced 
for 5 hours or overnight did not increase significantly. The molecular weight of 6xHis-
MDM2RING and 6xHis-MDM2RING△C are respectively, 14.3 kDa, and 12.7 KDa. The 
intense protein bands on the 15% SDS-PAGE gels are the over-expressed proteins. The 
estimated molecular weights of those bands were higher than expected, perhaps as a result of 
negative charged surface or the conformation of denatured proteins reduced the motilities of 
6xHis-MDM2RING and 6xHis-MDM2RING△C. Another protein, UbcH5a, was cloned 
into pET15b, which has a 6XHis tag and thrombin cleavage site at its N-terminus. 6xHis-
UbcH5a, contains 168 amino acids and its predicted molecular weight is 18.9 kDa. 
Expression trials on His-tagged UbcH5a produced bands of the correct estimated weight 
when analysed by SDS-PAGE (Figure 2-3D).  
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Solubility is critical for structural studies and biological characterisation. Overexpressed 
proteins may be incorrectly folded and can form inclusion bodies, therefore controlling how 
much soluble protein is produced is very important. The cell pellets were resuspended in 
lysis buffer, followed by sonication (10s x 10 cycles, at 10-sec intervals) on ice, the soluble 
and insoluble proteins were separated by centrifugation at 13,000 xg for 30 minutes. Total 
protein and soluble fractions were tested on 15% SDS-PAGE gels. The results showed that 













Figure 2-3: Expression of purification of MDM2RING, MDM2RING△C, and UbcH5a. (A) 
Expression trails of MDM2RING transformed into different host cell types, respectively, to 
BL21(DE3), BL21(pLys) Rosetta(DE3)(pLys) and Rosetta(DE3)(RIPL). IPTG is added to a final 
concentration of 1 mM and the cells grow for 3 hours and overnight (O/N) at 37 ℃ . (B) 
MDM2RING is induced by the addition of 1 mM IPTG at incubated for 3, 5, and 16 hours, 
respectively, at 18℃ and 37℃. (C) Solubility tests of overexpressed proteins.  More than 95% 
expressed proteins are soluble. “T” presented total proteins and “S” meant soluble proteins. (D) 
Overexpression of UbcH5a. Arrows in those figures show over-expressed target proteins. 
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2.4 Protein Purification Strategy 
Several purification techniques were combined to achieve the goal of producing high yields 
of highly pure target proteins. The protein purification strategy consisted of immobilised 
metal affinity chromatorgraphy (IMAC), desalt chromatography, thrombin cleavage, 
benzamidine affinity chromatography and size exclusion chromatography (SEC) (Figure 2-4). 
First, we utilised the IMAC column to remove most of the contaminating proteins. Thrombin 
was used to remove the fusion tag from the target protein. To increase protein purity and 
homogeneity, benzamidine and size exclusion chromatography were used.  
 
Three proteins, MDM2RING, MDM2RING△C and UbcH5a were successfully purified. In 
this section, the basis of each chromatographic technique used in the work will be introduced 
and the results of each purification presented. In summary, for each protein we were able to 
achieve approximately 95% purity. All the columns used were purchased from GE 
Healthcare and detailed information of those columns is available from this website 
(http://www. gelifesciences.como). Thanks to the EPPF staff in the University of Edinburgh 














Figure 2-4: Overview of protein purification strategies used. Each method is introduced in 
great detail in the text the following sections.  
 
 
2.4.1 Immobilised Metal Affinity Chromatography (IMAC) 
  The basis and applications of IMAC 
IMAC, immobilised metal affinity chromatography, is a method to achieve purification by 
the coordination of the His．Tag to metal ions, such as Ni, Co, Zn, Fe and Cd. Proteins have 
a variety of amino acids, especially histidine, which bind to divalent metal ions. However, to 
increase the efficiency of purification, a recombinant protein usually has a fusion tag, such as 
a His-Tag. In this work, all of our constructs (MDM2RING, MDM2RING△C and UbcH5a) 
are fused with a 6xHis-Tag (His-Tag), which has strong affinities with divalent metals. 
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IMAC columns contain immobilised chelating groups, such as sepharose, which are cross-
linked to the agarose beads. Those immobilised chelating groups are charged with divalent 
metal ions, such as nickel and cobalt, which of both have high affinity with histidine residues 
and are commonly used for IMAC purification (Yip et al., 1989).  
 
In this work, cell pellets were treated by sonication or French press, and proteins were 
released from the cells. Cell lysate is a mixture of our fusion proteins (with His．Tag), other 
proteins without His．Tag, nucleotides, RNA and other metabolites. To separate the target 
protein from the cell lysate mixture, IMAC is a convenient and effective method. As shown 
in Figure 2-5A, our proteins with His．Tag bound tightly to the IMAC column. Other 
proteins and mixtures passed through the IMAC column to the waste fraction. To elute the 
target protein, several methods are available such as competitive elution or pH adjustment. In 
this current work, competitive elution was used by the addition of an excess amount of 
imidazole, which has stronger affinity with the nickel, allowing the target protein to be 
eluted from the IMAC column.   
 
 MDM2RING and MDM2RING△C were purified by IMAC 
Cell pellets of MDM2RING and MDM2RING△C were resuspended in binding buffer A [50 
mM Tris, 500 mM NaCl, 10 μM Zn Acetate, 2 mM DTT, 20 mM imidazole, pH 7.8]. Cells 
were lysed by pulsed sonication (10s x 10cycles, at 10-sec intervals) on ice. Cell lysate was 
then centrifuged at 22,000 xg for 30 minutes at 4 ℃. The resulting supernatant was filtered 
through 0.45 μm filters to remove small particles that may block and damage the column. 
IMAC was used as the first step for the purification of the histidine tagged protein. An 
IMAC Sepharose 6 Fast Flow column was charged with excess nickel sulfate (NiSO4) 
according to manufacturers’ protocol, followed by three washes in binding buffer A. Filtered 
sample was loaded onto a 5 ml IMAC column at a flow rate of 1 ml/min. Binding buffer A 
[50 mM Tris, 500 mM NaCl, 10 μM Zn Acetate, 2 mM DTT, 20 mM imidazole, pH7.8] and 
elution buffer B [50 mm Tris, 500 mM NaCl, 10 μM Zn Acetate, 2 mM DTT, 750 mM 
imidazole, pH7.8] were prepared for IMAC purification. Imidazole gradient elution was used 
to elute the His-Tag gel proteins. 
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 MDM2RING and MDM2RING△C were purified to approximately 95% after the first 
purification step by IMAC (red arrows, Figure 2-5 A & B). Two steps were used to elute the 
proteins: the first step of the purification method was to remove the majority of 
contaminating proteins using a low concentration of imidazole containing about 60 mM 
imidazole. The second step used imidazole gradient elution (8% to 100% buffer B) to elute 
the target proteins. At this stage, about 10 ~ 15 mg 6xHis-MDM2RING and 6xHis-


















Figure 2-5: Purification using IMAC. MDM2RING (A) and MDM2RING△C (B) are purified 
using an IMAC Sepharose 6 Fast Flow column charged with Ni2+. Unwanted proteins are 
removed at 8 % buffer B (~60 mM imidazole). MDM2RING and MDM2RING△C are eluted by 
imidazole gradient (8 to 100 % buffer B). SDS-PAGE analysis of several fractions from the 
purification shows that greater than 95% purity was achieved for the target protein. Red arrows 
indicate the target proteins. M: Marker; S: total protein.  
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2.4.2 Desalting chromatography 
Desalting chromatography is a fast, simple one step process to remove low molecular weight 
substrates that may interfere with subsequent purification, the stability or activities of the 
target proteins. The desalting column resin, Sephadex, made by cross-linked dextran with 
epichlorohydrin, is commonly used. There are several types of Sephadex available to 
separate different sizes of molecules. In general, Sephadex G-25 is well suited for the 
separation of globular proteins (M.W. >5,000 Daltons) from other smaller molecules such as 
salts or imidazoles (M.W. <1,000 Daltons). A desalting column was often used to remove 
imidazole and exchange the sample into the desired buffer for further purification or activity 
studies. In this current work, a HiPrep 26/10 desalting column was used to buffer exchange 
our sample into the desired buffer [20 mM Tris, 150 mM NaCl, 10 μM Zn Acetate, 2mM 
DTT, pH 7.2] for the subsequent experiment, thrombin cleavage. Buffer exchange was 
necessary as enzymatic activity of thrombin is low in a high concentration of salt and 
imidazole. 
 
2.4.3 His．tag removed by thrombin cleavage 
To avoid the effects of those tags that may interfere with the protein activity, some vectors, 
such as pET15b, are designed to attach a thrombin-specific recognition site between the 
His．Tag and the target protein (Figure 2-1B). Thrombin (EC 3.4.21.5) is a “trypsin-like” 
serine protease and its molecular weight is 36 kDa. Thrombin can recognise sequences 
“LVPRGS” and cleaves between Arg and Gly (Chane et al., 1985; Law et al., 1984). After 
the sample is treated with thrombin at the optimal conditions, fusion tag moieties will be 
cleaved off from target proteins.  
 
To reduce the possibility that a His ． tag moiety may interfere with biophysical 
characterisation or might inhibit crystallisation, the His ． Tag was removed from 
MDM2RING and MDM2RING△C by thrombin cleavage. Following IMAC and desalting 
steps, thrombin was added to samples of both 6xHis-thrombin-MDM2RING and 6xHis-
thrombin-MDM2RING△C. The efficiency of thrombin cleavage depends on the amounts of 
the enzymes, the reaction time, and incubation temperature. Preliminary experiments were 
carried out to find the optimal conditions to achieve complete digestion. 6xHis-MDM2RING 
was completely cleaved by 1, 2, 2.5, 5 and 10U thrombin at 20℃ for 4 hours, while the 
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complete digestion of 6xHis-MDM2RING was achieved with 5U and 10U thrombin at 4℃ 
for 16 hours. SDS-PAGE results showed the higher molecular weight band was 6xHis-
thrombin-MDM2, and the smaller was cleaved MDM2RING (Figure 2-6A). Considering the 
stability and activity of the proteins, the optimal condition for thrombin cleavage was 
determined to be 5U thrombin for 16 hours at 4 ℃. Another protein, MDM2RING△C was 
also obtained using the same conditions as above (Figure 2-6B). Following thrombin 












Figure 2-6: SDS-PAGE analysis of the thrombin cleavage trials. (A) 6xHis-MDM2RING is 
completely cleaved with all the amounts of thrombin tested at 4℃ for 16 hours or at 20 ℃ for 4 
hours. In the right panel, the structure in green shows MDM2RING and the cyan and magenta 
rectangles are thrombin cleavage site and 6xHis-Tag. (B) 6xHis- MDM2RING△C is also 
completely cleaved by thrombin at the optimal condition: incubation with 5 U thrombin at 4℃ 
for 16 hours. 
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2.4.4 Benzamidine Column 
Benzamidine is known as a strong and specific thrombin inhibitor. A HiTrap Benzamidine 
FF (high sub) column used in this work is made of highly cross-linked 4% agarose with p-
aminobenzamidine (pABA). To stop the thrombin cleavage reaction, samples in the 
thrombin cleavage buffer were transferred to the benzamidine buffer [50 mM Tris, 500 mM 
NaCl, 10 μM Zn Acetate, 2 mM DTT, 20 mM imidazole, pH8.0]. The samples were then 
loaded onto the benzamidine column, the cleaved protein of interest collected in the flow-
through, and the thrombin bound to the column. The samples were loaded onto an IMAC 
column again to remove uncleaved 6X His-thrombin moieties. Native target proteins can be 
collected in the flow-through fraction. Subsequently, native proteins were loaded onto a size 
exclusion column, Sephacryl S-200HR. 
 
2.4.5 Size Exclusion Chromatography (SEC) 
2.4.5.1 The basis and applications of SEC 
Size exclusion chromatography (SEC, also known as gel-filtration chromatography) is a 
technique to separate molecules based on the size (more accurately, the hydrodynamic 
volume) when they pass through the SEC medium. SEC media covers the molecular range 
from 100 to 80,000,000 Daltons. Therefore, SEC is well suited for the separation of 
macromolecular complexes, such as proteins, polysaccharides, or nucleic acids. The porosity 
of the SEC medium is chosen according to the molecular weight of the protein of the interest. 
In this work, Hi-Prep Sephacryl S-200HR was used for the purification of MDM2RING and 
MDM2RING△C, while Superdex 75 was chosen for the purification of UbcH5a. Small 
molecules can diffuse into interior of the smaller pores and therefore, are retained for longer 
through the whole column compared to larger molecules. Larger molecules are eluted faster 
and are therefore separated from smaller molecules.  
 
 SEC profiles of MDM2RING & MDM2RING△C  
In the purification strategies used throughout this project, SEC was the last purification step 
used to increase sample purity and provide an estimate of the molecular size of the target 
protein. HiPrep Sephacryl S-200HR was used in the SEC purification of MDM2RING and 
MDM2RING△C. The resolution range of Sephacryl S-200HR is 5,000 ~ 250,000 Daltons. 
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The buffer used in the SEC purification was 20 mM Tris (pH7.5), 150 mM NaCl, 10 μM Zn 
Acetate and 2mM DTT.  
 
The molecular weights of monomeric MDM2RING and monomeric MDM2RING△C were 
estimated to be 12.4 kDa and 10.8 kDa, respectively, according to their amino acid 
compositions. The SEC profiles of MDM2RING showed two major peak fractions (Figure 2-
7A). Molecules in the first peak were eluted at Vret (the retention volume) of 40ml, and the 
molecular weights were greater than 250 kDa. The second fraction was eluted at Vrent = 65 
ml, and the molecular weight were estimated at about 26 kDa. To confirm if both fractions 
contained MDM2RING, SDS-PAGE analysis was carried out. The result revealed that the 
sizes of both products were the same. The SEC profile of MDM2RING showed that 
MDM2RING might exist as a dimer (Vret = 65 ml) or higher oligomers (Vret = 40ml) (high 
order structured oligomers or aggregates). Another protein, MDM2RING△C eluted as a 
single species (eluted at Vret = 70 ml), and its molecular weight was estimated to be 22 kDa 
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(A) MDM2RING 
Column:                 Sephacryl S-200HR
Sample: MDM2RING
Sample volume: 1 ml
Buffer: 20 mM Tris HCL, 150 mM NaCl, 
100 μM ZnAcetate, pH 7.2













Column:                 Sephacryl S-200HR
Sample: MDM2RING△C
Sample volume: 1 ml
Buffer: 20 mM Tris HCL, 150 mM NaCl, 
100 μM ZnAcetate, pH 7.2
Flow rate:   1.0 ml/min      
 
 
Figure 2-7: Purification using SEC. MDM2RING (A) and MDM2RING△C (B)  are purified 
using Sephacryl S-200HR. (A) There are two major peaks on the SEC profile of MDM2RING. 
The molecular weight of the fraction in the first peak is larger than 250 kDa. Second peak is 26 
kDa. (B) There is one species (~ 22 kDa) in the SEC profile of MDM2RING△C. 
  Chapter 2 
 58 
Our SEC profiles showed that MDM2RING existed as a dimer or multimers and 
MDM2RING△C, a MDM2RING lacking the last 13 amino acids, was a dimer. Differences 
in the oligomeric states between MDM2RING and MDM2RING△C revealed that the last 
C-terminal 13 residues were involved in the oligomerisation. These results were consistent 
with previous reports which indicate that the C-terminus of RING-type proteins is 
responsible for the dimerisation/ oligomerisation of RING-E3 ligases, such as cIAP2, and 
BRCA1 (Brzovic et al., 2001; Mace et al., 2008). Because a proportion of MDM2RING2 
eluted in the void volume, further experiments were carried out to confirm whether the 
protein exist as non-specific aggregates or specific high molecular supramolecules (Chapter 
4). Previous report showed that GST-MDM2 (400–484) is monomeric (Poyurovsky et al., 
2007). In contrast, our MDM2RING△C (386-478) is a dimer. It is possible that the dimeric 
MDM2RING△C was due to the interactions between the longer N-terminal fragments 
(residue 386-400). Further support for the hypothesis can be found in the basis of published 
crystal structures of other E3 ligases: dimerisation of the cIAP2 RING homodimer and 
BRCA1/BARD1 RING heterodimer (Brzovic et al., 2001; Mace et al., 2008) are through the 
interactions of their N-terminal and C-terminal fragments.  
 
In summary, MDM2RING and MDM2RING△C were more than 95% pure after the SEC. 
Dimeric MDM2RING and MDM2RING△C were used in further biophysical and structural 
studies, as well as in activity assays. 
 
2.5 Purification of 6xHis-UbcH5a 
UbcH5a was cloned into an expression plasmid (pET15b), producing 6xHis-UbcH5a. Its 
molecular weight is 18.9 kDa and its pI value is estimated to be 7.94. The purification 
protocol used two steps IMAC and SEC. Two buffers were used in the IMAC step: buffer A 
(20 mM Tris, 150 mM NaCl, 20 mM imidazole, pH7.2), and buffer B (20 mM Tris and 150 
mM NaCl, 750 mM imidazole, pH7.2). A Sepharose 6 Fast Flow column (IMAC) was used 
first to remove the majority of the contaminating proteins, achieved by a wash of 8% buffer 
B (~ 60 mM imidazole). The target protein, 6xHis-UbcH5a was eluted with a gradient 
elution step, 8% to 100% Buffer B, (20 mM to 750 mM imidazole). The protein was greater 
than 95% pure following the first step (Figure 2-8A). Subsequently, SuperdexTM 75 (10/300 
GL) was used as the second purification step to remove imidazole from the sample and also 
further increase the purity. The buffer used in SEC was 20 mM Tris, 150 mM NaCl (pH7.2). 
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The SEC profile of 6xHis-UbcH5a showed that one single peak (Vret equivalent to 13.8 ml) 
with an estimated molecular weight of 20 kDa (Figure 2-8B). The result revealed that 6xHis-
UbcH5 is a monomer. In the expression and purification protocols described, 6 mg 6xHis-







Column:        Sepharose 6 Fast Flow
Sample: 6xHis-UbcH5a
Buffer: A: 20 mM Tris HCL, 150 mM NaCl, 20 mM imidazole, pH 7.2
B: 20 mM Tris HCL, 150 mM NaCl, 750 mM imidazole, pH 7.2
Flow rate:   5 ml/min      
50 100 150 200





Vrent = 13.8 mlmonomer
S
Column:                 SuperdexTM 75 (10/300 GL)
Sample: 6xHis-UbcH5a
Sample volume: 0.25 ml
Buffer: 20 mM Tris HCL, 150 mM NaCl, pH 7.2
Flow rate:   0.5 ml/min      
0 2 4 6 8 10 12 14 16
Elution volume (ml)  
Figure 2-8: Two step purification of 6xHis-UbcH5a. (A) IMAC Sepharose 6 Fast Flow column 
charged with Ni2+ and (B) SuperdexTM 75 (10/300 GL). SDS-PAGE analysis of the eluted 
fractions reveal that the purity is greater than 95%. 
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2.6 Matrix-Assisted Laser Desorption/ionisation Flight-of-Time Mass 
Spectrometry (MALDI-TOF MS) 
2.6.1 The basis and applications of MALDI-TOF MS 
Matrix-Assisted Laser Desorption/ionisation Time-of Flight Mass Spectrometry (MALDI-
TOF-MS) is commonly used, and is a sensitive ionisation mass spectrometry technique to 
determine the mass of biomolecules, such as proteins, nucleotides, sugars or organic 
molecules (Tanaka. et al., 1988; Karas et al., 1987). Moreover, MALDI-TOF-MS is also 
often applied to detect modification of molecules such as phosphorylation or methylation. In 
this current work, MALDI-TOF-MS was used to measure the mass of our constructs, 
MDM2RING, MDM2RING△C and UbcH5a.   
 
MALDI-TOF MS is a combination of two methods: an ionisation mechanism (MALDI) and 
a mass analyser (TOF). MALDI is one method to ionise the molecules and TOF is one type 
of mass spectrometry commonly used to determine the mass of molecules via a time 
measurement (Wollnik, 1993).The basic principle of MALDI-TOF-MS is that the molecules 
are ionised to become charged molecules which are accelerated by an electric field through a 
vacuum channel at different velocities to reach the detector. The advantage of MALDI is that 
the matrix facilitates vaporization and ionisation of the molecules and also protects the 
molecules from being destroyed by the laser beam. The m/z (mass/ charge ratio) determines 
time taken for ions to travel through the flight tube.  
 
In this section, the equipment used was a Voyager DE STR MALDI-TOF MS (Applied 
Biosystems Co.). The first step involves ionisation of the protein sample. A laser beam hits 
the sample previously spotted onto a metal plate together with a small quantity of matrix, 
typically, sinapic acid (3,5-dimethoxy-4-hydroxycinnamic acid), which then results in a 
transfer of the energy from the laser beam, via the matrix, into the sample (Beavis & Chait, 
1989 a & b). The sample is therefore ionised, into a number of different charges by various 
ionisation mechanisms (Knochenmuss, 2006). Because the parameters of the flight distance 
and the strength of electric field are known, the mass of the molecule can be calculated.  
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2.6.2 Results and Discussions: MALDI-TOF MS 
MALDI-TOF MS experiments were used to determine an accurate molecular mass for 
purified MDM2RING, MDM2RING△C and UbcH5a. 0.5 μl protein sample was spotted on 
to a gold mass spectrometry specific plate and then 0.5 μl sinapic acid matrix was added to 
enhance the ionisation of the sample. After the drop dried, the MS plate was loaded into the 
Voyager DE STR MALDI-TOF MS, and the analysis started. 
 
The MALDI-TOF MS profile of MDM2RING showed that there was one strong ion peak (at 
m/z = 12852.3) and one weak ion peak (at m/z = 6432.3) (Figure 2-9A). The former peak 
was assumed to be the species with one proton ([MDM2RING+1H]1+) and the latter peak 
was the species with two protons ([MDM2RING+2H]2+). The experimental molecular 
weight of MDM2RING was 12.85 kDa similar to the theoretical molecular weight, 12.47 
kDa (Calculated using Protein Calculator v3.3, a website that estimates the mass of a protein 
according to its primary amino acid composition (http://www.scripps.edu/ 
~cdputnam/protcalc.html)). The MALDI-TOF MS profile of MDM2RING△C also revealed 
one strong ion peak (at m/z = 10872.8) and one weak ion peak (at m/z = 5432.2), suggesting 
that the experimental molecular weight was 10.93 kDa, similar to the theoretical molecular 
weigh of MDM2RING△C, 10.74 kDa (Figure 2-9B). The MALDI-TOF MS profile of 6x-
UbcH5a showed that there was one dominant peak (at m/z = 18785.1), indicating that the 
experimental molecular weight was 18.8 kDa, similar to the theoretical molecular weight, 
18.9 kDa (Figure 2-9C). 
 
MALDI-TOF MS data revealed that there was one species in each sample. The calculated 
molecular mass suggested that both MDM2RING and MDM2RING △ C existed as 
monomers. These results were not consistent with the SEC profile results, which showed that 
MDM2RING proteins were dimers or higher order structured oligomers and that 
MDM2RING△C was a dimer. These differences may be due to the different means of 
characterisation. Proteins might tend to be detected as monomers by MALDI-TOF MS, as 
they are charged by a high voltage laser which may disrupt the dimer-dimer interactions 
resulting in only monomers being observed in the experiment. According to the MALDI-
TOF MS data, the experimental molecular weight of each purified monomers, MDM2RING, 
MDM2RING△C and 6xHis-UbcH5a was as expected (Table 2-1).  
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(A) MDM2RING 
MDM2RING = 12.85 kDa






























4999.0 8999.4 12999.8 17000.2
 
(C) 6xHis-UbcH5a 
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Figure 2-9: The molecular weight of purified MDM2RING, MDM2RING△C and 6xHis-
UbcH5a determined by MALDI-TOF mass spectrometry. (A) MDM2RING is 12.85 kDa. (B) 
MDM2RING△C is 10.93 kDa. (C) UbcH5a is 18.79 kDa. 
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Table 2-1: Molecular weights of three constructs obtained using different methods. 
* Theoretical molecular weight was estimated using Protein Calculator v3.3 on the basis of 
primary amino acid sequences.
Molecular Weight (kDa)
Constrcut  on-gel theoretical* MALDI-TOF MS SEC
MDM2RING
(386-491)
20~ 25 12.47 12.85




20 ~ 25 10.74 10.93  ~ 22




To sum up, the purity of three proteins, MDM2RING (residues 386-491), MDM2RING△C 
(residues386-478) and UbcH5a were more than 95%. On the SEC profiles, there were two 
major species in MDM2RING, dimeric and higher molecular weight oligomers, while 
MDM2RING△C existed predominately as a dimer. The yields of dimeric MDM2RING and 
dimeric MDM2RING△C from 1L cell culture were approximately 0.6 mg, and 3 mg, 
respectively. The SEC profile of UbcH5a demonstrated that UbcH5a is a monomer, and the 
yield was about 6 mg from 1L Cell culture. The MALDI-TOF MS methods confirmed that 
the molecular weight of each protein was as we expected. Following optimisation of the 
purification protocol, the three proteins of interest were highly purified and can be used for 
further biochemical, biophysical and structural studies. 
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3 Biochemical and Biophysical Characterisation of 




In this chapter, several methods were used to study the biochemical, biophysical and 
structural characteristics of MDM2RING and UbcH5a (as outlined in Figure 3-1). in vitro 
ubiquitination assays were used to test whether MDM2RING, residues 386-491, and 
MDM2RING△C, residues 386-478, have E3 ligase activity and can ubiquinate p53 (Section 
3.1). To understand the oligomerisation state of those proteins, dynamic light scattering 
(DLS) and size exclusion chromatography (SEC) were used (Section 3.2). The thermal 
denaturation assay (TDA) has been used for identification of the folded state of proteins and 
to provide an assessment of the thermal stability of these proteins (Section 3.3). Circular 
dichroism spectroscopy (CD) also has been applied to study whether those proteins are 
folded or unfolded, and also to monitor the thermal stability (Section 3.4). Further structural 
studies using crystallization, negative staining transmission electron microscopy (TEM) and 






















Figure 3-1: The work flow of analyses applied in the characterisation studies of 
MDM2RING, MDM2RING△C and UbcH5a in this thesis. 
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3.1 in vitro ubiquitination 
3.1.1 the basis of in vitro ubiquitination 
Ubiquitination is a critical mechanism in cells (described detail in Chapter 1). Several 
proteins are involved: E1 (ubiquitin activating protein), E2 (ubiquitin conjugating protein), 
E3 (ubiquitin kinase protein) and Ub (ubiquitin) (detail introduced in Chapter 1). To test the 
E3 ligase activity of MDM2 protein, we carried out an in vitro ubiquitination reaction. 
MDM2 has a RING domain, which possesses E3 ligase activity; therefore, the in vitro 
ubiquitination assay data is an indicator which confirms whether our MDM2RING has 
proper E3 ligase function. As with in vivo ubiquitination, the reaction mixture contains E1 
(Ube1), E2, E3 and Ub proteins. In addition, ATP, substrates (such as p53), CK (creatine 
kinase) and CP (creatine phosphate) are also needed for the reaction. For the first step of 
ubiquitination, ATP is critical to activate Ub and induce the interaction of Ub and E1 protein. 
To maintain the concentration of ATP throughout the reaction, CP and CK are added to 
produce ATP from ADP. Following successful ubiquitination, the substrate will be modified 
with mono- or poly-ubiquitins (Figure 3-2). In this work, the E3 ligase activity of MDM2 
was characterised by the extent of p53 ubiquitination. After the ubiquitination reaction, the 
sample was analysed using gradient SDS-PAGE, ubiquitinated p53 were detected by western 
blotting (Figure 3-2B). Antibody D01 (against p53) was used to detect p53 and ubiquitinated 
p53.  
 






























Figure 3-2: in vitro ubiquitination assay. (A) Schematic representation of the in vitro 
ubiquitination assay. (B) MDM2RING protein shows E3 activity and ubiquitinated p53. 10 ng 
FLMDM2 is used in this experiment. 
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3.1.2 Materials and Methods: in vitro ubiquitination assay 
The protocol for an in vitro ubiquitination assay is as below (for 16 reactions): 366 μl H2O, 
10 μl 1M Hepes (pH8) (stored in fridge), 2.4 μl 1M MgCl2, 2μl 10% Triton X, 0.2 μl 1M 
DTT, 0.4 μl 1M benzamidine, 3.2μl 10mg/ml ubiquitin, 6μl ATP 0.2M , and mix them 
gently by inversion (remove bubbles on cap). 4 μl 1M CP (creatine phosphate) and 2μl 
10mg/ml CK (creatine kianse) were added into the reaction solution, and mixed gently by 
inversion. Next, 0.7 μl E1 Ube1 (0.55 mg/ml; 5μM; 110 kDa, purchase from Bioscience Co.) 
and 0.48 μl E2 UbcH5a (2.5 mg/ml) were added and mixed gently. Finally, the substrate was 
added for example p53 (0.5μg), and E3 ligase (0.2 μl/reaction, 120 ng). 22 μl reaction 
solution was aliquoted into each tube, and incubated at 30℃ for 10 minutes.  
 
To stop the reaction, 22 μl loading dye was added to each sample, followed by heating at 
95℃ for 5 minutes. Then samples were then put on ice before being loaded onto a ready 
made gradient gel, NuPAGE 4~12% (Invitrogen Co.). For each gel, a prestained marker (5 
μl/well) was loaded into one well, and 20 μl of each sample was loaded. The tank was filled 
with NuPAGE buffer (diluted to a 1 X stock). The gel was run at 180 Volts for 2 hours. 
Following electrophoresis, western blotting was used to transfer the proteins from the gel to 
nitrocellulose membrane using 130 volts for 1 hour. 1L transfer buffer contains 100 ml (10X 
transfer buffer), 200 ml methanol, and 700 ml H2O.  
 
The membrane was blocked using 5% milk in a 1X PBST (100ml 10X PBST, 1ml Tween 20 
in 900ml H2O) and put on the shaker at room temperature for 20 minutes. The membrane 
was given three five minutes washes in PBST.  The primary antibody used was D01, an anti-
p53 antibody, diluted 1 in 5000 in 1XPBST+5% milk. 3 ml of the diluted primary antibody 
was used for each membrane. After incubation with 1°-Ab, D01, for 1 hour at room 
temperature (or overnight in the cold room), the membrane was washed three times in 1X 
PBST each time for 5 minutes. The secondary antibody (A26, anti-mouse) was diluted 1 in 
2000 in 1XPBST + 5% milk. 3ml diluted 2°-Ab was added to each membrane, and the blot 
incubated on the bench for 1 hour. The membrane was given three times five minute washes 
in 1XPBST. Chemiluminescent development reagent (TCL: ECL =1:1 (v:v)) was prepared 
and mixed, prior to adding it to the membrane for 1 minute followed by detection using 
photographic film. 
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3.1.3 Results and Discussion: in vitro ubiquitination 
 MDM2RING, residues 386-491, ubiquitinates p53 
The in vitro ubiquitination method has been widely used to study the function of E3 ligases. 
The in vitro ubiquitination methodology used in this thesis has been developed in Kathryn 
Ball’s group (Wawrzynow et al., 2009), showing that FLMDM2 has E3 ligase activity to 
ubiquitinate p53 (Figure 3-2B). Several reports have shown that FLMDM2 can bind p53 
through interactions with the N-transactivation and acidic domains, and facilitate p53 
ubiquitination (Moll & Petrenko, 2003; Uldrijan et al., 2007; Wawrzynow et al., 2009). 
Previous work also showed that MDM2RING can autoubiquitinate itself (Kostic et al., 2006; 
Linke et al., 2008; Poyurovsky et al., 2007), however, there is no report yet to indicate that 
MDM2RING can ubiquitinate p53. 
 
Our construct MDM2RING, residues 386-491, can ubiquitinate p53, suggesting that 
MDM2RING may contain a putative p53 binding site. Moreover, on the basis of previous 
reports (Goldberg et al., 2002; Maya et al., 2001; Khosravi et al., 1999; Shinozaki et al., 
2003), MDM2 residue Tyr394 (phosphorylated by c-Abl) or Ser395 (phosphorylated by 
ATM) or Ser407 (phosphorylated by ATR) inhibits MDM2 E3 activity and activates p53 
function. Phosphorylated MDM2 has been shown to attenuate the cytoplasmic export of p53. 
It is still probable, however, that phosphorylated MDM2 changes its conformation which 
disfavours p53-binding. Alternatively, phosphate competes with p53 to bind to this motif. 
Presumably, if our MDM2RING has a new p53 binding site within the N-terminal fragment 
proceeding the RING domain, our MDM2RING should bind and ubiquinate p53. As we 
expected, in vitro ubiquitination assay results showed that our MDM2RING (residue 386-
491), could ubiquitinate p53 (Figure 3-3). These data demonstrated that there must be a 
motif in our MDM2RING constructs that interacts with p53 and facilitates MDM2-mediated 
ubiquitination of p53.  
 
To test the hypothesis that this new p53 binding motif was located in the N-terminal 
fragment of MDM2RING, one deletion construct, MDM2RING△C (residue 386-478) was 
chosen to test its E3 ligase activity. If the new p53-binding motif was positioned in the N-
terminus of MDM2RING, it should be possible to detect ubiquitinated p53. As shown in 
Figure 3-3, MDM2RING △ C did have E3 ligase activity against ubiquitinated p53, 
demonstrating that a new p53-binding motif must be at the N-terminus of MDM2RING. 
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Although the exact p53-binding site still needs to be identified, these data provide additional 
evidence that the N-terminus of MDM2RING is essential for MDM2-dependent 
ubiquitination of p53.  











Figure 3-3: in vitro ubiquitination studies of the MDM2RING or MDM2RING △ C- 
mediated ubiquitination of p53. Ubiquitination reactions are assembled with p53, E1, and E2 in 
the presence of MDM2RING or MDM2RING△C. Unmodified (p53) and ubiquitinated p53 
(p53-Ub(n)) are detected using antibody DO-1.  
 
 MDM2RING has higher E3 ligase activity than MDM2RING△C 
Titration experiments with MDM2RING showed that 10 ng MDM2RING had similar E3 
activity to than seen with 200 ng MDM2RING△C (Figure 3-3). To determine the minimum 
amount of MDM2RING required for an in vitro ubiquitination assay, titration experiments 
were carried out ranging from 1 ng to 500 ng of MDM2RING. Results showed that 1, 5, 10, 
50, and 100 ng MDM2RING had similar E3 ligase activities (Figure 3-4), whilst 200 ng and 
500 ng protein showed reduced E3 activity. Consistent with previous report (Poyurovsky et 
al., 2007), it is of note that MDM2RING (residues 400-491) has stronger E3 ligase activity at 
low concentrations than high concentrations. 
 
Moreover, Figure 3-3 showed that MDM2RING has stronger E3 ligase activity than 
MDM2RING△C (Figure 3-3), indicating that 200 ng of MDM2RING△C had weaker E3 
ligase activity compared to that seen with the same amount of MDM2RING (200 ng). These 
results are consistent with previous studies noting that the C-terminus of MDM2RING plays 
an important role in E3 activity (Fang et al., 2000; Kawai et al., 2007).  






Figure 3-4: The E3 ligase activity of FLMDM2 and MDM2RING using in vitro 
ubiquitination assay.  Titration experiments of MDM2RING are used to test its E3 ligase 
activity in the range of 1 to 500 ng. 
 
 the potential role of the MDM2RING N-terminus for E2-binding 
The larger MDM2RING△C construct has E3 ligase activity, inconsistent with other studies 
that indicate that MDM2 C-terminal mutants or deletions lose their E3 activity (Line et al., 
2006). For example, full length MDM2△7 (residue 1-484), full-length MDM2Y489A or 
full-length MDM2F490A lose their E3 activity (Poyurovsky et al., 2007; Uldrijan et al., 
2007). One possible explanation is that our MDM2RING△C construct has an extended N-
terminal domain which might provide necessary contacts with its cognate E2 protein, 
UbcH5a, facilitating the ubiquitination reaction. Based on the crystal structure of cIPA2-
UbcH5b, cIAP2 proteins have interactions with their E2 partners through two regions: the N-
terminus and C-terminus (Mace et al., 2008). Previous report indicated that the last five C-
terminal residues are essential for MDM2 E3 ligase (Linke et al., 2008). Their MDM2 
mutants (residues 432-479) or MDM2F490A mutant lost E3 ligase activity. Compared to 
previous MDM2 constructs, our MDM2RING△C (residues 386-478) has a longer N-
terminal fragment, suggesting that the additional residues may play a key role in E2-binding. 
Additionally, evidence comes from the crystal structure of the c-Cbl-Ubc13 complex, in 
which a linker preceding the U-type E3 domain seems to be responsible for the interactions 
with Ubc13 (Zheng et al., 2005) (Figure 3-5). The linker is between c-Cbl N-terminal TKB 
domain and C-terminal RING-type E3 domain including two intermolecular hydrogen bonds 
between C-Cbl Glu369 and UbcH7 Arg5 and c-Cbl Glu366 and UbcH7 Arg15. The c-Cbl 
linker contains several polar and charged residues. Corresponding residues in MDM2 are 
also polar and charged, and this observation may explain why our MDM2RING△C is E3 
active as the N-terminal region provides additional interaction with the E2 protein (Figure 3-
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5). Moreover, it has been noted that MDM2RING (residues 400-491) could autoubiquitinate 
itself, but MDM2RING deletion (residues 400-484) lost its E3 activity (Poyurovsky et al., 
2007). Taken together, our data suggest that an uncharacterised extended N-terminus 
(residues 386-400) in our MDM2RING△C may play an unidentified role in contributing to 
maintenance of MDM2RING△C E3 ligase activity. 
(A) 
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Figure 3-5: The role of the N-terminal fragment of RING/U-type E3 ligases. (A) Sequence 
alignment of c-Cbl linker and the N-terminal fragment proceeding MDM2/MDMX RING 
domain. Those fragments contain several polar and charged residues. c-Cbl residues forming H-
bonds with UbcH7 are highlighted by a red star. (B) MDM2 RING (green) domain is 
superimposed onto the cCbl RING domain (yellow) of the cCbl-UbcH7 complex (PDB code: 
1FBV). c-Cbl RING domain and the linker interact with UbcH7. 
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 a hypothesis of MDM2RING-mediated ubiquitination of p53 
It has been widely noted that the N-hydrophobic domain (i) and acidic domain (ii) in MDM2 
play essential roles in the interactions with p53 (Fang et al., 2000; Wallace et al., 2006). A 
careful analysis of the literature coupled with the new finding discussed in this work has 
allowed a new hypothesis to be proposed: a new motif preceding the N-terminal fragment of 
the RING domain (iii) is also critical for p53-binding (Figure 3-6). Both our MDM2RING 
and MDM2RING△C constructs could ubiquitinate p53, and this suggests that the motif 
responsible for the p53-binding must be located in the N-terminal fragment preceding the 
RING domain, rather than the C-terminus. Additional supporting evidence for our hypothesis 
comes from another MDM2RING construct, residues 396-491, which also ubiquitinates p53. 
Moreover, it has been noted that MDM2S386D can ubiquitinate MDMX, but not p53 (Cheng, 
et al., 2009).  
 
In our model, tetrameric p53 interacts with the hydrophobic domain (Hy), and the acidic 
domain (Ac) of MDM2 and induces a conformational change, subsequently opening the third 
p53-binding site to process the ubiquitination of p53 (Figure 3-6A). For the MDM2RING-
mediated ubiquitination, the third p53-binding site in MDM2RING is easily accessible for 
p53-binding (Figure 3-6B). Additionally, combined with our previous analysis of the 
sequence and structural alignments of MDM2 and c-Cbl, the N-terminal motif preceding the 
MDM2RING may play a role in the interaction with its cognate E2 (UbcH5a) as seen in the 
c-Cbl linker. Taken together, we proposed that the interaction of p53 with a third binding 
motif (iii) may be essential to bring MDM2RING domain (charged-UbcH5a attached) close 
to the substrate and facilitate the transfer of ubiquitin to p53 (Figure 3-6A & B). This model 
provides a putative explanation for FLMDM2-mediated and MDM2RING-mediated 
ubiquitination of p53. Consideration of MDM2 proteins easily becoming oligomers, we also 
propose a model of the interactions between the oligomeric MDM2 RING proteins with 
UbcH5a and tetrameric p53 (Figure 3-6C). However, these proposals await further 

















































(A) Full-length MDM2-mediated ubiquitination of p53
(B) MDM2RING-mediated ubiquitination of p53
 

































Figure 3-6: The proposed model of the p53-MDM2-UbcH5a-Ub complex. (A) Full-length 
MDM2-mediated ubiquitination of p53. Three binding sites on MDM2: hydrophobic domain (i), 
Acidic domain (ii) and the N-terminal fragment of MDM2RING (a linker, iii). (B) MDMRING-
mediated ubiquitination of p53 is achieved through binding of MDM2 linker (iii) to bring the p53 
and the charged-UbcH5a (Ub-UbcH5a) closer to facilitate the transfer of Ub. Hy: hydrophobic 
domain; Ac: acidic domain; RING: RING domain; Ub: Ubiquitin. (C) the interaction between 
oligomeric MDM2 RING proteins with UbcH5a and p53 
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3.2 Oligomeric state studies using dynamic light scattering 
3.2.1 The Principle of dynamic light scattering 
Dynamic light scattering (DLS) is used to measure the hydrodynamic size and polydispersity 
of molecules and particles, including proteins and nanoparticles, in solution. DLS is also 
referred to as Quasi-Elastic Light scattering (QELS) or Photon Correlation Spectroscopy 
(PCS) and was first used the 1960s (Berne and Pecora, 1976; Brown, 1993; Earnshaw and 
Steer, 1983; Johnson and Gabriel, 1994). The principle of DLS is that the laser beam passes 
through a focusing lens hits the moving particles in solution, resulting in light scattering at 
all angles while the light hit the particles (Figure 3-7). Generally, to simplify the effect of the 
scattered light, there is only one detector on the instrument at 90 degrees to record the 
scattered light. The scattered light passes through coherence optics and is detected by a 
photomultiplier, also called the digital correlator, which is designed to immediately convert 


















Figure 3-7: The diagram illustrates the basic mechanism of the dynamic light scattering 
(DLS) instrument. The size of the sample is able to be measured according to the intensity 
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The advantages are that sample concentration can be low and the sample can be recovered. 
DLS is used to measure the diameter of the hypothetical hard sphere of a particle. However, 
protein molecules are dynamic and non-spherical. Therefore, the measured diameter is the 
apparent size of the dynamic particle (the hydrodynamic diameter). Therefore, DLS can be 
used to determine the oligomeric state of proteins according to the measured hydrodynamic 
sizes. For small proteins, DLS may be less accurate when compared to classical light 
scattering. However, it is still a convenient preliminary method to determine the size of the 
samples in solution, the stability of the proteins in various buffer conditions, and also useful 
for preliminary screens to determine the optimum conditions for crystallography (Jia et al., 
2005; Wilson, 2003). In this section, the DLS analysis is performed on a Zetasizer APS 
instrument designed by Malvern Co. Furthermore, to avoid noisy signals produced by 
aggregates, the sample was filtered by the syringe filter (0.22 μm) prior to loading into the 
well. A minimum of 60 μl at 0.5 mg/ml was required for each sample to be analysed.  
 
3.2.2 Oligomeric states of MDM2RING 
 Hydrodynamic diameter of MDM2RING by SEC and DLS 
There were several peaks in the SEC profile of MDM2RING, when purified using a 
Sephacryl S-200HR column. The two major peaks were at a Vret of 40 ml (>160 kDa ), and at 
Vret of 65 ml (20 ~ 40 kDa) (Figure 3-8A). The theoretical molecular weight of monomeric 
MDM2RING was 12.47 kDa. The SEC profile suggested that MDM2RING might exist as 
higher molecular weight oligomers and as tetramer or dimer. To further characterise the 
oligomeric state of MDM2RING, dynamic light screening (DLS) was used.  
 
The concentration of protein required for DLS is at least 0.5 mg/ml. The second major peak 
from the Sephacryl S-200HR column was collected and the protein concentrated to 40 μM 
(=0.5mg/12470 daltons). The measured hydrodynamic diameter of 40 μM MDM2RING was 
6.7 nm (67 Å) (Figure 3-8B). According to the known crystal structure of the MDM2-
MDMX heterodimer (PDB code: 2VJE), the hydrodynamic diameter of a monomer is 
approximately 33.8 ~36.1 Å, and that of the dimer is approximately 33.7 ~ 47.7 Å (Figure 3-
8C). Therefore, 40 μM MDM2RING did not exist as either a monomer or a dimer. Moreover, 
the calculated molecular weight of MDM2RING by DLS is 58 ~60 kDa, the data therefore 
suggested that MDM2RING may exist as a hexamer.  
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(PDB: 2HDP)  
Figure 3-8: Oligomeric states of MDM2RING are measured by dynamic light scattering. (A) 
The SEC data show that there are two major populations of MDM2RING: higher molecular 
weight oligomers MDM2 at Vret = 40 ml (>160 kDa) and dimer/tetramer MDM2RING at Vret = 
65 ml about 20 ~ 40 kDa. (B) DLS data show that the experimental hydrodynamic diameter and 
the estimated molecular weight of the eluted protein solutions from the fraction (Vret=65 ml) is 
6.7 nm and 58~60 kDa, respectively. The concentration of the tested MDM2RING is 40 μM. (C) 
The hypothetical hydrodynamic diameter of monomeric MDM2RING or dimeric 
MDM2RING/MDMXRING is shown based on the crystal structure of MDM2-MDMX 
heterodimer (PDB code: 2VJE). 
 
 Concentration-dependent oligomerisation of MDM2RING 
During the purification of MDM2RING, we observed a concentration-dependent 
oligomerisation of the protein as seen in the SEC profiles when using a superdex 200 column 
(Figure 3-9A). At low concentrations, 0.3 mg/ml (24 μM) or 1.0 mg/ml (80 μM) 
MDM2RING, the major peak eluted at about 15ml (M.W.estm. = 25 ~ 30 kDa) (Figure 3-9A, 
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red & gray lines). When MDM2RING was concentrated to 1.7 mg/ml (136 μM) or 1.9 
mg/ml (152 μM), there were two major peaks on the size exclusion profile: one at 15 ml 
whilst higher molecular weight oligomers eluted at 10.7 ml (M.W.estm. > 440 kDa) (Figure 3-
9A, cyan and blue lines). The SEC data therefore suggests a concentration dependent 
oligomerisation of MDM2RING resulting in a very high proportion of multimers being 
produced at concentrations above 100 μM.    
 
To confirm the SEC data with respect to the concentration-dependent oligomerisation seen, 
DLS was used. Different concentrations of MDM2RING (42.6 μM, 82.0 μM and 163.9 μM) 
were used. DLS data shown in Figure 3-9B indicated that the hydrodynamic diameter of the 
42.6 μM and 82.0 μM MDM2RING samples were both approximately 7 nm with a predicted 
molecular weight of 68 kDa. As we expected, concentrated proteins (163.9 μM) formed 
larger particles (>1000 kDa).  
 
Differences were seen in the calculated molecular weights of MDM2RING as detected by 
SEC and DLS. One reason was that DLS detects the particles in solution in a mobile state, 
and was sensitive to any particle in the solution. The DLS technique is more sensitive to 
larger particles rather than small molecules, such as our constructs. Because the small 
particles are easily affected by Brownian motion, it is not easy to obtain an accurate 
molecular weight of the small particles at lower concentrations. However, results obtained 
from SEC and DLS both showed that MDM2RING became higher molecular weight 
oligomers at higher concentrations. This finding is similar to that of another group that also 
showed their construct, MDM2RING easily aggregates (or oligomerises) at a concentration 
higher than 120 μM (Kostic et al., 2006). We maintained our purified MDM2RING at less 
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(A) Size exclusion chromatography (superdex 200) 
 
 
(B) Dynamic light scattering 
 
 
Figure 3-9: The oligomeric state of MDM2RING appears concentration-dependent when 
analysed by size exclusion chromatography (SEC) and dynamic light scattering (DLS). (A) 
A greater proportion of proteins are eluted in the void fraction when a more concentrated sample 
of MDM2 RING protein is applied to the superdex200 column. Red curve: 24 μM, gray curve: 80 
μM, cyan curve: 136 μM and blue curve: 152 μM. (B) The results from dynamic light scattering 
indicated that highly concentrated MDM2RING easily become higher oligomers. MDM2RING 
42.6 μM and 82.0 μM exist as lower molecular weight entitles (~ 68 kDa), and became higher 
molecular weight oligomers at a concentration of 163.9 μM. 
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3.2.3 Oligomeric states of MDM2RING△C 
MDM2RING△C protein is a dimer based on the SEC data (Figure 2-7B). To test whether 
the MDM2RING△C protein also tends to become aggregated at higher concentrations (as 
seen with the MDM2RING), we analysed concentrated MDM2RING△C (~ 200 μM) by 
DLS. The result showed that the hydrodynamic diameter of MDM2RING△C was 
approximately 4.4 nm, with a predicted molecular size of 22~28 kDa. Monomeric 
MDM2RING△C theoretically was 10.88 kDa based on its amino acid sequence. These 
results suggest that MDM2RING△C exists as a homo dimer even at higher protein 
concentrations (Figure 3-10A). To clarify if the concentration of NaCl in the buffer affects 
the oligomeric status of MDM2RING△C, we also tested MDM2RING△C in different ionic 
strengths buffers, such as 50 mM and 150 mM NaCl (Figure 3-10B). Data showed that there 
were no differences in the size distribution of MDM2RING△C in both buffers. In summary, 
the differences seen in the oligomeric states of MDM2 RING△C and MDM2RING showed 
that the C-terminal thirteen amino acids play a critical role in the concentration-dependent 
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Figure 3-10: A high concentration 200 μM of MDM2RING△C protein are analysed by 
DLS (A), comparing two different ionic strength buffers (B). The predicted molecular weight 
suggests that MDM2RING△C was dimeric (~ 22 kDa) and not affected by change in ionic 
strength of the buffer.   
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3.2.4 Oligomeric states of UbcH5a 
The oligomeric state of UbcH5a was analysed by various methods, such as gel filtration 
chromatography, MALDI-TOF mass spectrometry and dynamic light scattering, and these 
results revealed UbcH5a was monomeric. There was single peak on gel filtration 
chromatography, with an estimated molecular weight of 20 kDa (Chapter 2, Figure 2-8B). A 
single major peak is seen with MALDI-TOF mass spectrometry (Chapter 2, Figure 2-8C) 
with an estimated molecular weight of approximate 18.8 kDa. We also used dynamic light 
scattering to further characterise the oligomeric status of UbcH5a and to test the stability of 
UbcH5a in the storage buffer (50 mM Tris, 150 mM NaCl, pH7.2). DLS data showed that 
the hydrodynamic diameter of UbcH5a was 3.95 nm, and the molecular weight was 
approximate 18 kDa. Consistent with our previous analysis, DLS data (Figure 3-11) 
demonstrated that UbcH5a existed as a monomer even at higher concentrations (2 mg/ml), 




Figure 3-11: The oligomeric status of UbcH5a was analysed by dynamic light scattering. 
Purified UbcH5a at a concentration of 2mg/ml in storage buffer (50 mM Tris, 150 mM NaCl, 
pH7.2) was analysed and showed that its calculated hydrodynamic diameter is 3.9 nm with an 
estimated molecular weight of approximately 18 kDa. 
 
3.3 Thermal Denaturation Assay (TDA) 
3.3.1 The Principle of TDA 
The thermal denaturation assay (TDA), also called thermal fluorescence assay (TFA) or 
thermal shift assay (TSA), is an efficient and simple technique to study the thermal stability 
of proteins. This technique has broad applications in screening for protein stability in 
different buffers with additives or salts to determine the optimal buffer for any given protein. 
It is critical to maintain the stability of proteins in an appropriate buffer to enable further 
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studies, such as biophysical characterisation, bioactivity, and structural studies, including 
NMR and crystallography (Chung, 2007; Ericsson et al., 2006). TDA is also a fast and 
efficient method to test the interaction of proteins and potential ligands (Lo et al., 2002; 
Pantoliano et al., 2001). Thermal stabilities of apo-protein and protein-ligand complexes are 
different. Moreover, several reports have shown that the melting temperatures (Tm) obtained 
by TDA are consistent with other techniques including circular dichroism (Kelly & Price, 
1997), and differential scanning calorimetry (Freirey, 1995). The Tm value, the melting 
temperature of the protein, is defined as the temperature at which the amounts of folded and 
unfolded proteins are equal in solution. The Tm value acts as an indicator of the stability of 
the protein. Compared to other methods, some of the advantages of TDA are that only a 
small amount of protein is required per experiment (1~15 μg) and that the experiment can be 
carried out on a commercially available real-time PCR machine, making the technique 
accessible to laboratories without ready access to highly specialised equipment. The 
technique is also relatively high throughput using a 96 well format plate with an average run 
time of less than an hour.  
 
The basic principle of the thermal denaturation assay is the detection of fluorescence emitted 
by a fluorophore bound to folded and unfolded proteins (Figure 3-12). A hydrophobic 
environmentally sensitive fluorophore, such as Sypro Orange (yellow star, Figure 3-12), is 
commonly used to monitor protein unfolding (Ericsson et al., 2006). The Sypro Orange 
probe is easily quenched in an aqueous environment within the folded protein. When the 
protein starts to undergo thermal unfolding as the temperature increases, hydrophobic region 
of the unfolding protein are exposed. Sypro Orange preferentially binds to hydrophobic 
regions of unfolded proteins, resulting in a significant increase in fluorescence emissions. 
After the fluorescence intensity reaches a maximum, the fluorescence intensity starts to 
decrease as the complex of denatured protein and Sypro Orange probe precipitates. The 
melting transition curves reveal differences in the fluorescence intensity of the folded vs. the 
unfolded protein as a function of temperature..  
 
3.3.2 Material and Methods: TDA 
1~15 μg protein and 5X Sypro Orange dye, a fluorescent dye, were added to each well of a 
96-well thin-wall PCR plate (Bio-Rad), the final volume of the sample was 50 μl. The plate 
was sealed with Optical-Quality Sealing Tape (Bio-Rad). The experiment was performed on 
an iCycler iQ Real Time PCR Detection System (IQ5) (BioRad): the experimental set up 
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was as described below: 1℃ increment per 30s hold time with temperature intervals from 20 
~ 90℃. The data were automatically analysed to provide a value for the melting point (Tm). 

















Figure 3-12: The principle of TDA method. Fluorescent dye, Sypro Orange (yellow stars), 
preferentially bind to hydrophobic residues (cyan ellipses), which usually are buried within the 
protein. As the temperature increases, the proteins unfold, exposing hydrophobic residues, 
allowing the Sypro Orange to bind to the hydrophobic residues, resulting in an increase in the 
fluorescence signals detected. The fluorescence intensities decrease when the proteins become 
denatured and aggregated at high temperatures. The red dashed line indicates the Tm value, the 
melting temperature referred to as the midpoint of the unfolding transition of a protein. 
 
 
3.3.3 Results & Discussions: TDA 
 MDM2RING is a metal-binding protein  
TDA results showed that there was no clear melting transition curves observed for 
MDM2RING. Besides, initially, high fluorescence intensities were observed that dropped 
gradually after the temperature increased (Figure 3-13A). Fluorescence intensities of 500 
RFU were detected at the start of the analysis for 10 μM MDM2RING. No clear melting 
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transition curves may be due to the high hydrophobicity of the metal-binding protein. The 
solution structure of MDM2 homodimer showed that MDM2 RING domain is folded tightly 
through interactions with two zinc ions (Kostic et al., 2006; Linke et al., 2008), possibly 
resulting in MDM2RING being thermally stable and being difficult to unfold as the 
temperature increases. At high temperature, precipitated MDM2RING might shield the 
hydrophobic part and Sypro Orange dye also denatured; therefore, there was no detectable 
increase in fluorescence intensity. In order to confirm the assumption that our MDM2RING 
is folded and tightly interacts with zinc ions, we added excess EDTA to chelate the zinc ions 
from MDM2RING, and test the thermal stability of MDM2RING in the buffer with EDTA. 
Two zinc ions have been noted to play a structural role in MDM2RING (Figure 3-14): the 
first zinc binding site is formed by Cys438, Cys441, Cys 461 and Cys 464, and the second 
one is formed by His452, His457, Cys475 and Cys478. Therefore, without the zinc ions, 
MDM2RING should have less structural integrity, resulting in the hydrophobic part of 
MDM2RING being easily exposed as the temperature increases. Sypro Orange could then 
bind to an exposed hydrophobic part of the unfolding MDM2RING, producing a rise in 
fluorescence intensity.  
 
As expected, in the presence of EDTA, our TDA studies of MDM2RING showed that there 
was a clear melting transition curve. Tm for MDM2RING in the presence of excess EDTA 
(about 10 fold) was approximately 47.6℃ (Figure 3-13B). If MDM2RING initially is an 
unfolded protein, there will be a similar melting transition curve of MDM2RING seen in 
solution with or without EDTA (Figure 3-13A). Because there was a clear melting transition 
curve observed after the addition of EDTA, these results confirmed that MDM2RING is a 
folded zinc binding protein, as addition of EDTA which chelates the zinc ions from 
MDM2RING resulted in MDM2RING becoming more flexible and easily unfolded at  
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Figure 3-13: The thermal stability of MDM2RING was analysed by TDA. (A) 10 μM 
MDM2RING was analysed using TDA and showed no clear transition melting curve. (B) After 
addition of a 10 fold excess of EDTA to MDM2RING, a Tm value for MDM2RING of 
approximately 47.6 ℃ was calculated. The panel on the left illustrates the fluorescence intensities, 
the panel on the right shows the value of –d(RFU)/dT as a function of the temperature. All 
samples were tested in triplicate (as shown by the black, red and blue curves).  
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Zinc binding site (II)
(PDB: 2VJE)
 
Figure 3-14: Zinc ion binding coordination in MDM2RING. The solution structure is one 
subunit of MDM2 dimers (PDB code: 2VJE). First zinc binding site (I) is formed by Cys438, 
Cys441, Cys461 and Cys464 while the second one (II) is formed by His452, His457, Cys475 and 
Cys478. Zinc is depicted as yellow spheres. Those zinc-binding residues are coloured in white 
stick representations.   
 
 MDM2RING is an ATP-binding protein 
It has been noted that MDM2 RING domain contains an ATP binding motif. ATP-bound 
MDM2 is preferentially located in the nucleolus (Poyurovsky et al., 2003). By definition, 
binding of ATP to the protein may induce a conformational change in the protein and shift 
the Tm value of MDM2RING. In this work, we tested the thermal stability of MDM2RING 
by TDA, with the addition of ATP and with or without EDTA. Although there was no clear 
melting curve shown by apo-MDM2RING, we wanted to test if ATP might bind to 
MDM2RING to make MDM2RING unfold and provide a transition melting curve.  
 
Results showed that addition of ATP had no effect on the data obtained (Figure 3-15A). 
However, on addition of EDTA and ATP, there was a clear melting transition curve seen. 
The Tm obtained for the mixture (5 μM MDM2RING + 500 μM ATP + 5 mM MgCl2 and 50 
μM EDTA) was about 62.0℃(Figure 3-15B). This compares with a Tm of 47.6℃ for 
MDM2RING and EDTA. Thus addition of ATP gives a thermal stability upward shift of 
approximately 14.4℃. (Figure 3-16). Such a significant increase in Tm provides clear 
evidence that not only there is an interaction between ATP and MDM2RING, but also 
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demonstrated that stabilization of MDM2RING is enhanced by ATP. Consistent with 
previous reports, it has been shown that ATP-binding to MDM2 is structurally dependent, 
and the affinity of ATP to MDM2 was approximate 0.77 μM (Priest et al., 2010). ATP plays 
diverse roles in mediating the function of MDM2 including regulation of sub-cellular 
compartmentalization of MDM2 (Poyurovsky et al., 2003), acting as molecular chaperone 
for p53 (Wawrzynow et al., 2007), and enhancing MDM2-mediated inhibition of the DNA-
binding function of E2F1 (Stevens et al., 2008). In summary, these TDA studies provide 
biophysical data showing that MDM2RING contains metal ions and also revealed that ATP 
interacts with and stabilises MDM2RING.  
 




































































Figure 3-15: TDA studies of MDM2RING in the presence of ATP with and without EDTA. 
(A) 5 μM MDM2RING + 500 μM ATP + 5 mM MgCl2. (B) 5 μM MDM2RING + 500 μM ATP 
+ 5 mM MgCl2 + 50 μM EDTA. There is detectable thermal melting curve while both ATP and 
EDTA were present in the sample. All samples were tested in triplicate. 
 

































Figure 3-16: Comparison of the Tm values of MDM2RING with and without ATP. 
Compared to the Tm value detected in the absence of ATP, a dramatic increase of 14.4 ℃ is 
observed, in the presence of ATP, suggesting that ATP binds to and stabilizes MDM2RING. 
 
 Thermal stability of UbcH5a 
Our thermal denaturation studies of UbcH5a showed a clear melting transition curve (Figure 
3-17). Data demonstrated that after purification, UbcH5a is a folded protein with a melting 
temperature (Tm) of 55.4℃ (Figure 3-17 A). This result also revealed that UbcH5a is stable 
at the reaction temperature (30℃) used in the in vitro ubiquitination assay.   
 
To test whether there is an interaction between UbcH5a and MDM2RING, 5 μM UbcH5a 
and 10 μM MDM2RING was incubated for 30 minutes prior to TDA analysis. The 
assumption was that if there was an interaction between these two proteins, the Tm of 
UbcH5a may change. In the presence of MDM2RING, TDA results showed that there was a 
downward/negative shift from 55.4℃  (apo-UbcH5a) to 53.7℃  (UbcH5a-MDM2RING) 
(Figure 3-17C). Differences in Tm provide evidence that there was interaction between the 
two proteins, and the downward Tm shift suggests that MDM2RING-binding destabilised 
the conformation of UbcH5a. This finding suggests that the conformational change in 
UbcH5a induced by MDM2-binding is necessary for the release of ubiquitin from E2 to the 
substrate. However, further analysis is needed to confirm this hypothesis.  
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Figure 3-17: Comparison of the Tm of apo-UbcH5a and UbcH5a-MDM2RING using TDA. 
(A) & (B) showed that the Tm of 5 μM UbcH5a is 55.4℃. (C) The Tm of 10 μM MDM2RING + 
5 μM UbcH5a was about 53.4℃ (magenta line), and the Tm of apo-5 μM UbcH5a was 55.4℃ 
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3.4 Circular Dichroism (CD) 
3.4.1 The Principles of CD 
The basic principle of circular dichroism (CD) technology is that plane-polarised light 
passing through chiral molecules produce differential absorbance for right- and left-handed 
circular polarised light. For achiral molecules, there is no CD signal and generate plane-
polarised radiation. For chiral molecules, at some wavelengths, the CD signal is generated as 
elliptically polarised light. Ellipticity (θ), in dimensions of millidegrees, is commonly used 
as a CD measurement unit. For proteins the peptide bond in isolation is a chromophore 
which the nπ* transition is at ~220 nm and ππ* transition ~190 nm. Generally, a CD 
spectrum of a protein is mainly recorded in the UV region, because protein polypeptide 
backbones produce dominant peaks in the far UV region (from ~260 nm to ~ 190 nm). 
Information on protein conformation is generated based on the chiral features of the three-
dimensional secondary structure. As shown in Figure 3-18, α-helix structures produce one 
positive CD peak at ~190 nm and two negative CD peaks at ~222 nm and ~208 nm; β-sheet 
structure produce one negative CD peak at ~215 nm and one positive CD peak at ~195 nm. 
Proteins are composed of different secondary structure elements of α-helix, β-sheet and β-
turns. Therefore a CD spectrum can be considered as a sum of spectra contributed by each 
secondary structure type of the protein sample. The CD data may give a meaningful 
interpretation of overall secondary structure of the protein sample.  
 
 
Figure 3-18: The Far UV CD spectrum of four proteins. The solid line represents a α–helical 
protein; dashed line is the spectrum of a β–sheet protein; dotted lines and short lines are the 
spectrum of unfolded proteins (Johnson et al., 1990). 
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In this work, the CD method was used to primarily demonstrate that these protein clones, 
overexpressed and purified for all experiments were folded, and also to measure the thermal 
stability. Solvents should be carefully selected as their absorption properties vary and some 
chemicals, such as chloride and Tris molecules, show strong absorption at the far UV region 
and affect the quality of CD data (Kelly & Price, 2000). Therefore, the CD buffer used was 
PBS and sodium fluoride (NaF), instead of the characterisation Tris buffer and NaCl used in 
other biophysical experiments.  
 
3.4.2 Materials and Methods: CD 
The CD spectra were collected using a Jasco J800 with a 10 mm pathlength cuvette. Prior to 
the experiments, UbcH5a was dialysed into a suitable buffer (20 mM PBS, 150 mM NaF, 
pH7.5) for the CD analysis. A protein concentration of 0.12 mg/ml UbcH5a was used for the 
CD measurements. Both samples were measured using the following experimental 
parameters: bandwidth 1 nm; response 1 s; measurement range 185 – 285 nm; scanning 
speed 20 nm/min; scan 10 times; temperature 25℃. For thermal denaturation experiments, 
each sample was tested using the same experiments parameters as previously described. 
Each sample was incubated at a specific temperature for 15 minutes before collecting the CD 
spectra for five repeated scans. Experimental temperatures were 25, 35, 45, 55, 65, and 75℃. 
All CD spectra were analysed using Dichroweb (http://dichroweb.cryst. bbk.ac.uk/html/ 
home.shtml) (Whitmore & Wallace, 2004), and the CONTIN program using reference set7.  
 
3.4.3 Results & Discussions: CD 
 UbcH5a is folded 
Because CD directly monitors the secondary structures of proteins, CD experiments were 
conducted to assess whether our purified UbcH5 was folded. As shown in Figure 3-19, it was 
clear that the CD spectrum of UbcH5a has minima at 208 nm and 222 nm and a maximum in 
the range of 190~195 nm, revealing that Ubc5Ha is a folded protein with a mixture of α-
helical and β-sheet structures (Figure 3-19). The secondary structure contents of UbcH5a 
analysed using Dichroweb, and the COTIN program with reference set 7 showed that the 
secondary structure of UbcH5a contained an average content of 31.4 % α-helix and 19.3% β-
sheet. Our far-UV CD data of UbcH5a secondary structure was similar to the X-ray structure 
data of UbcH5a (2C4P) (30 % α-helix and 18% β-sheet) (Table 3.1), suggesting that our 
UbcH5a is folded correctly.   






















Figure 3-19: Analysis of the folding state of UbcH5a by Far-UV CD spectroscopy. 
Secondary structure contents of UbcH5a (0.12 mg/ml) is studies using the circular dichroism 
analysis. Data are recorded on 25 ℃ at the wavelength 185 nm ~ 285 nm. CD data are analysed 
using Dichroweb. The spectrum is an average of representatives of ten scans.  
 
Table 3-1: Secondary structure content of UbcH5a was analysed using CD data and X-ray 
structure. 
α-helix β-sheet
CD data 31.4% 19.3%
X-ray 30% 18%
The spectra were analysed at the Dichroweb sever using the 
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 Thermal stability of UbcH5a using CD 
The stability of protein is correlated with its conformation; hence heat treatment of protein 
will change the tertiary structure of the protein. The change in the CD spectra as a function 
of temperature was used to monitor the thermal stability of UbcH5a. In these experiments, 
CD spectra were collected at the wavelength 185 ~ 285 nm at different temperatures, 25, 35, 
45, 55, 65, and 75℃ (Figure 3-20A). As shown in Figure 3-16A, at the temperatures of 25, 
35, 45, 55℃, there were similar far-UV CD spectra seen, indicating that UbcH5a was stable 
at 55℃ . Increasing the temperature to 65℃ , the far-UV CD spectra of UbcH5a was 
significantly changed, showing that UbcH5a lost its native conformation and was denatured 
at 65℃. Using the information we obtained from these data, we analysed the data of the CD 
spectra obtained at 208nm and 222 nm for studies of the unfolding state of proteins, because 
there were broad CD minima at these two wavelengths, indicative of α-helical content 
(Figure 3-20B). We also monitored the changes of the CD spectra at 216 nm, as an indicator 
of β-sheet content (Figure 3-20B). All CD data suggest that the conformational change of 
UbcH5a started at 55 ℃. The midpoint of thermal melting temperature (Tm) of UbcH5a 
using CD at all three wavelengths was about 60 ℃ (Figure 3-16B). The difference between 
the Tm measured using TDA (56.4 ℃) (Figure 3-20A) and CD may be due to the buffer 
conditions. It has been noted that the stabilities of proteins are buffer-dependent. In the CD 
spectroscopy experiments, sodium fluoride (NaF) was used to avoid the noisy signals 
resulting from sodium chloride (NaCl). The buffer system was 20 mM PBS instead because 
the Tris buffer may produce some noisy signals. Overall, both Tm values measured using 
TDA and CD revealed that UbcH5a is a thermally-stable protein. Importantly, during our in 
vitro ubiquitination experiments, the reaction is incubated at 30℃, and UbcH5a was stable at 
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Figure 3-20: The thermal stability of UbcH5a analysed on circular dichroism. (A) 0.12 
mg/ml UbcH5a is used on this assay. Different colours represent different temperatures. While 
increasing the temperature, the changes of the CD spectra are observed. (B). The changes of the 
CD spectra of UbcH5a are observed at three wavelength, 208 nm (blue), 216 nm (green) and 222 
nm (red).   
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3.5 Conclusions 
The in vitro ubiquitination assay data showed that our purified MDM2RING and 
MDM2RING△C are E3 active and MDM2RING has stronger E3 activity than 
MDM2RING△C. MDM2RING and MDM2RING△C can ubiquitinate p53 which suggests 
that there is a new p53-binding site within our MDM2RING construct. Additionally, 
according to the dynamic light scattering and size exclusion chromatography data, the 
oligomeric states of MDM2RING were concentration-dependent whereas MDM2RING△C 
exists as a dimer at all concentrations. Thermal denaturation data of MDM2RING revealed 
that zinc binding plays a role in the folding and stability of MDM2RING. Moreover, the 
thermal denaturation data also provides evidence that ATP interacts and stabilises 
MDM2RING.   
 
UbcH5a was a stable monomer as confirmed by size exclusion chromatography and dynamic 
light scattering. According to the circular dichroism analysis, it showed that the secondary 
structure of UbcH5a consisted of 19.3 % β-sheet, 31.4% α-helix and 49.3% loop or random 
coil. The thermal stability of UbcH5a was also verified by a thermal denaturation assay and 
circular dichroism analysis, showing that the thermal melting temperature (Tm) were 
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Crystallisation trials were set up for the following proteins, MDM2RING (residues 386- 491), 
MDM2RING △ C (residues 386-478), and the MDM2RING-UbcH5a complex. 1-
dimensional nuclear magnetic resonance (1D-NMR) was used to investigate the folded state 
of these protein constructs. To study the interaction of MDM2 and UbcH5a, we used 2-
dimensional heteronuclear single quantum coherence NMR (2D-1H,15N HSQC NMR) to 
monitor chemical shifts in 15N-UbcH5a following the addition of MDM2RING △ C. 
Furthermore, we used negative-staining transmission electron microscopy to study the 
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4.1 Macromolecular Crystallisation 
4.1.1 The principles of crystallisation  
To determine the structure of macromolecules, including proteins and nucleic acids by X-ray 
diffraction, the production of high quality crystals is pivotal. However, finding favourable 
conditions for crystallisation has always been a bottleneck in the structure determination 
process, because useful crystals grow only under specific conditions, frequently at the 
boundary between nucleation and metastable zones (Durbin & Feher, 1996). If the 
conditions produce too many nuclei, no high-quality crystals grow, instead, microcrystals, or 
amorphous precipitate is generated. Protein-protein interactions in a crystal are very complex, 
achieving the thermodynamically metastable state, known as supersaturation, is difficult. 
Supersaturated proteins are within the nucleation or metastable zones (introduced in greater 
detail in the following paragraph). Therefore, one of the pivotal steps in crystallisation is the 
control of nucleation.  
 
Optimisation of crystallisation conditions is usually achieved following the guidance of the 
crystallisation phase diagram (Chayen, 2004; Chayen, 2005). Figure 4-1 shows a 
crystallisation phase diagram that includes four distinct zones presenting different 
supersaturation states. (i) In the highest supersaturation zone (precipitation zone), all 
macromolecules aggregate. (ii) At the zone of moderate saturation (nucleation zone), 
spontaneous nucleation will occur. (iii) At the zone of lower supersaturation, known as the 
metastable zone (just below the nucleation zone), crystals may grow and no further 
nucleation will take place. This condition is favourable for crystal growth. (iv) At the zone of 
under-supersaturation, macromolecules are fully soluble and no crystallisation will occur. 
Crystal quality is dependent on several parameters, including concentration of 
macromolecule, buffer composition, pH, incubation temperature, the degree of 
stability/homogeneity of the macromolecule and many other parameters (McPherson, 2004). 
Several methods have been developed to achieve supersaturation of the macromolecular 
solution inducing nucleation and generating crystals suitable for X-ray diffraction analysis 
(McPherson, 1999). Currently, vapour diffusion is the most popular crystallisation method.  
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Figure 4-1: The crystallisation phase diagram. As described, there are four zones representing 
different supersaturation states: (i) precipitation zone, (ii) nucleation zone, (iii) metastable zone, 
and (iv) under saturation. Nucleation and subsequent crystal growth often take place within the 
nucleation and metastable zones, respectively, as protein concentration changes over time.  
 
 
● The vapour diffusion method 
There are two common variations of the vapour diffusion method: hanging and sitting drops 
(Figure 4-2). The mother liquor (a mixture of crystal growth reagents) is in the well. A drop 
is in suspended (hanging) or supported (sitting) and contains protein solution (usually 
between 0.5 ~ 20 μl) mixed with the same volume of mother liquor. In the sealed system, 
equilibrium is achieved by the evaporation of water or volatile reagents from the drop, 
resulting in an increase in the concentration of the protein reaching a supersaturated state and 
hopefully forming crystals. Many rounds of screening, continually optimising parameters 
including protein concentration, precipitants/additives used may be required to produce well 
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Figure 4-2: Vapour diffusion methods. Illustration of the two most commonly used methods in 
crystallisation (A) hanging drop preparation & (B) sitting drop preparation.  
 
 
4.1.2 Materials & Methods: crystallisation 
In this work, the vapour diffusion method was used. Glass coverslips used were siliconised 
followed by a water wash. The well contained 500 μl mother liquor (crystallisation buffer). 1 
μl protein solution was pipetted onto the treated coverslip and 1 μl of mother liquor was 
pipetted onto the protein solution. The coverslip was then inverted, placed over the reservoir 
and sealed as shown in Figure 4-2A. The plates were stored at two temperatures 4 and 18℃. 
Microscopy was used to monitor the drops.  
 
4.1.3 Results & Discussions: Crystallisation 
The published crystallisation conditions for MDM2-MDMX heterodimers (Linke et al., 2008) 
were used first, in an attempt to produce crystals of MDM2RING and MDM2RING△C. It 
has been noted that different constructs can behave very differently and may not produce 
crystals under the same conditions.  A number of commercially available crystallisation 
screening kits including Crystal Screen I & II, PEG/Ion Screen (HR2-126) and Natrix Screen 
(HR2-116) (Hampton Research Hamilton-Screen Kits). The kits have been developed from 
analyses of the protein structure database and are comprised of variations of the most 
successful conditions found in the PDB. Meanwhile, we also systematically varied a number 
of parameters including protein concentration, type and concentration of precipitants 
including ammonium sulfate (AS), pH and percentage of glycerol in the mother liquor. After 
several rounds of screening, microcrystals were grown but unfortunately were of insufficient 
quality for further studies.    
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Crystallisation trials using UbcH5a in complex with MDM2RING were set up, once again 
using the commercial available screens. Many hundreds of crystallisation trials were set up, a 
few crystals were seen with one buffer condition  (0.2 M ammonium acetate, 0.01M calcium 
chloride dihydrate, 0.05 M sodium cacodylate trihydrate (pH6.5), and 10% w/v polyethylene 
glycol 4000) (Figure 4-3). However, the microcrystals were not of sufficient quality for X-
ray diffraction studies. 
 
 The screening trials produced one potential lead for any further attempts to crystallise the 
UbcH5a-MDM2RING complex. In the future, further optimisation of crystallisation 
conditions will be necessary to obtain good quality crystals for X-ray diffraction. Cloning of 
multiple constructs of the target proteins could be attempted to find proteins with greater 






Figure 4-3: Crystallisation of the MDM2RING-UbcH5a complex.  Crystal grows from10% 
w/v polyethylene glycol 4000, 0.2 M ammonium acetate, 0.01 M calcium chloride dihydrate, 
0.05 M sodium cacodylate trihydrate pH6.5, at 18℃. Those microcrystals are with dimension 













  Chapter 4 
 99 
4.2 Negative Staining Transmission Electron-Microscopy (negative 
staining  TEM) 
4.2.1 The basis and applications of negative staining TEM 
Negative staining TEM (transmission electron microscopy) is one technique available to 
observe the ultrastructure of macromolecules, such as cells, viruses or larger proteins (Ohi et 
al., 2004). The resolution of light microscopy is limited to approximately 0.25 μm whilst 
with TEM resolution down to 0.2 nm can been achieved. Negative staining is a mild 
technique to enhance contrast, highlighting the structures of macromolecules in the image 
produced. Therefore, in negative staining TEM, protein is deposited on to a carbon-coated 
copper grid, followed by staining with a negative stain solution, such as 1-3% uranyl acetate. 
The images of the topography of the macromolecules are recorded by a CCD camera 
(charged-coupled device camera). The images generated by TEM of the stained sample 
provide pictures of the morphology of the specimen. TEM images of soluble proteins display 
the particles in bright field sharply contrasting with the dark environment surrounding them 
(Figure 4-4). Because the energy of the electron beams is absorbed by heavy metals used in 
the stain, the dark regions in the images represent the environment surrounding the sample or 
aggregates. Brighter areas represent soluble proteins. Conversely, particles of insoluble 
aggregates were also viewed as in the dark field. In this thesis, negative staining TEM 
method was used to study the topography of the high molecular weight MDM2RING.  
 
4.2.2 Materials & Methods: negative-staining TEM 
To ascertain whether large-molecular-weight MDM2RING (Figure 4-4A) was present as 
aggregates or as a supramolecular assembly, negative staining TEM was used. Firstly, 
copper grids, as a supportive membrane for the samples, were coated with a carbon film. 
Then, the carbon-coated copper grid was discharged as the carbon becomes hydrophobic 
after some time. The samples (0.1 mg/ml MDM2RING (usually 2.5 μl)) were then deposited 
onto the discharged carbon-coated copper grid under low pressure in a vacuum chamber.  
Then the sample on the grid was washed with two drops (2.5μl) of deionised water, and 
stained with two drops of the heavy metal salt reagent, 1% uranyl acetate. Electron 
micrographs were recorded on a CCD camera at a magnification of 20,000X with a Phillips 
CM120 Biotwin (http://coil.bio.ed.ac.uk/TEM.html) operating on 200 kV.  
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4.2.3 Results & Discussions: Negative staining TEM images of the high 
molecular weight form of MDM2RING  
Figure 4-4A shows that two forms of MDM2RING are eluted by gel filtration using a 
Sephacryl S-200 HR column. The molecular mass of the high molecular weight form present 
in the void volume is presumed to be greater than 660 kDa (void volume = 40 ml). The 
dimeric form (with an elution volume of 65 ml) has an estimated molecular weight of 26 
kDa. To ascertain whether the protein in this fraction were aggregates or soluble proteins 
(supramolecular assembly), negative staining TEM was applied.  
 
TEM images showed that each MDM2RING particle displayed a regular donut-like structure 
(Figure 4-4B, insets). The width of the particles viewed in one dimension were 7~15 nm. 
The diameter of the high molecular weight form of MDM2RING particles was 
approximately 7.4 x 11.1 nm (white arrow, in Figure 4-4B).To some extent, the different 
appearances of the particles might also be due to the different viewing angles. The 
heterogeneity in shape and size might be due to differential absorption of the protein onto the 
grid or the presence of different subunits in the supramolecular assembly. It has been noted 
that MDM2RING (residues 432-491) and other RING domain proteins, such as Z protein or 
BRCA1/BARD1, tend to become supramolecular assemblies at high concentrations (Kentsis 
et al., 2002; Poyurovsky et al., 2007). Consistent with previous reports, negative staining 
TEM provided evidence that our high molecular weight form of MDM2RING are not 
aggregates; instead, they exist as regular donut-like proteins in a larger supramolecular 
assembly.   
 
The molecular weight of MDM2RING was greater than 660 kDa as estimated from the size 
exclusion profile (Figure 4-4A). Since the theoretical molecular weight of monomeric 
MDM2RING is 12.47 kDa, this suggests that the high molecular weight MDM2RING 
fraction is composed of a mixture of larger complexes of at least 50 subunits. Since the 
negative staining TEM images showed that high molecular weight MDM2RING was 
detectable as a soluble regular donut-like shaped protein, an important step was to clarify 
whether high molecular weight MDM2RING still has E3 ligase activity. Using in vitro 
ubiquitination (see Chapter 3), the data showed that MDM2RING (supramolecular assembly, 
large) was E3 active (Figure 4-4C). To understand if there are different levels of E3 ligase 
activities between the two forms of MDM2RING (larger and small), 100 ng of each 
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MDM2RING form was tested. Results showed that the small MDM2RING form has higher 
E3 ligase activity than larger MDM2RING, as more ubiquitinated-p53 ladders were detected. 
This result was consistent with a previous report (Poyurovsky et al., 2007), which also 
indicated that small MDM2RING (residues 432-491) is more E3 active than large 
MDM2RING (residue 432-491). From a biological viewpoint, the equilibrium between small 
and large MDM2 proteins may play a critical role in determining the degree of ubiquitination 
in cells. When more dimeric MDM2 exists, p53 or other MDM2-binding substrates may be 
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Figure 4-4: Characterisation of larger-molecular-weight MDM2RING. (A) The molecular 
weight of large-molecular-weight MDM2RING is estimated to be greater than 660 kDa. (B)  
Negative staining TEM images of MDM2RING are recorded at a magnification of 20,000X. 
MDM2RING is deposited onto a carbon-coated copper EM grid and stained with 1% uranyl 
acetate before being visualised using transmission EM. The arrow highlights one particle of 
approximately 7.4 x 11.1 nm. Scale bar = 100 nm. Inset: high molecular weight MDM2RING 
forms a regular donut-like structure. The frame size of the magnified particles in a gallery is 15 
nm. (C) Data from in vitro ubiquitination confirms that the high-molecular-weight MDM2RING 
has E3 ligase activity.  
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4.3 Nuclear magnetic resonance (NMR) spectroscopy  
4.3.1 The basis and applications of NMR spectroscopy 
 NMR spectroscopy 
NMR spectroscopy, Nuclear Magnetic Resonance spectroscopy, is a technique to obtain 
chemical, physical, and structural information on molecules of interest. The resonance 
frequency that is detected by NMR spectroscopy is proportional to the magnetic field applied 
to a nucleus. The motion of the electrons is induced by the external magnetic field and 
produces a small magnetic field to the nucleus. The electron distribution of a nucleus (e.g. 1H, 
13C and 15N) varies according to the local geometry (binding partners, bond lengths, angles 
between bonds). The change in the effective magnetic field experienced by a nucleus causes 
the resonance frequencies to shift. Over the last few decades, NMR chemical shift 
perturbation methods have been successfully used to obtain the structure of macromolecules 
(Rehm et al., 2002; Yee et al., 2002; Yee et al., 2006) and for mapping the residues involved 
in the protein-protein or protein-ligand interactions (Brzovic et al., 2006; Coles et al., 2003; 
Kalus et al., 1997; Shuker et al., 2006).  One of the limitations of NMR spectroscopy is the 
overlap of the signals that results if the macromolecules are too large. Therefore, NMR is 
suitable to study small proteins (<25 kDa), such as one domain of a larger protein. Compared 
to crystallography, NMR provides structural information on a macromolecule closer to 
physiological conditions in solution with additional information on stability, solubility and 
conformation. NMR is also an alternative method to obtain structural information from 
macromolecules that are refractory to crystallisation. Moreover, recently, NMR has become 
a powerful tool in the pharmaceutical industry to study the interactions between protein 
target and small molecule ligands (Lepre et al., 2004; Moore, 1999; Viegas et al., 2009).  
 
In our project, we used  1-dimensional NMR (1D-NMR) to monitor whether UbcH5a and 
MDM2RING△C are folded and then applied 2-dimensional heteronuclear single quantum 
coherence NMR (2D-HSQC NMR) to study the structural and conformational changes of 
15N-UbcH5a with or without MDM2RING△C (in this chapter) or with selected ligands 
(Chapter 5). Residues involved in protein-protein interactions or in ligand-receptor 
interactions are easily determined by chemical shift changes of the cross-peaks.  
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4.3.2 Materials & Methods: 1D & 2D NMR 
NMR experiments discussed in this thesis were performed using a Bruker AVANCE 600 
MHz spectrometer for the 1D-NMR experiments and a Brucker AVANCE 800 MHz 
spectrometer for the 2D-HSQC NMR (Edinburgh Biomolecular NMR Unit). NMR data were 
collected using the Topspin interface. The CCPNMR software suite Analysis 2.1.1 was used 
for data analysis.  
 
 1D NMR: sample preparations  
For 1D-NMR experiments, UbcH5a, MDM2RING and MDM2RING△C, respectively, were 
purified as described in Chapter 2. High concentrations of salts, such as NaCl, affect NMR 
experiments; therefore, samples were buffered exchanged into an “NMR buffer” with lower 
ionic strengths (50 mM NaCl, 20 mM Tris, pH7.2) prior to the experiments. A 500 μl sample 
(containing 10% (v/v) deuterated water (D2O)) at a protein concentration of 50 μM was 
required for each NMR experiment. D2O was used to produce a deuterium lock signal to 
enable the correction of inhomogeneity in the magnetic field. Samples were transferred into 
a 5-mm NMR tube (Wilmad HighPrecision), data recorded at a temperature of 300 K.  
 
 1H, 15N-HSQC 2D-NMR: sample preparations 
For 1H, 15N-HSQC experiments, isotopically labelled samples were prepared as follows.  A 
single colony of His‧tagged-MDM2RING△C or UbcH5a was picked and used to inoculate 
12.5 ml LB medium (with carbenicillin, at 100 μg/ml) followed by overnight incubation at 
37℃ with shaking at 250 rpm. Cells were centrifuged, the LB medium discarded and the 
pellets washed gently three times using minimal medium [1X M9 salt solution including 8.4 
mM Na2HPO4, 4.8 mM NaH2PO4, 1.8 mM NaCl]. This procedure is to reduce the amount of 
unlabelled nitrogen in the sample which may produce noisy signals in the 1H, 15N-HSQC 
NMR data. Then for the scale-up incubation, cell pellets were resuspended using 500 mL 
specific grow medium to label the nitrogen atoms [1X M9 medium, 0.8 mM (15NH4)2SO4, 1 
mM Mg2SO4, 50 μM CaCl2, 0.5% (w/v) 
15N-labelled Isogro (Sigma), 50 μg/ml thiamine and 
1% PTM1 salts].  Cells were grown at 37℃ with shaking at 250 rpm for approximately 6 ~ 8 
hours until an O.D.600 of 0.8 was reached. IPTG to a final concentration of 1 mM was added 
to the growth medium and the cells were incubated for another 16 ~ 20 hours at 20℃. At this 
stage cells grew slowly as the growth medium is low in nutrients. Cells were collected and 
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flash frozen. The 15N-labelled samples were purified using the purification procedure 
outlined in Chapter 2. The 15N-labelled His‧tagged-MDM2RING△C and UbcH5a were 
concentrated to 0.5 mg/ml and 1 mg/ml, respectively. For 2D-NMR experiments, 500 μl 
samples containing 25 μM purified 15N-labeled samples and 10% (v/v) D2O (the same buffer 
for 1D experiments) were transferred into a 5-mm NMR tube and data recorded at a 
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4.3.3 Results & Discussions: 1D & 2D NMR 
 1D 1H NMR spectrum of UbcH5a 
In one-dimensional 1H NMR spectra, there are three major chemical shift regions giving an 
indication as to the folding state of a protein (Rehm et al., 2000): (1) the amide region; (2) 
the aromatic region; and especially (3) the methyl group region (between 1 ~ -1ppm). In 
Figure 4-5, the 1D 1H NMR spectrum of UbcH5a showed distinct cross-peak dispersions 
with sharp linewidths. Strong Peaks at 3.5 ~ 4 ppm were derived from the Tris in the buffer. 
Several distinct peaks were detected between 6~11 ppm, representing amide/aromatic 
regions, indicative of folded UbcH5a. Moreover, several peak shifts were detected around 0 
ppm, and the signals were generated from the buried methyl groups. Those peaks further 
confirmed that there are soluble UbcH5a proteins in solution.  
 
 
Figure 4-5: 1D 1H-NMR spectrum of UbcH5a. 50 μM non-labeled UbcH5a (in 20 mM Tris 
buffer, 50 mM NaCl, pH 7.2.) is recorded at 600 MHz at a temperature of 300 K. Data are 
processed using “Topspin”. Blue peaks represent the NMR spectrum of apo-UbcH5a. Red peaks 
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 1D-NMR spectrum of  His‧tagged-MDM2RING△C  
In Figure 4-6, the 1D-NMR spectrum of His‧tagged-MDM2RING△C showed a minor 
peak in the  methyl group region (~ 0.5 ppm) and a few peaks shifts in the amide/aromatic 
regions (6.5 ~ 9 ppm). The pattern of this type of 1D-NMR spectrum may indicate the 
protein is aggregated. Broader linewidths (around 8~8.5 ppm) are correlated to the tumbling 
rate of a molecule in solution, such as non-specific aggregation or higher-order oligomers 
(Hill & DeGrado, 2000). On the basis of the 1D 1H NMR spectrum of His‧tagged-
MDM2RING△C (Figure 4-6), it is difficult to distinguish whether proteins are forming 
properly folded or the NMR signal is caused by folded proteins with a high molecular weight. 
The previous biophysical studies on the non His‧tagged- MDM2RING△C construct 
(Chapter 3) showed that the protein formed a dimer in solution. In order to study the 
His‧tagged construct, which appear to have higher molecular weight, two-dimensional 1H, 




Little indication proton signals 




for Methyl group 




Figure 4-6: 1D 1H NMR-spectrum of His‧tagged-MDM2RING△C. 100 μM non-labeled 
His‧tagged- MDM2RING△C (in 20 mM Tris buffer, 50 mM NaCl, pH 7.2.) was analysed at 
600 MHz at a temperature of 300 K. Data are processed using “Topspin”.  
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 2-dimensional heteronuclear single quantum coherence NMR (2D HSQC NMR)  
HSQC-NMR (Heteronuclear Single Quantum Coherence NMR) is one of a number of 2-
dimensional NMR techniques (Bodenhausen & Ruben, 1980). The signals from a protein on 
a 1D-NMR spectrum are overlapping and it is difficult to distinguish the peaks. Therefore, 
alternative NMR techniques are required to provide better resolution of the NMR spectrum 
of a macromolecule. HSQC-NMR becomes significant for protein NMR which can be 
performed using isotopically labelled protein. For example, 2D-[1H, 15N] HSQC NMR 
spectrum provides more “frequency space” and fewer overlapping cross peaks in a 2D 
dataset compared to 1D 1H NMR. Each cross-peak represents a 1H (x-axis) and 15N (y-axis) 
chemical shift of each backbone NH proton in a protein. The dispersion of each cross-peak is 
determined by the amino acid identity and its local magnetic environment (which 
corresponds to its neighbouring amino acids). A 2D-[1H, 15N] HSQC NMR spectrum of a 
protein produces a unique of “protein fingerprint”.  
 
[1H, 15N]-HSQC-NMR is a cheap and quick experiment, and therefore, it has become the 
first choice technique to study conformational changes in the folded versus unfolded state 
(Dyson et al., 2004; Hanoulle et al., 2009), wild-type versus mutant protein (Boeckler et al., 
2008; Chatterjee & Hosur et al., 2006; Tevelev et al., 1996), or apo-protein versus protein- 
ligand complex (Johnson et al., 2000). If the protein is folded, each cross-peak is 
distinguished and there is a correlation between the number of cross-peaks and the number 
of amino acids. For the ligand-binding experiments, to compare the HSQC spectra of the 
labelled protein in the absence and presence of the ligand, changes in chemical shifts of the 
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 2D- 1H,15N- HSQC NMR spectrum of 15N-His‧tagged-MDM2RING△C 
2D-HSQC NMR spectrum of 15N-His‧tagged-MDM2RING△C showed that it is largely 
unfolded because it had poor cross-peak dispersions (Figure 4-7). Most amide 1H chemical 
shifts were dispersed at a narrow range (8.0 ~8.5 ppm) and some were at 7 and 7.5 p.p.m 
(Figure 4-7), showing that those peaks originate from flexible residues of the protein. In 
addition, data supported by the DisMeta results (Figure 4-7B) showed that a disordered 
segment was located in the N-terminal 52 residues (residues 386-438) of MDM2RING△C. 
The DisMeta Server (www-nmr.cabm.rutgers.edu/ bioinformatics/ disorder) was developed 
by the NESG (The Northeast Structural Genomics Consortium), and offers several sequence-
based structural tools for the predictions of unknown proteins of unknown structure (Rossi et 
al., 2010).  
 
To sum up, the 1H, 15N-HSQC NMR spectrum of His‧tagged-MDM2RING△C suggested 
that this protein is largely unfolded. However, the biochemical studies showed that native 
MDM2RING△C has E3 ligase activity (Figure 3-3). Furthermore, the ESI-MS analysis 
showed that native MDM2RING △ C is folded (Figure 5-7). Taken together, the data 
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Figure 4-7: 1H,15N-HSQC NMR spectrum of His‧tagged-MDM2RING△C. (A) A spectrum 
of 50 μM His‧tagged-MDM2RING△C (in 90% buffer/10%D2O (v/v)) was recorded at 800 
MHz at a temperature of 300 K. (B) The output from the DisMeta sever shows that the N-
terminal 53 amino acids (residues 386-438) of  His‧tagged-MDM2RING△C are predicted to 
be disordered.  
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 2D- 1H,15N-HSQC NMR spectrum of UbcH5a 
1H, 15N-HSQC-NMR experiments were used to monitor the folded state of the protein and to 
compare any change in chemical shifts of the proteins with and without ligand. A 1H, 15N-
HSQC NMR spectrum of UbcH5a was recorded, and the resulting cross-peaks were properly  
dispersed, indicating that UbcH5a is folded (Figure 4-8). The spectrum from a 15N-HSQC 
NMR experiment alone is not enough to determine the structure; other techniques are 
required. There is an alternative method to make the backbone assignment of UbcH5a, 
comparison with previous published NMR spectra of the same proteins. Published chemical 
shift assignments for an UbcH5a (NMR accession number: 6584), referred to as “UbcH5aref”, 
was used as a reference to assign our UbcH5a (Figure 4-8). The amino acid sequence of 
UbcH5aref  is very similar to that of our construct UbcH5a except two residues (K51F and 
S62F) have been mutated and residues at the N terminus, not part of the core UbcH5a, are 
different (Figure 4-8A).   
 
The spectra of the known solution structure of UbcH5aref and our UbcH5a were similar 
(Figure 4-8B). Differences in the positions of the peaks were due largely to the samples 
being in different buffer solutions because the positions of the cross-peaks in a NMR 
spectrum are solvent dependent. The buffer for UbcH5aref NMR experiments was (150 mM 
KCl, 20 mM KPi (pH 7.0), 10 mM ZnCl2, 5% D2O); however, our protein did not produce 
good data in this buffer. Therefore, our UbcH5a was stored in Tris buffer for the NMR 
experiments. Although the peak positions were slightly different, the overall dispersion of 
the cross-peaks was similar. Manual assignments of each cross-peak to a specific residue in 
UbcH5a was guided by the assignments of the known structure of UbcH5aref. We tried to 
assign about 109 residues (65% of total residues) of our UbcH5a. Manually-optimised NMR 
assignment of our UbcH5a was ready to be used as a reference for further studies into the 
interactions of 15N-UbcH5a with MDM2RING△C (discussed in the following section) or 
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1H (p.p.m.)  
Figure 4-8: 1H,15N-HSQC NMR spectrum of UbcH5a. (A) Sequence alignment of UbcH5aref 
(BMRB code: 6584) and our constructs, UbcH5a. (B) The NMR spectrum of our construct, 
UbcH5a, (right panel) was recorded at 300 K in the NMR buffer [20 mM Tris, 50 mM NaCl, 
pH7.2] on an 800 MHz NMR spectroscopy.  Using UbcH5aref (left panel) as a reference, 65% of 
UbcH5a residues are identified and labelled as shown (page 112). HSQC spectra of both proteins 
show similar cross-peaks dispersions.   
 
 The HSQC spectrum of  15N-UbcH5a in the presence of MDM2RING△C  
NMR data of 1H, 15N-UbcH5a (25 μM) in the presence of MDM2RING△C showed that 
there were no shifts of cross-peaks; instead, a decrease in the signal intensities of the cross-
peaks was observed (Figure 4-9). The molecular weight of apo-UbcH5a is 18 kDa, and the 
molecular weight of the UbcH5a-MDM2RING△C complex is approximately 40 kDa. The 
larger size of the complex increased the tumbling time, meaning less signals detected in a 
reasonable amount of time, resulting in substantially reduced signal intensity being recorded. 
This data provided evidence that MDM2RING△C interacted with UbcH5a. Corresponding 
residues of UbcH5a that had no or lower level signal intensities were depicted on the 
spectrum (Figure 4-9). After the addition of a 4 fold amount of MDM2RING△C (100 μM), 
the relative signal intensity of each residue on 15N-UbcH5a was reduced (Figure 4-10). 
Signal intensity of each peak reduced in most cross-peaks.  Signal intensities of residues that 
completely disappeared were Phe31, Tyr74, Asn77 Ser101, and Ile106. Relative signal 
intensities of cross-peaks only remaining less than 25% (compared to the signal intensities of 
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cross-peaks on the apo-15N UbcH5a) were Arg5, Leu10, Ser11, Val54, Phe69, Ile78, Ile84, 













































Figure 4-9: 1H,15N-HSQC NMR spectra of 15N-UbcH5a in the absence/presence of 
MDM2RING△C. Upper panel is the HSQC spectrum of apo-15N-UbcH5a (50 μM). Lower 
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panel is the HSQC spectrum of 15N-UbcH5a (50 μM) in the presence of MDM2RING△C (200 
μM). Signal intensities of all cross-peaks are reduced in the presence of MDM2RING△C. 
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Figure 4-10: Relative signal intensity of each peak of UbcH5a (25 μM) in the presence of 
MDM2RING△C (100 μM). Each assigned cross-peak representing each residue of UbcH5a is 
labelled, and the relative signal intensity observed in the presence of MDM2RING△C compared 
to apo-15N-UbcH5a is plotted in the bar chart. The secondary structure of UbcH5a is shown 
below the sequence.  
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 Residues  involved in the MDM2RING△C interaction were mapped on the structure 
of UbcH5a  
Residues which may be involved in the interaction with UbcH5a were mapped onto the 
structure of UbcH5a (Figure 4-11), showing that some of those residues were positioned in 
the canonical E3-binding site, including Arg5, Leu10, Ser11 (at the α1) and Phe31 (L2, the 
loop between the β1 and β 2). 
 
Our NMR data in the presence of MDM2RING△C showed that a peak representing Asn114 
decreased in intensity (less than 25% remaining). Previous reports have found that Asn114 
plays a role in regulating the exposure of the groove near the active cysteine residue (Cys85) 
to allow access of the acceptor ubiquitin (Sakata et al., 2010). Combining the published 
crystal structural data of the UbcH5a~Ub intermediate with our current NMR data, these 
observations suggested that on binding, MDM2RING△C may have a allosteric effect on the 
orientation of N114 (Figure 4-11) affecting ubiquitin binding. In addition, a previous report 
that showed mutations of Lys8, Ile37, Leu89, Ile106, Asn114 weakened the UbcH5b-
CONT4 mediated ubiquitination (Ozkan et al., 2005). Consistent with this notion, signal 
intensities of peaks representing these residues (except un-assigned Ile37), of UbcH5a were 
reduced or diminished (Figure 4-10) after the addition of MDM2RING△C, providing 
evidence that these residues play a role in communication between the MDM2RING△C and 
UbcH5a. A hypothesis has been proposed that E3-binding to UbcH5a or the thioester-bond 
ubiquitin-binding to UbcH5a may allosterically induce communication between the E3-
binding site and the active site of UbcH5a (Ozkan et al., 2005). The observation from our 
NMR data was consistent with this hypothesis.  
 
In summary, NMR data showed that UbcH5a interacts with MDM2RING△C. Since the E2-
E3 interaction is essential for ubiquitination (Deshaies & Joazeiro, 2009), this HSQC NMR 
data supports our previous hypothesis that there is interaction between MDM2RING△C and 
UbcH5a, because the in vitro ubiquitination data showed (Figure 3-3) that MDM2RING△C 
is E3 active.  
      















































Figure 4-11: Mapping of the perturbed residues on UbcH5a upon binding to 
MDM2RING△C. Residues (The intensity of peaks completely diminished) are coloured in red, 
and residues (with less than 25% remaining signal intensity) are shown in magenta. The active 
cysteine (Cys85) is coloured in yellow. Ribbon and surface diagrams are both provided.  
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4.4 Summary 
In this work, we carried out crystal trials to screen the optimal conditions to form UbcH5a-
MDM2RING△C and UbcH5a-MDM2RING complex. Unfortunately, no suitable crystals 
have yet been produced for diffraction studies. According to the DisMeta results, 
MDM2RING (residue 386-491) or MDM2RING△C (residues 386-478) has flexible 
segments at the N-terminal 52 residues. Note that a flexible region often complicates 
structural determination by suppressing crystal formation or generating a poor dispersion of 
the NMR spectrum. Hence, in the future experiments for the structural determination, using 
NMR or X-ray crystallography, it would be better to make new constructs in which the 
disordered sequences are removed, to increase the stability of the ordered core of a folded 
protein.  
 
15N-UbcH5a has a good quality NMR spectrum, and signal intensity reduction of 15N-
UbcH5a was observed in the presence of MDM2RING△C, suggesting that there was 
interaction between MDM2RING△C and UbcH5a. Mapping the peaks which had reduced 
signal intensity (Figure 4-11) showed that some residues were located at the canonical E3-
binding site, and other residues play roles in communication of the E3-binding and the active 
site of UbcH5a upon allosteric regulation.  
 
Negative staining transmission electron-microscopy provided evidence that the structure of 
the purified fraction of higher oligomers of MDM2RING is a supramolecular assembly 
(regular donut-like particles), consistent with other group findings (Poyurovsky et al., 2007). 
Moreover, in vitro ubiquitination data demonstrated that the higher oligomers of 
MDM2RING had E3 ligase activity.  
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5 Biophysical Studies of the interaction of the MDMX C-




MDM2 is an attractive drug target against p53-related tumours. It has been shown that 
MDM2 regulates p53 through transrepression and ubiquitination. A number of small 
molecules have been developed to inhibit MDM2-mediated transrepression function by 
disruption of p53-binding onto the hydrophobic domain of MDM2. Recently, a potential 
inhibitory peptide, peptide 9, has been found (K. Ball’s group, unpublished data). It has been 
shown that peptide 9 binds to FLMDM2 and inhibits MDM2 E3 ligase activity; however, the 
mechanism is unclear. Moreover, peptide 9 was synthesised based upon the C-terminal 
twelve amino acids (KEIQLVIKVFIA) of MDMX. From previous reports, the C-terminal 
amino acids of MDMX binds to the C8-binding site; therefore, presumably peptide 9 binds 
to MDM2RING in a similar way. In this work, we studied the interaction between peptide 9 
and MDM2 using a number of techniques, including intrinsic tryptophan fluorescence, 
thermal denaturation assay, fluorescence anisotropy, and electrospray ionisation mass 
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5.1 The initial finding: peptide 9  
A potential peptide inhibitor, peptide 9 was identified by K. Ball’s group (courtesy of Dr. 
Susanne Patterson, unpublished data) and was found to have an identical sequence to the C-
terminal 12 residues of MDMX. Results of both in vitro and in vivo pulldown experiments 
showed that peptide 9 interacted with FLMDM2 (Figure 5-1A). The MDMX C-terminal 
twelve residues, KEIQLVIKVFIA, has been synthesised and called “peptide 9” (Figure 5-
1B). The crystal structure of the MDM2/MDMX heterodimer showed that peptide 9 may 
interact with FLMDM2 through the C8-binding site of the RING domain (Figure 5-1B). 
Several groups (Kawai et al., 2007; Poyurovsky et al., 2007) and our previous data 
(discussed in Chapter 3) have proved that dimerisation/ oligomerisation is critical for MDM2 
E3 ligase activity. If peptide 9 binds and disrupts the dimerisation of MDM2, it is likely that 
monomeric MDM2 will lose its E3 ligase activity. As expected, in vitro ubiquitination data 
show that 10 μM peptide 9 completely inhibited the E3 activity of FLMDM2, and also 
inhibited the E3 activity of MDM2RING (Figure 5-1C). Moreover, a truncated peptide, 
KEIQLVIKVF, lacking last two amino acids, showed no inhibition of MDM2 E3 ligase 
activity (Dr. Susanne Patterson, unpublished data), suggesting that the truncated peptide 
cannot bind to FLMDM2, and the last two amino acids, Ile489 and Ala490, are critical for 







Figure 5-1: The interaction of peptide 9 and MDM2. (A) in vitro and in vivo peptide pulldown 
experiments reveal that peptide 9 interacts with FLMDM2. (data from Dr. S. Patterson). p1: 
peptide 1; p9: peptide 9. DMSO is used as a negative control. (B) MDMX C-tail bound to the 
C8-binding site of MDM2 RING domain. The crystal structure is from PDB structure 2VJE. 
(Left) MDMX RING domain is shown in cyan. MDMX C terminal-tail is shown in stick 
representations (magenta) (C= white; O = red; N = blue; S = yellow). MDM2 is shown in surface 
representations (white).peptide 9 is synthesised based upon the MDMX C-terminal twelve 
residues; therefore, peptide 9 is assumed to bind to the C8-binding site of MDM2. (C) in vitro 
ubiquitination assays of FLMDM2 (left) and MDM2RING (right) show that peptide 9 inhibits 
their E3 activity. Reactions are resolved by gradient SDS-PAGE, and detected by 
autoradiography using p53 antibodies (D01).  
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5.2 peptide 9-binding changes the conformation of FLMDM2  
Peptide 9 is synthesised according to the C-terminal twelve amino acids of MDMX and has 
been shown to inhibit MDM2 E3 ligase activity (Figure 5-1C). To support our hypothesis 
that peptide 9 binds to and induces conformational change in FLMDM2, we used intrinsic 
tryptophan fluorescence and measured the emission fluorescence spectra of apo-FLMDM2, 
FLMDM2-peptide 9, and FLMDM2-truncated peptide (Figure 5-2). 
 
5.2.1 The principle of intrinsic tryptophan fluorescence 
Intrinsic tryptophan fluorescence is a well-characterised and convenient method to detect 
changes in protein conformation under different conditions including pH, temperature, 
ligand-bound state or as a result of mutagenesis experiments (Crang & Rumsby, 1979; van 
Duffelen et al., 2004; Ramalingam et al., 2008). The fluorescence intensity of a folded 
protein is derived from the contributions from the intrinsic fluorescence of its constituent 
amino acids. Proteins contain three aromatic amino acids which exhibit fluorescence: 
tryptophan, tyrosine and phenylalanine. These three amino acids have different absorption 
and emission wavelengths. Tryptophan is a stronger emitter and has a higher quantum yield 
than tyrosine and phenylalanine. When a ligand binds to a target protein, it may induce 
conformational changes within the target protein. The local environment of tryptophan 
residues within the target protein may change, resulting in changes in the intrinsic tryptophan 
fluorescence spectrum between apo- and ligand-bound proteins. 
 
5.2.2 Methods and Materials: intrinsic tryptophan fluorescence 
Tryptophan intrinsic fluorescence experiments were carried out using a FLUOROMAX-3 
(HORIBA Jobin Yvon) spectrofluorometer. All measurements were carried out at 25 ℃. 
Each sample contained 1 ml solution in each eppendorf with 10 μM FLMDM2 in the buffer 
(25 mM HEPES, pH 7.5, 50 mM KCl, 2 mM DTT, 10 μM ZnSO4, 5% (v/v) glycerol) as 
used in previous experiments (Wawrzynow et al., 2009). 10 μM FLMDM2 with 10 μM 
peptide 9 or 10 μM truncated peptide was incubated on ice for 5 minutes prior to transfer of 
the mixture to 1 cm path length Quartz cuvette. The sample was allowed to equilibrate for 15 
minutes before intrinsic fluorescence intensities were measured.  For detection of tryptophan 
intrinsic fluorescence, experimental parameters were: excitation wavelength (λexc) set to 295 
nm, intrinsic fluorescence emission spectra (λemi) was collected over the range of 300 to 400 
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nm, and the bandwidth set to 5 nm. The data were corrected by subtraction of buffer 
fluorescence. All samples were measured in triplicate.  
 
5.2.3 Results and discussion: intrinsic tryptophan fluorescence 
FLMDM2 contains four tryptophan residues: W245, W303, W323 and W329 (Figure 5-2A). 
W245 is in the acidic domain and the other three residues are within the zinc finger domain. 
Hence, although there is no structure of FLMDM2 available, intrinsic tryptophan 
fluorescence is a useful technique to study the structural integrity of FLMDM2, the 
FLMDM2-peptide 9 complex and the FLMDM2-truncated peptide complex (Figure 5-2B). 
Our results showed that the maximum fluorescence intensity of apo-FLMDM2 (green line, 
Figure 5-2B) was 369950.7 cps with a λmax peak at 343 nm as seen in earlier experiments 
(Wawrzynow et al., 2009). Following incubation of 10 μM truncated peptide with FLMDM2, 
the tryptophan fluorescence spectrum of the mixture was similar to that seen with apo-
FLMDM2. The maximum fluorescence intensity is 356956.0 cps at 342.5 nm (blue line, 
Figure 5-2B), showing that the truncated peptide did not induce any conformational change 
in FLMDM2. These results are consistent with previous data showing that there is no 
binding between truncated peptide and FLMDM2 (Dr. Susanne Patterson, unpublished data). 
When 10 μM peptide 9 was incubated with FLMDM2, the tryptophan spectrum of 
FLMDM2-peptide 9 obtained showed that the maximum fluorescence intensity has increased 
to 411609.34 cps with a λmax peak at 340 nm (red line, Figure 5-2B). A significant increase in 
the intensity of the signal suggests that peptide 9 induced a perturbation in the folded state of 
FLMDM2. The blue shift (from 343 nm to 340 nm) also suggested that peptide 9 interacts 
with FLMDM2 and induces a conformational change in FLMDM2. The major shift of the 
λmax peak to a shorter wavelength means binding of peptide 9 may induce the reorientation of 
the tryptophan residues of FLMDM2 to adopt a more nonpolar environment. There is 
another minor emission peak at 358 nm, possibly contributed by one of the four tryptophan 
residues within FLMDM2. 
 
Previous reports indicate the C-terminus of MDM2 or MDMX is essential for the 
dimerisation of MDM2/MDM2 homodimer or MDM2/MDMX heterodimer (Poyurovsky et 
al., 2007). Because our peptide 9 has the same sequence as that of the MDMX C-terminal 
twelve amino acids, the binding site of peptide 9 to FLMDM2 is proposed to be located in 
the C8-binding site of MDM2 RING domain as seen in the model structure (Figure 5-1B). 
FLMDM2 contains four tryptophan residues which are located in a flexible region. The blue 
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shift to a shorter wavelength provides evidence that peptide 9 induces structural changes in 
FLMDM2. However, the actual binding site of peptide 9 to FLMDM2 is as yet unclear. 
Further studies are required to determine whether the changes in intrinsic fluorescence were 
caused by the direct interaction of peptide 9 with tryptophan or by an allosteric effect.  
 
In summary, our tryptophan intrinsic fluorescence data were consistent with previous data 
(Figure 5-1), and provide evidence that peptide 9 bound to FLMDM2, inducing a 
conformational change in FLMDM2 to buried the tryptophan in more hydrophobic 
environment. Our findings also suggest that the last two amino acids of peptide 9, Ile489 and 
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 10 μM FLMDM2+10 μM peptide 9 








10 μM FLMDM2 343.0 369950.7
10 μM FLMMDM2 + 10 μM truncated peptide 342.5 356956.0
10 μM FLMMDM2 + 10 μM peptid 9 340.0 411409.3  
Figure 5-2: peptide 9 induced a conformational change in FLMDM2. (A) FLMDM2 has four 
tryptophan residues (highlighted in red in the sequence): one is located in the acidic domain, with 
three in the zinc finger domain. (B) Intrinsic tryptophan fluorescence spectra of FLMDM2 
(green), FLMDM2-truncated peptide (blue), FLMDM2- peptide 9 (red).  
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5.3 The putative peptide 9-binding site: the C8-binding site of 
MDM2RING 
Previous studies confirmed that peptide 9 bound to FLMDM2 and inhibited its E3 activity 
(Figure 5-1, 5-2). The next question we asked was what is the peptide binding site within 
FLMDM2? Our initial assumption was that the MDM2 RING domain was likely to be the 
binding site for peptide 9 (a MDMX C-terminus). The crystal structure of the 
MDM2/MDMX heterodimer (PDB: 2VJE) showed that the MDMX C-terminus interacts 
with the C8-binding site of MDM2 RING domain (Figure 5-1B).  
 
In general, the interaction interface is a critical determinant of protein-protein affinities: a 
greater buried surface provides higher binding affinities (Hoeflich & Ikura, 2002). A newly 
built structure of the MDM2-peptide 9 complex (Figure 5-3A) was generated based on the 
crystal structure of MDM2-MDMX (PDB: 2VJE). Here, peptide 9 was assumed to bind in 
the same way as the last twelve C-terminal residues of MDMX. This modelled structure was 
used as a template for the calculation of the buried surface areas (BSA) of the MDM2-
peptide 9 interaction using the PISA program (Protein Interfaces, Surfaces, and Assemblies), 
that is available to calculate the buried surface based on coordinate data from the PDB 
(http://www.ebi.ac.uk/msd-srv/ prot_int/pistart.html). The results showed that in the MDM2-
peptide 9 complex, the buried surface area of peptide 9 and MDM2 within the complex were, 
respectively, 503.1 Å2 and 444.7 Å2 (Table 5-1). The buried surface of peptide 9 amounted to 
88% of the accessible surface of the complex. Generally, if the ligand fits well in the binding 
site of the target, buried surface areas of both ligand and target should be similar (Wu et al., 














Figure 5-3: Three dimensional structure of the putative peptide 9 binding site within the 
C8-binding site. (A) peptide 9 (a MDMX C-terminal twelve amino acids) is highlighted in 
yellow and MDM2RING is shown in surface representation coloured according to atom types 
(C= white; O = red; N = blue; S = yellow). (B) The structure of the peptide 9-MDM2 complex, 
same as (A), generated using the PISA program.  MDM2 is shown in cyan spheres and peptide 9 
is coloured according to the contribution of each residue to the buried surface areas of the 
MDM2-peptide 9 complex.  (Contribution: green, high; red, medium, and blue: low). Both 
figures are based on the crystal structure of MDM2-MDMX (PDB: 2VJE). 
 
Table 5-1: The buried surface areas (BSA) of MDM2-peptide 9 and MDM2-truncated 
peptide are calculated using PISA program. The CPS and the number of H-bonds were also 
shown.  
Buried sureface area (Å²)    
peptide MDM2 CPS H-bond
MDM2-peptide 9
(KEIQLVIKVFIA)
503.1 444.7 0.71 8
MDM2-truncated peptide
(KEIQLVIKVF)
311.8 282.0 0.06 5
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Interaction interface studies also revealed that the last two residues, Ile and Ala, were critical 
for the interaction of MDM2 with peptide 9. There were eight intermolecular H-bonds in the 
MDM2-peptide 9 complex (Figure 5-4B): Lys486-amide to Lys454-oxygen; Lys486-oxgen 
to Thr455-Og1; Lys486-oxgen to Leu458-amide; Phe488-amide to Gly456-oxygen; Phe488-
oxgen to Leu458-amide, Ile489-oxygen to Asn433-Nd2; Ala490-oxygen to Lys446-Nz; and 
Ala490-amide to Leu458-oxygen. Results also showed that the last 8 residues of peptide 9 
contributed most to the complete buried surface areas (Figure 5-4A). Buried surface areas 
between the truncated peptide and MDM2 in the complex, were respectively, 311.8 Å2 and 
282.0 Å2 (Table 5-1). However, the truncated peptide interacted with MDM2 through only 
five H-bonds (Figure 5-4B). Moreover, the last two residues in peptide 9, Ile and Ala, 
contributed approximately 43% of the buried surface areas in the complex and also provided 
three H-bonds (Figure 5-4A). Those results could explain why the truncated peptide lost 
binding ability in our intrinsic fluorescence experiments. Moreover, the CPS value of 
MDM2-peptide 9 and MDM2-truncated peptide 9 were 0.713 and 0.06 (Table 5-1). The CPS 
values range from 0 to 1 and a higher score means a greater likelihood of complexation. This 
provides additional support for the importance of the last two residues of peptide 9 in the 
interaction with MDM2 (Table 5-1). In summary, according to our analysis of buried surface 
areas in the MDM2RING-peptide 9 complex, the C8-binding site of MDM2RING is likely 








Figure 5-4: The putative peptide 9 binding site is in the C8-binding site of MDM2RING 
domain. (A)The sequence and the putative secondary structure of peptide 9 are shown. The bar 
graph above the sequences of the peptide presents the buried surface area of each peptide 9 
residue complexed with MDM2RING. (B) The corresponding residues contributed to the H-
bonds between MDM2-peptide 9 (upper left panel) and MDM2-truncated peptide (upper right 
panel). MDM2 is shown in white surface representation and the residues shown in cyan surface 
are involved in the H-bond interaction. Both peptides are shown in magenta cartoon and residues 
involved in the H-bonds are highlighted in yellow sticks. The H-bonds are also shown in dashed 
red lines. 
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Eight  putative H-bonds 
between peptide 9 and  MDM2
Five  putative H-bonds between 

















  Chapter 5 
 129 
5.4 Does peptide 9 really bind to the C8-binding site of MDM2RING?  
A previous report shows that the MDM2 RING domain can allosterically regulate the 
conformation of MDM2 (Wawrzynow et al., 2009). Additional supporting data was obtained 
from our intrinsic tryptophan fluorescence experiments with FLMDM2-peptide 9 (section 
5.2) and the analysis of the buried surface areas of the MDM2-peptide 9 complex (section 
5.3). The data suggested that the C8-binding site of MDM2 could be the binding site for 
peptide 9. To evaluate this assumption, studies of the interaction of MDM2RING and 
peptide were required. MDM2RING (residues 386-491), contains no tryptophan residues; 
therefore intrinsic tryptophan fluorescence experiments are not appropriate to study this 
interaction. An alternative approach was required to study the interaction of peptide 9 with 
MDM2RING or MDM2RING△C. MDM2RING△C (residues 386-478) was also chosen 
here because it lacks the C-tail and may therefore have an accessible C8-binding site for the 
binding of peptide 9. A number of techniques were used:  fluorescence anisotropy to study 
the affinity of peptide 9 to MDM2RING, and electrospray ionisation mass spectrometry 
(ESI-MS) to analyse whether peptide 9 bound to MDM2RING.   
 
5.4.1 The principles of fluorescence anisotropy 
The principle behind fluorescence anisotropy is to monitor fluorescence intensities of the 
fluoroprobe-labeled ligand apo- and holo- molecules (Figure 5-5). Free fluoroprobe-labeled 
ligands can be peptides or small molecules. Free fluoroprobe-labeled ligands have a very fast 
relaxation time and show low anisotropy, because the tumbling rate is fast. However, when 
the fluoroprobe-labeled ligands bind to their targets, such as proteins, the tumbling rate of 
the larger complex becomes slower; resulting in an increase in the fluorescence emission 
(high anisotropy). The fluorescence anisotropy assay has been widely used to measure the 
binding affinity of protein to ligands (Brown et al., 2008; Harker et al., 2009; Hernandez-
Valladares et al., 2010). The binding affinity of a ligand to the target can be calculated from 
the fluorescence intensity change of fluorescently-labeled ligands as a function of protein 
concentration (Figure 5-5). To confirm our hypothesis that peptide 9 binds to the C8-binding 
site, we used fluorescence anisotropy assays to monitor the binding affinities of peptide 9 
with two MDM2RING domain constructs, MDM2RING and MDM2RING△C.  




































labeled- peptides bound to protein,
Tumbling is slow
 
Figure 5-5: The basis of fluorescence anisotropy. The detection of the fluorescence intensity 
depends on the tumbling rates of the fluoroprobe -labeled molecule. The fluoroprobe is shown as 
a yellow star. When more fluoroprobe-labeled ligands bind to the target protein, the value of the 
anisotropy increases. 
 
5.4.2 Materials and Methods: Fluorescence anisotropy 
Fluorescence anisotropy was used in this work to measure the binding affinity of peptide 9 
for MDM2RING, MDM2RING△C or UbcH5a. To determine the dissociation constant of 
peptide 9 with MDM2RING, fluorescein-labeled peptide 9 (FITC-peptide 9) was used.  As a 
negative control, a FITC-truncated peptide was synthesised. All peptides were dissolved in 
100% DMSO.  
 
Fluorescence anisotropy experiments were performed in 96-well black plastic plates using a 
Thermo-fluorescence reader. Fluorescence anisotropy was measured using the following 
conditions: the excitation wavelength was set to 490 nm, the emission fluorescence was 
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measured at 530 nm, with an accompanying cutoff at 515 nm. Serial dilutions were prepared 
prior to being titrated into the fluorescein-labelled peptides. MDM2RING and 
MDM2RING△C were prepared in Tris-buffered solution (20 mM Tris, pH7.2, 150 mM 
NaCl, 10 μM ZnSO4), UbcH5a was also prepared in the same solution minus ZnSO4. The 
final concentration ranges of those three proteins were from 0.02 to 20 μM. The final 
reaction volume was 200 μl, each containing target protein and 250 nM fluorescein-labelled 
peptide 9. To allow the reaction to reach equilibrium, the samples were incubated for 30 
minutes at room temperature, the fluorescence anisotropy of each well was then measured. 
To minimise the decay of fluorescein, the plate was covered with foil during the incubation. 
Averaged fluoresce anisotropy was plotted as a function of the protein concentration. All 
averaged fluorescence anisotropy values were determined from at least three sets of samples. 
The dissociation constant (Kd) was calculated using the Hill coefficient using the equation 
below (Heyduk & Lee, 1990):  


















  F     measured average fluorescence polarization 
  F L    fluorescence polarization of free labelled peptide  
  F LP   maximum fluorescence polarization of the peptide-protein 
  Kd   equilibrium dissociation constant of the peptide-protein complex   
  [L]T  total concentration of labelled peptide  
[P]T  total concentration of protein 
 
 
5.4.3 Results and Discussions: Fluorescence anisotropy 
In our fluorescence anisotropy experiments, peptide 9 was labeled with a FITC probe, which 
is excited by light at a wavelength of 495 nm, and emits a fluorescence signal at 530 nm. The 
initial assumption is that when FITC-peptide 9 binds to the target protein, MDM2RING, the 
complex would immobilise the labeled peptide making the fluorescence signal readily 
detectable. Using this method, the binding affinities of peptide 9 to MDM2RING and 
MDM2RING△C can be calculated. 
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The C8-binding site of MDM2RING has been shown to be buried within the dimer (Figure 
5-1B). Another construct, MDM2RING△C, lacking the C-tail, was used in this experiment 
as its C8-binding site is likely be solvent exposed and accessible for peptide 9-binding. 
Therefore, if the binding site of peptide 9 within MDM2 is as expected, the C8-binding site 
of the RING domain, binding affinity of peptide 9 to MDM2RING△C should be higher than 
that seen with MDM2RING. In addition, to exclude the possibility that peptide 9 binds 
nonspecifically, BSA protein was used as a negative control in this assay. No significant 
fluorescence anisotropy change of peptide 9 in the presence of BSA was seen (Figure 5-6A), 
suggesting peptide 9 binds specifically. Fluorescence anisotropy studies showed that peptide 
9 interacted with MDM2RING and MDM2RING△C (Figure 5-6A). The Kd of FITC-
peptide 9 with MDM2RING was approximately 355.6 ± 113.6 nM, that of MDM2RING△C, 
Kd = 314.3 ± 157.9 nM (Figure 5-6B).  
 
Previous work in Kathryn Ball’s lab had characterised a truncated peptide which did not 
inhibit FLMDM2 E3 ligase activity. We used the truncated peptide (missing residues of IA 
at the C-terminus) as negative control for fluorescence anisotropy, and showed that no 
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MDM2RING exposed / buried





































MDM2RING [uM]  
Kd (nM)
MDM2RING 355.6 ± 113.6
MDM2RING△C 314.3 ± 157.9
    
(PDB: 2HDP)
        
Figure 5-6: Fluorescence anisotropy analysis of the interaction of peptide 9 with MDM2 
RING domain. (A) Fluorescence anisotropy change of FITC-peptide 9 with three proteins: 
MDM2RING (red line), MDM2RING△C (blue line) and BSA (). (B)The Kd of FITC-peptide 
9 to MDM2RING is calculated to be 355.6 ± 113.6 nM. (C) The Kd of FITC-peptide 9 to 
MDM2RING△C is 314.3 ± 157.9 nM. The Kd was calculated as described as in the Materials 
and Methods section. 
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5.5 ESI-MS: the interaction of peptide 9 and MDM2RING 
5.5.1 The principle of ESI-MS 
To further confirm that peptide 9 binds to MDM2RING, we carried out ESI-MS 
(electrospray ionization mass spectrometry) experiments. ESI-MS is commonly used to 
identify the mass of a molecule, and has recently also been used in the study of protein-
ligand interactions (Burkitt, et al., 2003; Blackburn, et al., 2010; Keith-Roach, 2010). The 
output of ESI-MS is similar to that of MALDI-TOF-MS (introduced in Chapter 2). The mass 
of a molecule measured by these two mass spectrometry methods are both based on the ratio 
of the mass to charge (m/z) value (Feng & Konishi, 1992; Hillenkamp, et al., 1991; Richard, 
1997). Since matrix and sample are ionised by a high voltage laser used in MALDI-TOF, 
oligomers or a protein-ligand complex are easily separated into discrete species. ESI-MS is a 
gentle method to ionise the molecules, producing less fragmentation of complexes, which is 
especially important for weakly bound complexes using noncovalent interactions (Bruce, et 
al., 1991; Katta & Chait, 1991). In ESI-MS experiments, by determining the charge of ions 
in the sample, the mass can be calculated and for protein-ligand interactions, the m/z shift of 
the complex compared to that expected from apo-protein provides the required information. . 
  
5.5.2 Materials and Methods: ESI-MS 
Positive-ion ESI mass spectra were generated by the instrument (LCQ Deca, ThermoFischer) 
to monitor the charge state distribution of proteins and of the protein-peptide complex. There 
were two proteins studied in the work: 14 μM MDM2RING△C and 10 μM UbcH5a. 
Moreover, proteins were titrated with peptide 9. For protonation of proteins, both were 
exchanged into experimental ESI-MS buffer (20 mM ammonium acetate, pH6.0). peptide 9 
was dissolved in 50% MeOH with 50% ddH2O (v/v) for interaction studies with 
MDM2RING△C. peptide 9 was dissolved in 2.5% acetic acid with  95% ddH2O for 
interaction studies with UbcH5a. The protein-peptide 9 complex was incubated in an 
eppendorf at room temperature for 30 minutes prior to infusion. The parameters for the 
operation were set as below: analyte flow rate 15 μl min-1; capillary voltage 3.3 kV; cone 
voltage 30 V; source block temperature 80℃ and desolvation gas temperature 100℃. The 
ESI mass spectrum plots relative abundance as a function of mass-to-charge (m/z). The mass 
of each charge state species was calculated using the deconvolution program.  
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5.5.3 Results and Discussions: ESI-MS data of MDM2 RING△C and peptide 9 
 apo-MDM2 RING△C 
MDM2RING△C was chosen to the study the interaction with peptide 9 using ESI-MS as 
MDM2RING△C is single species (a dimer, as discussed in Chapter 2) and also has been 
shown to have high affinity to peptide 9 (Figure 5-6). As high concentrations of salts and 
detergents can interfere with ESI-MS analysis, after extensive trials, we finally found 
appropriate conditions for the ionisation of MDM2RING△C. MDM2RING△C protein was 
expressed and purified in media and buffers containing zinc acetate, rather than zinc sulfate, 
as acetate is volatile and can improve protonation during the electrospray process. 
Additionally, to eliminate salt effects and have high mass accuracy in the ESI-MS 
experiment, the protein was buffer exchange into the “experimental” buffer (20 mM 
ammonium acetate, pH6.0) prior to ESI-MS analysis. 
 
The ESI-MS mass spectrum of apo-MDM2RING △ C showed a discrete charge state 
distribution (Figure 5-7A) and the resulting ESI-spectrum illustrated that MDM2RING△C 
was likely to be folded as only a narrow range of charge-states are dominant in the spectrum. 
Protein calculator (http://www.scripps.edu /~cdputnam/protcalc.html), a program designed to 
predict molecular weight, the amounts of basic amino acids and pI from a protein sequence.  
A theoretical pI of MDM2RING△C is 6.3 (Table 5-2A). The pH value of the experimental 
buffer used in ESI-MS is 6.0; this means that MDM2RING△C should carry positive ions in 
the ESI-MS experiments (Table 5-2A). Considering MDM2RING△C has a number of basic 
amino acids (9 lysines, 3 arginines and 3 histidines), the measured charge distribution of the 
protein could have up to 15 protons attached. There were two dominant charge state species 
seen in the ESI-MS spectrum: “P7” ([MDM2RING△C+7H]7+) at an m/z of 1567.6 and “P6” 
([MDM2RING△C +6H]6+) at an m/z of 1828.8 (Figure 5-7A). Here, “P” represents protein 
(MDM2RING△C) and “number” represents the charge state. It is evident that some basic 
amino acids are buried in the folded protein and therefore, these two peaks with fewer 
protons were observed (Patriksson et al., 2007; Lafitte et al., 1999). A more detailed analysis 
showed that there were secondary peaks at an m/z of 1558.7 and 1818.1 (lower intensities) 
immediately adjacent to the major peaks. A deconvolution software package was used to 
calculate masses. The mass of the two species of MDM2RING△C were 10,966 and 10,903 
Daltons, respectively (Figure 5-7B, Table 5-2B). The difference in the mass (△mass = 63) 
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between the two species suggested that one form may be MDM2RING△C with two zinc 
ions (10,966 Daltons) and the other could be MDM2RING△C with one zinc ion (10,903 
Daltons). The mass of one zinc molecule is 65.38 Daltons. This suggests that 
MDM2RING△C might lose one zinc molecule during the expression or purification process. 
Overall, the ESI-MS spectrum demonstrated that MDM2RING△C is a well-folded protein, 
suitable for ligand-binding experiments.   
(A) 
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Figure 5-7: The ESI mass spectrum of MDM2RING△C (14 μM in 20 mM ammonium 
acetate). (A) The original ESI-MS spectrum shows there are two major charge state species: P7 
and P6 with 7 and 6 protons attached, respectively. (B) The mass-converted deconvolution 
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spectrum of MDM2RING△C. Two major species are detected: MDM2RING△C(Zn)2 and 
MDM2RING△C(Zn)1. Data was obtained on an LCQDeca (ThermoFischer instrument). The 
source temperature was 80℃. 
 
 
Table 5-2: The theoretical and experimental mass and charge state of MDM2RING△C. (A) 
The theoretical pI and the numbers of basic amino acids in MDM2RING△C. (B) After the 
deconvolution process, the average of the experimentally derived mass is less than 1% different 
from the theoretical mass. (C) The mass is calculated from the higher charge part of the ESI-mass 
spectrum of MDM2RING△C with two strong maxima of around seven and six attached protons.  
(A) (B) 
MDM2RING△C
*estimated pI = 6.3
 *basic amino acids:
lysine (9); arginine (3), histidine (3)  










Peaks charge ions m/z mass estimated composition 
P7 7+ 1567.6 10966.2 MDM2RING△C-(Zn)2
7+ 1558.7 10903.9 MDM2RING△C-(Zn)1
P6 6+ 1828.8 10966.8 MDM2RING△C-(Zn)2
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 Expected m/z value of MDM2 RING△C-peptide 9 
To evaluate the binding affinity and the stoichiometry of peptide 9 with MDM2RING△C, 
we carried out titration experiments using ESI-MS. In this experiment, peptide 9 was 
dissolved in 10% MeOH, because DMSO has deleterious effects upon ESI-MS. In the 
experiments, 14 μM MDM2RING△C in solution (buffer with 10% MeOH) was used and 
peptide 9 was titrated into MDM2RING△C, using several protein: ligand (P:L) ratios, such 
as 1:2, 1:4, 1:8, and 1:10, followed by incubating at room temperature for 30 minutes prior to 
ESI-MS analysis. If peptide 9 bound to MDM2RING△C, an m/z shift should be observed. 
The calculated molecular weight of the complex (PL) was 12379.3 Daltons (10979.8+1399.5 
= 12379.3). The mass of peptide 9 used in the work was 1399.5 Daltons. Therefore, peaks at 
m/z of 1768.5 and 2063.2 for [PL+7H]7+ and [PL+6H]6+ (Table 5-3) might be expected.  
 








expected peak at m/z
[PL+7H]7+ (12379.3+7) / 7 = 1769.5 
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  peptide 9 was detected using ESI-MS  
Representative plots of the ion intensities of peptide 9 as a function of the m/z value with 
different ratios of protein to peptide (P:L) clearly revealed that peptide 9 was saturated at a 
ratio of 1:8 or 1: 10. As Figure 5-8 shows, the predominant peaks representing peptide 9 in 
this spectrum were seen in with a protein: peptide ratio of 1: 10. There were two dominant 
peaks at m/z values of 700.7 and 1399.5, that represented the species “L2” ([peptide 9 
+2H]2+) and “L1” ([peptide 9+1H]1+), respectively. Here, “L” represents peptide 9 and 
“number” represents the charge state. After deconvolution, the mass of peptide 9 was 1399.4 






























[peptide 9 + 2H] 2+













L2 700.7 2 1399.5 1399.4 100.0%
L1 1399.5 1 1399.5 1398.5 99.9%  
 
Figure 5-8: ESI-MS data of peptide 9 detected at different titration points. (A) There are two 
dominant species in a solution: “L2” ([peptide 9 + 2H]2+) and “L1” ([peptide 9 + 1H]1+) at the 
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 apo-MDM2RING△C in ESI-MS buffer (20 mM ammonium acetate with (10% MeOH) 
In this work, peptide 9 was largely insoluble in ddH2O, therefore, 10%MeOH was added to 
dissolve peptide 9. Following mixing of peptide 9 (dissolved in 90% water and 10% MeOH 
(v/v)) with MDM2RING △ C, the pH of the sample was monitored throughout the 
experiment, and was shown to be between pH5.5~ 6.0. ESI-MS titration experiments were 
carried out in a buffer in which MDM2RING△C is stable and monodisperse. Under these 
buffer conditions, MDM2RING△C and peptide 9 carry positive ions. The spectra of the 
titration experiments showed there were distinct charge state species in solution (Figure 5-9 
& 5-10, Table 5-4). The data from the experiment (protein only) showed that there were two 
major peaks with m/z values of 1591.1 (“P7”, [MDM2RING△C +7H]7+) and 1854.1 (“P6”, 
[MDM2RING △ C+6H]6+), with calculated masses of 11,137.7 and 11,118.0 Daltons, 
respectively (Figure 5-9). The accuracy associated with the theoretical mass of the apo-
protein was approximately 98.6% and 98.8 %, respectively. In ESI-MS experiments, it has 
been shown that identical samples in different sample buffers can generate different spectra, 






















































apo-protein P7 1591.1 7 10979.8 11130.7 98.6% monomer
P6 1854.0 6 10979.8 11118.0 98.8% monomer
P5 2222.2 5 10979.8 11106.0 98.9% monomer  
Figure 5-9: ESI-MS spectrum of apo-MDM2RING△C (in 20 mM ammonium acetate with 
5% MeOH). There are two major charge state species with m/z value of 1591.1 (with 7 protons) 
and 1854.0 (with 6 protons). The experimental mass is shown in the table. Major charge state 
species are labelled as P7, P6, and P5. 
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 New peaks observed in the spectrum of MDM2RING△C in the presence of peptide 9 
In the presence of peptide 9, new peaks are observed in the spectra (PPL8, PPL7 and PPL6) 
and the relative abundance of original peaks representing apo-MDM2RING△C (P7, P6 and 
P5) reduced (Figure 5-10).  With high concentrations of peptide 9 in solution (P:L =1:8), L1 
and L2, representing peptide 9, became more dominant because peptide 9 is readily ionised 
with positive charge.  
 
On the basis of the ESI-MS data, the experimental mass of P7, P6, and P5 (ratios of 1:2, 1:4, 
and 1:8) was approximately 11062 ~112459 Daltons, demonstrating that these species 
existed as an apo-monomer (Table 5-4B). In theory, if peptide 9 did not interact with 
MDM2RING△C, the P3 (at an m/z pf 3197.0) and P2 (at an m/z of 3741.2) species (Figure 
5-11) detected in the sample (P:L =1:8) would correspond to the charge state with three 
protons ([MDM2RING△C +3H]3+) and two protons ([MDM2RING△C +2H]2+), with a 
calculated mass for P3 and P2 of 9588.0 and 7480.4 Daltons, respectively, with an accuracy 
of 87.7% and 68.1% compared to the theoretical mass of monomeric MDM2RING△C 
(Table 5-4B). Because the level of accuracy was very low, this suggests that the P3 and P2 
species are not monomeric MDM2RING△C. 
 
After a manual calculation, the data (Table 5-4C) showed the charged states of those new 
species are PPL8 (at an m/z of 2864.6), PPL7 (at an m/z of 3209.3) and PPL6 (at an m/z of 
3741.2) being likely +8, +7 and +6, respectively, with an experimental mass range of about 
22323 ~ 22919 Daltons (Table 5-4C). According to the mass of these species, the PPL8, 
PPL7 and PPL6 species were likely the 2MDM2RING△C-peptide 9 complex (2P + L) 
(theoretical mass: 23359.1 Daltons). The experimental mass of each species compared to the 
theoretical mass of each species was at least 96% accurate (Table 5-4C). For example, the 
data obtained from the (P:L=1:8) sample showed the experimental mass of the predominant 
PPL8 in the charge state of 8 protons was approximately 22908.8 Daltons, with an accuracy 
of 98.1% (Figure 5-10 & Table 5-4C). 
 
Consistent with our fluorescence anisotropy experiments, these data provided evidence that 
peptide 9 interacts with MDM2RING△C. Our initial assumption is that peptide 9 binds to 
the C8-binding interface interface of MDM2RING△C at ratio of 1:1; however, the 
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MDM2RING△C-peptide 9 (P+L) complex was not detected. Instead, in the presence of 
peptide 9, MDM2RING△C is predominately dimeric, forming the 2MDM2RING△C –
peptide 9 complex (PPL). Presumably, peptide 9 interacts with the C8-binding interface of 
each MDM2RING△C. The data suggest that, under the conditions of the mass spectrometry 
experiment, peptide 9 interacts with a ring dimer and appears not to disrupt the protein-



















Figure 5-10: ESI-MS spectra of MDM2RING△C with peptide 9. The ESI- MS spectra show 
that relative abundance against the m/z function, and four samples are tested: apo-protein, P:2L  
(1:2), P:4L (1:4), and P:8L (1:8). After peptide 9 is incubated with MDM2 RING△C, three 
charge species appear: PPL8, PPL7 and PPL6. In the spectrum generated with a ratio (1:8), the 
m/z value of each species is shown and the possible composition in each species is presented: 
protein (green sphere) and peptide 9 (yellow arrows).  
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Table 5-4: Estimated charge-states and molecular weights of MDM2RING△C monitored 
by the ESI-MS. 
(A)  
oligomeric state mass (Da)
P: MDM2RING△C 10979.8
L: peptide 9 1399.5
P+L 12379.3
2(PL) 24758.6
2P+L 23359.1  
 (B)   









apo-protein P7 1591.1 7 10979.8 11130.7 98.6%
P6 1854.0 6 10979.8 11118.0 98.8%
P5 2222.3 5 10979.8 11106.5 98.9%
1:2 P7 1581.5 7 10979.8 11063.5 99.2%
P6 1853.7 6 10979.8 11116.2 98.8%
P5 2239.4 5 10979.8 11192.0 98.1%
P4 2861.1 4 10979.8 11440.4 96.0%
P3 3190.0 3 10979.8 9567.0 87.1%
P2 3743.2 2 10979.8 7484.4 68.2%
1:4 P7 1581.4 7 10979.8 11062.8 99.2%
P6 1842.7 6 10979.8 11050.2 99.4%
P5 2222.3 5 10979.8 11106.5 98.9%
P4 2865.9 4 10979.8 11459.6 95.8%
P3 3191.1 3 10979.8 9570.3 87.2%
P2 3739.7 2 10979.8 7477.4 68.1%
1:8 P7 1581.4 7 10979.8 11062.8 99.2%
P6 1853.1 6 10979.8 11112.6 98.8%
P5 2222.3 5 10979.8 11106.5 98.9%
P4 2864.6 4 10979.8 11454.4 95.9%
P3 3197.0 3 10979.8 9588.0 87.3%
P2 3741.2 2 10979.8 7480.4 68.1%  
(C) 









1:2 PPL8 2861.1 8 23359.1 22880.8 98.0%
PPL7 3190.0 7 23359.1 22323.0 95.6%
PPL6 3743.2 6 23359.1 22453.2 96.1%
1:4 PPL8 2865.9 8 23359.1 22919.2 98.1%
PPL7 3191.1 7 23359.1 22330.7 95.6%
PPL6 3739.7 6 23359.1 22432.2 96.0%
1:8 PPL8 2864.6 8 23359.1 22908.8 98.1%
PPL7 3197.0 7 23359.1 22372.0 95.8%
PPL6 3741.2 6 23359.1 22441.2 96.1%  
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5.6 Does peptide 9 also bind to E2 protein, UbcH5a?  
The importance of the MDM2-C terminus for MDM2 E3 ligase activity has been confirmed 
by mutagenesis, deletion, and biochemical studies (Kawai et al., 2007; Linke et al., 2008; 
Uldrijan 2007). They suggest that the MDM2 C-terminus is responsible for the dimerisation 
that is a determinant for MDM2 E3 ligase activity. Moreover, there is one report showing 
that MDM2-MDMX△C7 is E3 active and MDMX-MDM2△C7 does not have E3 activity 
(Uldrijan et al., 2007). This result suggests that MDMX C-terminus rescues the function of 
MDM2 C-terminus. Other reports mention that MDM2 C-terminus may be involved in the 
interaction with its cognate E2 protein (Poyurovsky et al., 2007). We assumed that MDMX 
C-terminus should have the same interactions as MDM2 C-terminus and presumably also 
interact with MDM2 cognate E2 proteins.  
 
5.6.1 Thermal denaturation assay: the interaction of UbcHa5a and peptide 9 
In this work, to verify the assumption that peptide 9 might interact with MDM2 cognate E2, 
peptide 9 (an MDMX C-terminal 12 residues) was used to study the interaction with one of 
MDM2 cognate E2 partners, UbcH5a. Firstly, to examine if peptide 9 binds to UbcH5a and 
affects the thermal stability of UbcH5a, we used the thermal denaturation assay to 
characterise the thermal unfolding transition peak of UbcH5a. The theoretical basis of 
thermal denaturation assay was described in detail in Chapter 3. The technique can be used 
to detect the midpoint temperature (Tm) of a thermal unfolding transition peak which is an 
indicator of the thermal stability. The fluorescence emission (RFU) of 2.5 μM apo-UbcH5a 
started to increase at 52℃, reaching a maximum at 62℃ (blue line, Figure 5-11), while the 
fluorescence emission of the solution containing 2.5 μM apo-UbcH5a with 25 μM peptide 9 
increased from 41℃  to a maximum of 59℃  (red line, Figure 5-11). The fluorescence 
intensity of the complex was higher than that of apo-UbcH5a. To exclude the possibility that 
the higher fluorescence intensity might be generated by peptide 9, we also monitored the 
thermal unfolding transition peak of peptide 9 alone (25 μM) (orange line, Figure 5-11). The 
data showed that peptide 9 itself did not affect the background in the experiment. The 
increased fluorescence intensities detected in the presence of 2.5 μM apo-UbcH5a with 25 
μM peptide 9 suggested that peptide 9 might induce conformational changes in UbcH5a, 
exposing interior hydrophobic residues, detectable by an increased signal from the SYPRO 
Orange dye. Plotting the gradient of fluorescence intensities as a function of temperature 
revealed that the Tm of the thermal unfolding transition of UbcH5a was 58℃, the Tm of the 
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UbcH5a-peptide 9 complex dropped to 54℃ (Figure 5-11). Taken together, this significant 
reduction in the Tm of the complex and the increased fluorescence intensities detected in the 
presence of 2.5 μM apo-UbcH5a with 25 μM peptide 9 suggested that peptide 9 might 
destabilise UbcH5a exposing more hydrophobic residues to the environment.  
 
















2.5 μM UbcH5a +25 μM peptide 9






















2.5 μM UbcH5a +25 μM peptide 9
25 μM peptide 9
 
Melting temperature
2.5 μM UbcH5a 58℃
2.5 μM UbcH5a +25 μM peptide 9 54℃
25 μM peptide 9 N.D.  
 
Figure 5-11: Thermal stability of UbcH5a, the UbcH5a-peptide 9 complex and peptide 9. 
The melting point (Tm) of the thermal unfolding transition of each sample is monitored over the 
range of 20℃ to 95℃ by TDA, using SYPRO Orange fluorescence dye. The unfolding transition 
curve of apo-UbcH5a, UbcH5a-peptide 9, and peptide 9 are coloured in blue, red, and orange, 
respectively.  
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5.6.2 Fluorescence anisotropy studies: the interaction of UbcHa5a with 
peptide 9 
To evaluate the binding affinities of peptide 9 to UbcH5a, we utilised the fluorescence 
anisotropy technique. In this work, UbcH5a was titrated into two derivates of fluorescein 
(FITC) labeled peptides, FITC- N’-peptide 9, and FITC-C’-peptide 9, the FITC moiety being 
attached onto the N-terminus and C-terminus of peptide 9, respectively. FITC-truncated 
peptide, lacking of the last two amino acids compared to peptide 9, was used a negative 
control. Different concentrations of UbcH5a were incubated with 250 nM peptides for 60 
minutes; changes in fluorescence anisotropy were measured. The data showed that both 
FITC-labeled peptide 9 molecules interacted with UbcH5a because both fluorescence 
anisotropy curves ascended according to the plot of the gradient of anisotropy as a function 
of concentrations of UbcH5a (Figure 5-12). The calculated Kd of UbcH5a to FITC-
N’peptide 9 and FITC-C’ peptide 9 were 101.4 ±70.7 nM and 143.1 ± 60.0 nM, respectively. 
The result showed that UbcH5a has similar binding affinities with these two peptides. 
Changes in the fluorescence anisotropy curve were observed; demonstrating that peptide 9 
interacted with UbcH5a. As expected, a negative control, FITC-truncated peptide 9 did not 





















●FITC-N’-peptide 9          
■FITC-C’-peptide 9            
▲FITC-truncated peptide 
  
UbcH5a with Kd (nM)
FITC-N'-peptide 9 101.4 ±70.7 
FITC-C'-peptide 9 143.1 ± 60.0 
FITC-truncated peptide N.D.   
Figure 5-12: Fluorescence anisotropy binding studies. UbcH5a titrated into different 
fluorescein (FITC)-labelled peptides (250 nM): FITC-N’-peptide 9 (●), FITC-C’- peptide 9 (■), 
and FITC-mutant peptide (▲).  N.D.: not determined. 
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5.6.3 ESI-MS study: the interaction of UbcHa5a and peptide 9 
 ESI-MS spectrum of apo-UbcH5a  
To confirm the interaction between UbcH5a and peptide 9, we used ESI-MS to monitor peak 
distributions in the spectra of both UbcH5a and the UbcH5a-peptide 9 complex. The mass 
spectrum of apo-UbcH5a showed a classical bell-shaped charge state distribution (Figure 5-
13). The dominant peak was P9 ([UbcH5a+9H]9+)at m/z of 2071.1. There were other peaks 
present representing, species with different charge states. Based on the amino acid sequence 
of UbcH5a, the Protein Calculator 3.3 program calculated a mass of 18896.5 Daltons, with 
an estimated pI value of 7.94, with 28 basic amino acids including 10 lysines, 6 arginines 
and 12 histidines (Table 5-5). Moreover, apo-UbcH5a was stored in a solution of 20 mM 
ammonium acetate, pH6.0, showing that apo-UbcH5a was positively charged under these 
conditions. The ESI-MS spectrum of apo-UbcH5a showed the dominant species in solution 
carried 9 protons (at m/z=2071.1) which has the experimental mass was 18630.9 Daltons 
with an accuracy of 98.1 %. (theoretical mass: 18896.5 Daltons) (Figure 5-13), in broad 
agreement with the calculated charge. Moreover, if UbcH5a was unfolded, more positive 
charges would be seen due to the presence of the 22 basic amino acids of UbcH5a. Therefore, 
the ESI-MS data demonstrated that under this buffer condition UbcH5a is folded. 
 
 
Table 5-5: Theoretical and experimental mass and charge states of UbcH5a. (A) The 
theoretical pI and the numbers of basic amino acids in UbcH5a. (B) Experimental mass and 
charge state of apo-UbcH5a was obtained by ESI-MS.  
UbcH5a
*theoretical mass =  18896.5 Daltons
*estimated pI = 7.9
 *basic amino acids (28):
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E2_MeOH #300 RT: 22.40 NL: 1.15E7
F: + c m s [ 100.00-4000.00]
































































































P10 1863.4 10 18996.5 18624.0 98.0% monomer
P9 2071.1 9 18996.5 18630.9 98.1% monomer
P8 2333.1 8 18996.5 18656.8 98.2% monomer  
 
Figure 5-13: ESI-MS spectrum of apo-UbcH5a. A characteristic bell-shaped charge state 
distribution is observed. The dominant peak (P9) at an m/z value of 2071.1 represents 
[UbcH5a+9H]9+. Data are collected on LCQDeca (Thermo Fisher Instrument). Samples are tested 
at pH6.0 (20mM ammonium acetate) with a source temperature of 80℃. Experimental mass of 
three species, P8, P9 and P10, were showed in the table, all with an accuracy of at least 98% 
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  ESI-MS spectrum of the UbcH5a in the presence of -peptide 9 
Following addition of 200 μM peptide 9 into a solution of 20 μM UbcH5a, numerous new 
peaks were detected (Figure 5-14A). The significant differences seen in the data in the 
presence of peptide 9 might be due to the pH effect. As a consequence of reduced solubility 
of the UbcH5a-peptide 9 complex when compared to that of the peptide 9- 
MDM2RING2△C complex (solubilised in 90% 20 mM ammonium acetate + 10% MeOH, 
pH6.0), the UbcH5a-peptide 9 complex was soluble under more acidic condition (pH4.5). 
Acidic solutions certainly increase the protonisation of proteins, providing an explanation for 
the new charge state species which appeared at pH4.5. In agreement with the prediction, 
Figure 5-14A showed species with a charge state of 20 protons at an m/z of 931.8, with an 
experimental mass of 18616.0.  
 
 pH effect on the oligomeric state of UbcH5a  
A pH effect on the oligomeric state of UbcH5a required consideration that the peaks seen 
were as a result of the effect of solution pH. Some proteins exist in different forms at 
different pH (Cheng et al., 1996), and it could be supposed that the peaks newly seen 
represented the dimeric UbcH5a, charge states. The experimental masses are shown in the 
Figure 5-14, suggesting that UbccH5a could dimerised under low pH concentration, 
irrespective of any interaction with peptide 9. If peptide 9 did not interact with UbcH5a, 
there should be peaks (at an m/z of 716 or 1399.5) representing peptide 9 as illustrated in 
Figure 5-8. However, there are no significant peaks at these points, demonstrating that 
peptide 9 interacted with UbcH5a and the new peaks were the UbcH5a-peptide 9 complex, 
rather than dimeric protein. Furthermore, apo-UIbcH5a in two pH buffers was analysed by 
DLS. The hydrodynamic diameter of UbcH5a measured under both conditions was 4.6 nm. 
The hydrodynamic diameter of UbcH5a calculated from a crystal structure of human 
UbcH5a (PDB: 2C4P) is 4.8 nm for a monomer (Figure 5-16B). These results confirmed that 
UbcH5a existed as a monomer in the initial ESI-MS buffer solution (pH6.0) and acidic 
solution (pH4.5). Those data suggest that new species are not dimeric UbcH5a; those 
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E2_lig_4 # 100 RT: 7.43 NL: 1.45E6
F: + c ms [ 100.00-4000.00]





















































































































































P20 931.8 20 18896.0 18616.0 98.5% monomer (P)
PP16 2347.7 16 37792 37547.2 99.4% PP
P8 2347.7 8 18896 18773.6 99.4% P
PP15 2521.2 15 37792 37803.0 100.0% PP
PP14 2665.4 14 37792 37301.6 98.7% PP
P7 2665.4 7 18896 18650.8 98.7% P
PP13 2908.0 13 37792 37791.0 100.0% PP
PP12 3119.9 12 37792 37426.8 99.0% PP
P6 3119.9 6 18896 18713.4 99.0% P
PP11 3419.9 11 37792 37607.9 99.5% PP
PP10 3722.0 10 37792 37210.0 98.5% PP
PP5 3722.0 5 18896 18605.0 98.5% P  
 
Figure 5-14: ESI-MS data of UbcH5a in the presence of peptide 9. Experimental mass 
showed that new peaks could be dimeric UbcH5a. However, no free peptide 9 was detected at 
m/z of 716 (red, circle). Therefore, those newly formation of peaks should represent other species 
in solution (seen Figure 5-15). “PP” represents dimeric species.  

































Figure 5-15: The oligomeric states of UbcH5a in pH 6.0 and pH6 4.5 were measured by the 
dynamic light scattering (DLS). The hydrodynamic diameters of UbcH5a in both buffers were  
4.6 nm, consistent with that observed in the crystal structure (PDB: 2C4P). 
 
 ESI-MS spectrum of the UbcH5a-peptide 9 complex 
After superimposing these two spectra (Figure 5-16A), the relative abundance of the major 
peaks in the spectrum of apo-UbcH5a (green lines) diminished, and more new peaks (black 
lines) appeared. In particular, some new peaks were seen between two “original” peaks. For 
example, there was new peak at an m/z of 2521.2 between the original peaks at the m/z of 
2347.4 and 2665.4. Following deconvolution, this peak (PL8) has an m/z of 2521.2 
corresponding to a charge state of 8 protons, with a mass of 20161.6 Daltons, closer to the 
theoretical mass of the UbcH5a-peptide 9 complex, 20295.5 Daltons, with an accuracy of 
99.3% (Table 5-6) The experimental mass of each of the other new peaks with different 
charge states were also closer to the theoretical mass, demonstrating that peptide 9 interacts 
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(A) 
E 2 _ l ig _ 2 d a y # 3 0 0 R T: 2 2 .5 9 N L : 1 .2 0 E 6
F: +  c  m s  [ 1 0 0 .0 0 -4 0 0 0 .0 0 ]




































2 0 7 0 .2
2 0 9 7 .8
1 6 9 2 .9
2 1 0 7 .2
2 3 2 9 .2
1 8 6 8 .0 2 1 3 7 .21 6 8 4 .3
2 3 5 3 .4
1 0 3 7 .6
1 1 6 3 .2
1 2 4 0 .7
1 0 3 3 .8
1 4 3 2 .2 2 6 6 7 .5
2 9 0 5 .61 5 5 4 .1 1 8 7 1 .2
3 1 4 7 .21 3 3 3 .9
2 7 2 0 .5
3 4 4 8 .1 3 7 2 4 .13 1 3 4 .92 3 9 2 .3
3 7 8 2 .63 1 5 6 .13 1 1 5 .69 3 1 .5 2 5 2 3 .3 3 3 9 5 .7
2 9 5 5 .0
3 8 0 4 .9
3 1 9 1 .3
3 4 8 8 .3 3 8 2 2 .98 8 6 .4 3 3 0 6 .4
3 4 8 9 .8
8 4 1 .1
6 7 3 .4
3 8 6 .8 5 4 3 .53 1 4 .5













































































































































E2_lig_4 # 100 RT: 7.43 NL: 1.45E6
F: + c ms [ 100.00-4000.00]























































































































Figure 5-16: Positive ion ESI mass spectrum of apo-UbcH5a and the complex of UbcH5a-
peptide 9. (A) Comparison of the spectra of apo-UbcH5a (green line) and the UbcH5a 
complexed with peptide 9 (black lines). (B) The UbcH5a-peptide 9 complex ESI mass spectrum 
reveals that there are monomers and the UbcH5a-peptide 9 complex in the sample. The graph 
shows the different charge state distributions between the two ESI mass spectra. Species (PL8) at 
2521.2 m/z are discussed in the text (yellow star). 
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Table 5-6: Predictions the masses, the charge state species, and the oligomeric states of the 











P20 931.8 20 18896.5 18616.0 98.5% monomer (P)
P8 2347.7 8 18896.5 18773.6 99.3% monomer (P)
PL8 2521.2 8 20295.5 20161.6 99.3% PL
P7 2665.4 7 18896.5 18650.8 98.7% monomer (P)
PL7 2908.0 7 20295.5 20349.0 99.7% PL
P6 3119.9 6 18896.5 18713.4 99.0% monomer (P)
PL6 3419.9 6 20295.5 20513.4 98.9% PL
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5.6.4 HSQC NMR study: the interaction of UbcHa5a and peptide 9 
 1H, 15N- HSQC  NMR spectra of UbcH5a  titrated with peptide 9  
To identify the residues in UbcH5a interacting with peptide 9, we carried out preliminary 
experiments using 1H,15N-HSQC NMR. However, the results revealed that no detectable 
chemical shifts in the 1H,15N-HSQC NMR spectra. Instead, overall signal intensities of 
cross-peaks decrease (Figure 5-17). Besides, the sample aggregated easily upon titration with 
high concentration of peptide 9. NMR experiments require higher concentration of proteins 
and in this case 25 μM was used. Aggregation may result from the equilibrium between high 
concentrations of proteins and peptides. Additionally, the TDA data also revealed that 
peptide 9 may destabilise UbcH5a, this might explain the aggregation phenomena observed 
during the NMR experiments. Therefore, under the given experimental conditions, 1H, 15N-
HSQC NMR was not useful in attempts to identify residues in 15N-UbcH5a responsible for 
peptide 9-binding.  
 
 peptide 9 disrupts the UbcH5a-MDM2RING△C interaction 
1H,15N-HSQC NMR experiments can be used to monitor antagonist-mediated dissociation of 
a protein-protein interaction (D’Silva et al., 2005). In general, the protein-protein complex 
(>40 kDa) produces a poorly dispersed NMR spectrum as the large complex generates broad 
NMR resonances, resulting in the disappearance of cross-peaks (Pellecchia et al., 2002; 
Rehm  et al., 2002; Riek et al., 2000). In the presence of the antagonist, the protein-protein 
interaction dissociates, resulting in the reappearance of the cross-peaks of the labelled 
protein.   
 
According to our previous work, peptide 9 can interact with MDM2RING△C and also with 
UbcH5a. It will be interesting to further understand whether peptide 9 is able to dissociate 
the UbcH5a-MDM2RING△C complex. First, apo-15N-UbcH5a provides a well dispersed 
NMR spectrum with clear cross-peaks (Figure 5-18A). In the HSQC spectrum of 15N-
UbcH5a complexed with MDM2RING△C, some cross-peaks disappear (Figure 5-18B) as 
the large complex broadens the resonance (reducing the signal intensity). As expected, 
following addition of peptide 9, cross-peaks re-appear, providing evidence that peptide 9 
dissociated the UbcH5a-MDM2RING△C complex (Figure 5-18C).  











Figure 5-17: 1H-15N HSQC spectrum of folded UbcH5a with various concentrations of 
peptide 9. The protein concentration is 25 μM. The titration ratios of protein to peptide tested are 
1:0.5, 1:1, 1:2, 1:3, 1:4, 1:5, and 1:10.    














Figure 5-18: NMR analysis of the peptide 9 disrupting the interaction between UbcH5a and 
MDM2RING△C. (A) 1H-15N HSQC spectrum of 15N-labelled UbcH5a (25 μM). (B) 1H-15N 
HSQC spectrum of 15N-labelled UbcH5a (25 μM) complexed with MDM2RING△C (25 μM). 
Unlabelled MDM2RING△C is incubated with 15N-UbcH5a for 1 hour at 4℃ prior to the NMR 
experiment. Some cross-peaks disappeared (red arrows compared to A). (C) 1H-15N HSQC 
spectrum of 15N-labelled UbcH5a complexed with MDM2RING△C in the presence of peptide 9 
(25 μM). Peptide 9 was added into the solution containing the complex and incubated for 1 hour 
at 4℃ prior to the experiments. The HSQC spectra showed that those cross-peaks re-appear (red 
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5.8 Summary  
In conclusion, peptide 9, (the C-terminal 12 amino acids of MDMX C) has been proven to 
bind to FLMDM2 by in vivo and in vitro pulldown experiments (courtesy of Dr Susanne 
Patterson, unpublished data). Tryptophan intrinsic fluorescence was used to show that 
peptide 9 formed a complex with FLMDM2. Peptide 9 binding caused a blue-shift in the 
tryptophan fluorescence signal suggesting that either peptide 9 directly interacts with a 
tryptophan or induces an allosteric effect which buries tryptophan in a more hydrophobic 
environment (section 5.2). Modelling studies using the X-ray structure of the MDM2RING-
MDMXRING complex suggested that a possible binding site for peptide 9 was at the dimer 
interface. Calculation of buried surfaces of peptide 9 docked onto MDM2RING showed the 
importance of the two terminal amino acids (I489-A490) (section 5.3). Fluorescence 
anisotropy studies of FITC-peptide9 binding to MDM2RING and MDM2RING△C show 
that Kd values are similar (with Kd values of 355nM and 314nM respectively). ESI-MS data 
from MDM2RING△C show that it behaves as a folded monomer. On addition of peptide 9 
there are significant changes in peak intensities and some new peaks appear which are 
consistent with one molecule of peptide 9 binding to a dimer of MDM2RING△C. In 
addition, fluorescence anisotropy, ESI-MS and the thermal denaturation assay were used to 
show that peptide 9 also interacts with UbcH5a. Interestingly peptide 9 was found to 
decrease the thermal stability of UbcH5a. 
 
Our in vitro ubiquitination assay data showed that peptide 9 had potent inhibitory effect upon 
MDM2-mediated ubiquitination of p53. Presumably, peptide 9 inhibits MDM2-mediated 
ubiquitination by interacting with MDM2 or UbcH5a. These results suggest that peptide 9 
could be a good lead for further drug development studies. Although the binding mode of 
peptide 9 with MDM2 and/or UbcH5a is as yet unknown, in the following chapter, 
modelling and virtual screening is used to derive a possible binding interface based upon all 
available data. Some peptide 9 mimetics are found to be inhibitory to MDM2RING E3 ligase 
activity.  
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This chapter describes how we successfully used a virtual screening methodology for the 
development of MDM2 E3 inhibitors. There were three druggable target sites: (i) the C8-
binding site of MDM2RING, (ii) the E2-binding site of MDM2RING and (iii) the E3-
binding site of UbcH5a. Four inhibitors and one activator selected from millions of chemical 
compounds were shown to affect full-length MDM2 E3 activity. Additionally, four inhibitors 
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6.1 Introduction 
MDM2, a oncoprotein, is critical in regulating the level of p53 in cells; therefore, MDM2 has 
become an attractive drug target for anti-tumour therapy. As p53 plays a significant role in 
cell cycle arrest and apoptosis (Levine et al., 2006; Coutts & La Thangue., 2007; Brooks & 
Gu, 2004; Moll & Petrenko, 2003), reduction in the cellular concentration of p53 can result 
in tumour formation, such as sarcomas, brain tumour (Vogelstein et al., 2000; Vousden & 
Lane, 2007), MDM2 regulates p53 by interacting with p53 thorough its N-terminal 
hydrophobic and acidic domains. Ubiquitination of p53 is achieved by the E3 ligase activity 
of the C-terminal RING domain of MDM2 (Figure 6-1). To date, a number of drugs have 
been developed to inhibit the interaction between p53 and MDM2, such as Nutlin, Rita or 
MI-43 (Vassilev et al., 2004; Vassilev 2004; Issaeva et al., 2004; Shangary et al., 2008). 
These drugs were designed to mimic the structure of the p53 residues that bind to the surface 
of MDM2, Phe19-Trp23-Leu26. Few drug leads, such as HL198 (Yang et al., 2005), have 
been designed to inhibit MDM2 E3 ligase activity. Therefore, designing ligands to inhibit 
MDM2 E3 activity is a major goal of this project.  
 
Ubiquitination is a well-characterised global posttranslational mechanism in cells used to 
determine the fate of proteins. The type of the linkage of ubiquitin attached to protein 
determined the protein fate, as introduced in Chapter 1. MDM2 is a RING-type E3 ligase and 
its cognate E2 partner is UbcH5a. The interaction of E2-E3 is essential for the transfer of 
ubiquitin to the substrate (Christensen & Klevit, 2009; Deshaies & Joazeiro, 2009). However, 
the RING-type E3-dependent ubiquitination mechanism is still unclear, providing exciting 
opportunities to search for MDM2 E3 ligands. The study of the effects of ligands on MDM2 
is likely to provide insight into the mechanism of MDM2-dependent ubiquitination, in 
particular, the role of the C-terminus of MDM2 and the interactions between MDM2 with 
UbcH5a might be characterised.  
 
A number of promising results will be discussed in this chapter: several small molecules 
found to affect MDM2 E3 activity were identified using a virtual screening strategy (VS). 
The aim was the development of small molecules that can inhibit MDM2 E3 ligase activity 
thus rescuing p53 activity. MDM2 E3 activity is associated with the RING domain; therefore 
one of our target sites is the MDM2 RING domain. The second target is UbcH5a, because 
the MDM2 RING domain interacts with its cognate E2 protein for successful ubiquitination. 
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There are three potential drug target sites (Figure 6-1): (1) the C8-binding site of 
MDM2RING, (2) the E2-binding site of MDM2RING, and (3) the E3-binding site of 
UbcH5a, the MDM2 cognate protein. In the following sections, the strategy behind selection 
of those MDM2 E3 ligase target sites will be presented followed by an outline of the virtual 
screening strategy used and will conclude with experiments to validate the efficacy of the 



































Virtual Screening (VS)  strategies:  inhibitors of  MDM2-UbcH5a
Drug target (1) 
MDM2
Drug target (3) 
UbcH5b
Drug target (2) 
MDM2-RING
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Figure 6-1: Protein-protein interactions: MDM2 and its binding partner. (1) A schematic 
diagram shows the interaction interface of MDM2 (orange) and p53 (cyan), through the two 
dominant binding motifs: the hydrophobic domain (Hy) of MDM2 with the BOX-I motif of p53, 
and the acidic domain (AC) of MDM2 with the BOX-V motif of p53. MDM2 binding partner, 
UbcH5a (purple), interacts with MDM2 through the RING domain (RING) (green). Dimerisation 
of MDM2 is achieved through its RING domain, especially the C-terminal region (or C-tail). ZF 
is a zinc finger motif. The red dashed line highlights the targets: MDM2-MDM2 C8-binding site 
and MDM2-UbcH5a interface. (B) Three potential target sites: (1) C8-binding site of MDM2, (2) 
the UbcH5a-binding site of MDM2; (3) the MDM2-binding site of UbcH5a2. MDM2 E3 ligands 
are shown in green stick representations. The MDM2-UbcH5a complex model was built based on 
the cIAP2-UbcH5b complex (PDB: 3EB6). 
 
 
6.2 Virtual screening strategy 
Virtual screening (VS) is a powerful technique saving time and resources during the drug 
discovering process. VS is a combination of several programs, the basis of which was 
described in Chapter 1. In this section, the programs used in this project will be briefly 
introduced. UFSRAT and LIDAEUS were used to design the template and also in the 
selection of small molecules from the database; EDULISS is a database of small molecules; 
AutoDock is used to simulate of the binding mode of small molecules onto the target site, 
and to predict binding energy (△G) and binding affinity (Kd). 
 
In this work, the virtual screening strategy developed utilised several steps. Figure 6-2 
outlines a virtual screening strategy and all other strategies used in this chapter were broadly 
similar: (1) The first step is to determine what the target site is and to define which residues 
in the target protein may be involved in the interaction with residues of its partner (Figure 6-
2 A); (2) The second step is template design. The template is usually designed according to 
the structure of the target protein’s partner. There are several programs available for template 
design including UFSRAT and LIDAEUS (Figure 6-2 B, C & D). (3) After information 
about the target site and appropriate small molecule libraries are generated from steps 1 and 
2, AutoDock is used to simulate small molecules binding to the target site. A ranked list 
dependent upon the simulated binding energy between the target and the small molecules is 
produced by AutoDock (Figure 6-2E). (4) The simulated binding modes of the small 
molecules onto the target, together with an estimate of the binding energy are used to guide 
the purchase of a number of small molecules to be further characterised.  
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(A) Target protein (B) Residues in target protein 
involved in the interaction
(D) dots as the template for UFSRAT
(C) Dots created based on residues of 
the binding partner of the target protein




Figure 6-2: Outline of the virtual screening strategy used. (A) Determine the target protein. 
MDM2RING, and define the target site (green). (B) Define the potential interacting residues of 
the MDM2-binding partner, UbcH5a, (yellow stick representation) located in the E2 binding 
surface of MDM2 (green surface representation). (C) Create the dots (magenta), representing 
each atom in a residue, that may be involved in an interaction with the target. (D) These dots 
form the template for UFSRAT, to search the EDULISS database for small molecules with 
matching atoms. (E) Simulation of the binding mode of small molecules onto the target site by 
AutoDock. A molecule found by UFSRAT is shown in a magenta surface representation. The 
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6.3 Drug target site (1): the C8-binding site of MDM2  
6.3.1 Biochemical studies identifying the MDM2 dimerisation site as a 
druggable target  
The MDM2 RING domain has E3 ligase activity and exists in different oligomeric forms. It 
is well-known that the dimerisation of MDM2 is related to its E3 ligase activity and 
numerous reports illustrate the importance of the C-terminal amino acids for MDM2 E3 
ligase activity and oligomerisation, showing that MDM2 homodimers and MDM2-MDMX 
heterodimers are essential for E3 ligase activity (Sharp et al., 1999; Tanimura et al., 1999; 
Stad et al., 2001). It has also been reported that monomeric MDM2 RING has reduced levels 
of E3 activity (Poyurovsky et al., 2007). A solution structure of MDM2-MDM2 homodimer 
(PDB: 2HDP) (Kostic et al., 2006) and a crystal structure of MDM2-MDMX heterodimer 
(PDB: 2VJE) (Linke et al., 2008) clearly showed that the C-terminus of each subunit is 
located in the C8-binding site, interacting with the other subunit (Figure 6-3A). cIAP/XIAP 
and BRCA1/BARD1 heterodimers have a similar interaction that involves the same residues 
in dimerisation and E3 ligase activity (Brzovic et al., 2001; Silke et al., 2005).  
 
Several MDM2 C-terminal mutants have been studied and highlight the importance of the 
MDM2 C-terminus, and the MDMX C-terminus for MDM2 E3 ligase activity (Poyurovsky 
et al., 2007; Linke et al., 2008; Uldrijan et al., 2007). Previous reports show that MDM2 
deletion mutant, MDM2△C7 is monomeric and has no E3 activity (Poyurovsky et al., 2007; 
Uldrijan et al., 2007). The MDM2 RING mutant, F490Q, exists as a monomer and has 
reduced E3 activity. Surprisingly, the C-terminus of MDMX can rescue the E3 activity of the 
MDM2 RING F490Q mutant, revealing that the compact C-terminus of MDM2 is a key 
determinant for its E3 activity (Uldrijan et al., 2007; Poyurovsky et al., 2007). The Y489A 
mutation in MDM2 was also found to completely abolish its E3 ligase activity (Linke et al., 
2008). The equivalent residue in cIAP2, F602, mutated to alanine also resulted in reduced E3 
activity and disruption in the dimerisation of cIAP2 (Mace et al., 2008). The six C-terminal 
residues of cIAP1, a homologue of cIAP2, were mutated and disrupted the 
heterodimerisation of cIAP1/XIAP E3 ligase activity (Silke et al., 2005). These reports 
indicate that the C-terminus of RING type E3 ligase is critical to its E3 activity, and that the 
integrity of the C-terminus of E3 RING domain is critical for the E2-E3 interaction (Petersen 
et al., 2007).  
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The STP program was used to identify druggable sites in MDM2RING, to test the hypothesis 
that the C8-binding site of MDM2 is a druggable target (Figure 6-3B). STP is a simulation 
program used to predict potential binding sites (“hot spots”) in proteins (Mehio et al., 2010). 
A great deal of work has focused on and characterised hot spots within proteins. A number 
of common features found in hot spots include specific residue composition and 
conformations which can suggest protein-protein interaction sites in proteins (Huang et al., 
2006; Morita et al., 2008; White et al., 2008). Potential binding sites (or hot spots) for 
MDM2 are shown in Figure 6-3B. The blue colour suggests the region is unlikely to be a site 
of protein-protein/ligand interactions, the red means the region is likely to be involved in 
protein-protein/ligand interactions. Analysis by STP suggests the C8-binding site of MDM2 
is indeed a hot spot. Overall, those findings suggest that the C8-binding site of MDM2 is a 
good druggable target site and that the C-terminus of MDM2 (or MDMX) is a good starting 
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Figure 6-3: The C8-binding site of MDM2 is a druggable target site. (A) Left: 
MDM2/MDM2 homodimer (PDB code: 2HDP), right: MDM2/MDMX heterodimer (PDB code: 
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2VJE). The C-terminus of MDM2 (yellow β-strand) or MDMX (magenta β-strand) interacts with 
the C8-binding site of the other MDM2 subunit (in white surface representation). (B) The output 
from the STP programme. The hot spots predicted by STP are shown in red and orange, 
highlighting the C8-binding site as a potential interaction site for proteins or small molecules.  
 
 
6.3.2 Virtual screening for inhibitors of MDM2 dimerisation 
Following selection of the C8-binding site of MDM2RING as a druggable target site, the 
next step was to define a virtual screening template. There were two candidates available: the 
MDM2 C-terminus and the MDMX C-terminus. MDM2 can form both homodimers and 
heterodimers with MDMX through the C-terminal fragments. Enzyme activities and binding 
affinities have shown that MDM2/MDMX heterodimers have greater E3 ligase activity than 
MDM2/MDM2 homodimers (Badciong & Haas, 2002; Kawai et al., 2007; Singh et al., 
2007). This implies that C-terminal MDMX may have stronger binding affinity to the C8-
binding site of MDM2 than the C-terminus of MDM2. MDMX C-terminus is therefore likely 
to be a better candidate template for virtual screening. Furthermore, previous work also 
revealed that the peptide 9, the last twelve MDMX C-terminal residues, has high binding 
affinity with MDM2 and also inhibits MDM2 E3 ligase activity (Chapter 5). The decision to 
use peptide 9 as a virtual screening template is further supported by studies using PISA of 
the correlation of the buried surface areas of both MDM2 and MDMX C-terminal regions 
with the C8-binding site  of MDM2 subunit (as described in Chapter 5). When the sequences 
of the C-terminal 12 residues in MDM2 and MDMX were aligned, the results showed that 
MDM2 C-terminus has three hydrophilic, two aromatic and no charged residues, whereas 
MDMX C-terminus contains one hydrophilic, one aromatic and three positively charged 
residues (Figure 6-4A). Comparisons of the structures of MDM2-MDM2 C-terminus and 
MDM2-MDMX C-terminus revealed they have similar binding modes at the C8-binding site 
(Figure 6-4C). According to a study of buried surface areas of MDM2-MDM2 C-terminus 
and MDM2-MDMX C-terminus, the data provide explanation why the MDM2/MDMX 
heterodimers are preferred over MDM2/MDM2 homodimers. The buried surface of MDM2-
MDMX C-terminus is 503.1 Å whereas that of MDM2-MDM2 C-terminus is 387 Å. Larger 
buried surfaces between two proteins or protein-ligand usually suggests there is higher 
possibility that binding affinities should be higher, consistent with larger numbers of H-
bonds and van der Waal contacts between the two molecules. For example, there are eight 
H-bonds within the MDM2-MDMX C-terminal complex and only three within the MDM2-
MDM2 C-terminal complex (Figure 6-4B). MDM2 C-terminal residues, L487 and Y489, 
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form three H-bonds with MDM2 residues, G456 and L458. MDMX- C-terminal residues, 
K486, F488, I489, and A490, interact with the residues of MDM2RING, N433, K446, K454, 
T455, G456, and L458 forming eight H-bonds (Figure 6-4C). Overall, analysis of this 
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Figure 6-4: Comparison of the two template candidates for the C8-binding site of MDM2: 
MDM2 C-terminus and MDMX C-terminus. (A) Alignment of the final 12 C-terminal 
residues. Residues are coloured according to their characteristics. (B) Comparisons of buried 
surface areas with those two complexes. The graph represents the buried surface area of each 
residue in MDM2 C-terminus (green) or MDMX C-terminus (yellow) complexed with another 
MDM2RING. Residues forming H-bonds are highlighted in red. The table summarises overall 
buried surface areas and the number of H-bonds within each complex. (C) Comparisons of the 
modelled structure of two peptide candidates with MDM2 subunit. MDM2 C-terminus 
(MDM2C8) and MDMX C-terminus (MDMXC8) both are coloured in green stick 
representations, and MDM2RING is coloured in a white surface representation. Residues in 
MDM2RING that interact with MDM2 C-terminus or MDMX C-terminus are shown in yellow. 
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6.3.3 Virtual screening results: MDMX-C terminus mimetic 
Following selection of both target and template, virtual screening experiments were initiated. 
In this work, the combination of virtual screening strategies was as follows: (1) 1000 small 
molecules from the EDULISS database were selected using UFSRAT; (2) binding modes, 
binding energies and binding affinities were simulated using AutoDock. Following manual 
evaluation of both the simulated binding mode and predicted substrates of the small 
molecules, the top 10 compounds were purchased. 
 
The template for the UFSRAT search was the eight residues of the MDMX C-terminal 
octapeptide, LVIKVFIA (Figure 6-5A). The aim was to find small non-peptide molecules 
with drug-like characteristics (Bemis & Murcko, 1996; Bemis & Murcko, 1999; Lipinski et 
al., 1997). UFSRAT is a structural similarity simulation program, and a smaller template is a 
better starting point to select similar compounds from the EDULISS database. Importantly, a 
proportion of the druggable dimer surface is composed of the C-terminal octapeptide (Figure 
6-5A). Out of a total of 1082.4 Å2, the MDMX octapeptide contributed 503.1 Å2 (Figure 6-4). 
The residues responsible for the formation of H-bonds with MDM2 were included in the 
template. Residues of MDM2 within 4Å of the template, LVIKVFIA,  are N433, A434, 
K446, G453, K454, T455, G456, H457, L458, M459, and V477 (yellow and pink surface, 
Figure 6-5B). There are eight H-bonds within the complex: K454[O], G456[O], L458[O], 
T455[OG1], G456[N], L458[N], N433[ND2] and K446 [NZ] of MDM2, respectively, 
interacts with K486 [N], F488 [N], A490 [N], K486[O], K486[O], F488 [O], I489[O] and 
A490[O] of MDMX C-terminus (red dashed line, Figure 6-5B; details in Figure 6-4C & 
Figure 5-4B). Those residues provide essential information on the interaction mode for 




































Figure 6-5: The modelled structure of MDM2-MDMX C-terminal octapeptide complex. (A) 
The structure of MDMX C-terminal octapeptide, 483LVIKVFIA490, is shown in green sticks. 
This structure is a template for a UFSRAT similarity search. (B) Residues in MDM2 are located 
within 4Å distance around the MDMX C-terminus are coloured in yellow and pink. Residues in 
MDM2 forming H-bonds with MDMX C-terminus are highlighted in yellow. (C) The binding 
mode of MDMX C-terminal octapeptide 9 (green surface/sticks) onto MDM2 C8-binding site 
(white surface).  MDMX C-terminus are shown in green surface form (left panel) and green 
sticks (right panel). Red dashes represent H-bonds. 
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Because the template LVIKVFIA is a contiguous peptide, these eight residues provide a 
straightforward structural conformation for UFSRAT searches. 1000 compounds from the 
EDULISS program were firstly filtered by UFSRAT and those small molecules were a group 
of MDMX C-terminus mimetics, known as the D-series compounds (D-series). Similarities 
of those MDMX C-terminus mimetics to the template varied from 50.1 % to 35.7 % (Figure 
6-6).  
 
The top 1000 compounds were tested using AutoDock. Autodock requires the following 
information- a library of small molecules, the target site, and the putative binding residues of 
the target site. AutoDock data revealed that most of the selected compounds fitted well into 
the C8-binding site of MDM2 (Figure 6-7). Following manual analysis of the simulation data 
to evaluate the proposed binding mode of the small molecules to the target site, a ranked list 
was prepared. It was also important to consider the solubility, toxicity and suggested binding 
affinities of the hit compounds, to choose and purchase the “top ten” compounds from Spec. 
Co. Estimated binding energies (△G) of these top 10 compounds to the C8-binding site of 
MDM2 varied from -9.3 kcal/mol to -7.7 kcal/mol with predicted binding affinities of 155.6 
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Figure 6-6: Alignments of D-series onto MDMX-C octapeptide. S.I. (similarity) values are 
calculated by UFSRAT. D-series compounds are shown in green sticks and the template 
octapeptide in magenta lines. (C=green or magenta, N=blue, O=red, and S=yellow). * S.I. 
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Table 6-1: Characteristics of the D-series compounds. Information includes the product 
code for the supplier. The estimated binding energies and affinities are estimated following the 










D01 0.4 -9.3 155.6 nM -0.24 604.8
D02 N.D. -9.2 190.3 nM 3.5 544.6
D03 0.5 -8.9 298.8 nM 3.1 542.4
D04 0.4 -8.6 507.1 nM 3.9 602.7
D05 0.4 -8.3 798.6 nM 3.5 588.6
D06 0.5 -8.1 1.2 μM 1.9 630.7
D07 0.4 -7.9 1.6 μM 0.2 462.5
D08 0.5 -7.8 N.D. 0.2 582.7
D09 0.5 N.D. N.D. 1.7 536.6
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Figure 6-7: The binding modes of the D-series compounds onto the C8-binding site of 
MDM2 as determined by AutoDock. Those compounds are shown in green sticks. The target 
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  Characterisation of the effects of the MDMX C-terminus mimetics on MDM2 E3 
activity 
An in vitro ubiquitination assay was used to determine how the compounds selected by 
virtual screening affect MDM2 E3 activity. All compounds were dissolved in 100% DMSO. 
The assay was as follows: 500 μM of each compound was incubated with 100 ng FLMDM2 
or with 100 ng MDM2RING and incubated at room temperature for 10 minutes. The other 
essential components for in vitro ubiquitination were added to start the reaction, followed by 
incubation at 30℃for 10 minutes. To stop the ubiquitination, 2X loading dye solution was 
added into each sample. The samples were analysed on 4~12% gradient gels, ubiquitinated-
p53 was detected by an anti-p53 antibody (D01). The in vitro ubiquitination assay was 
described in great detail in Chapter 3. 
 
 Different D-series compounds inhibit FLMDM2 and MDM2RING E3 activity 
D-series compounds were designed to bind to the C8-binding site of MDM2, as reports have 
shown that dimerisation of MDM2 plays an important role in its E3 ligase activity. Inhibition 
of dimer formation by D-series compounds could therefore inhibit MDM2 E3 ligase activity. 
Exciting results showed that three compounds, D03, D04 and D05 (at a concentration of 500 
μM) significantly inhibited FLMDM2 E3 ligase activity (Figure 6-8A). Interestingly, D04 
and D05 are chemically closely related (Table 6-1). Correlation between the isoforms might 
imply that this type of compound tends to interact with FLMDM2. Although the exact 
binding mode of the compound-protein complex is as yet experimentally undetermined, such 
a small molecule might make a useful starting template for a second round of virtual 
screening.  
 
Presumably, if those compounds bind to the C8-binding site of MDM2, there should be 
similar inhibition effects observed on MDM2RING E3 activity. However, D03 only slightly 
inhibited MDM2RING E3 activity, whilst D04 and D05 showed no inhibition of 
MDM2RING E3 activity (Figure 6-8B). It is still possible, however, that D04 and D05 
compounds did bind to the C8-binding site of FLMDM2 and MDM2RING, but induced 
distinct effects. The D04/D05-binding may allosterically regulate the conformational 
structure of FLMDM2; hence they reduced the interaction of p53-FLMDM2 or FLMDM2-
UbcH5a, but there was no effect on the interaction of p53-MDM2RING or MDM2RING-
UbcH5a. It was reported that MDM2 RING domain allosterically controls FLMDM2 
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conformation and activity (Wawrzynow et al., 2009). Surprisingly, other compounds from 
the series, D07, D08, D09, and D10 (500 μM), significantly inhibit MDM2RING E3 ligase 
activity (Figure 6-8B), and reduce the possibility of the second ubiquitin being transferred to 
p53-Ub1. It has been noted that monomeric MDM2 mono-ubiquitinates p53, and dimeric or 
higher order MDM2 oligomers induce poly-ubiquitinated p53 (Cheng et al., 2009).  
Moreover, protein fate is determined by the type of ubiquitin linkage attached: mono-
ubiquitinated protein is usually directed to non-proteolytic functions, such as endocytosis, 
transcriptional activation, or enzyme activation (Fang & Weissman, 2004; Marchenko, et al., 
2007). D07, D08, D09, and D10 might provide a very useful model for the study of the 









































Figure 6-8: in vitro ubiquitination studies of the D-series compounds on FLMDM2 and 
MDM2RING E3 ligase activity. 500 μM compounds are incubated with 100 ng FLMDM2 or 
100 ng MDM2RING for 10 minutes at R.T. Then other components required for in vitro 
ubiquitination (detail described in Section 3.1) are added and incubated at 30℃ for another 10 
minutes. These samples are analysed using 4~12% gradient gels and ubiquitinated p53 are 
detected by anti-p53 antibody D01.  
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 Potential interactions between D-series compounds and MDM2RING domain 
To clarify whether there are similar binding patterns between those complexes of MDM2 
and D-series compounds, we analysed the simulated docking model to determine which 
residues of MDM2 interact with docked D-series compound (Figure 6-9). We illustrate the 
MDM2 residues that are located within 4Å distance around each of the docked D-series 
compounds according to the docking models. Specifically, MDM2 residues that potentially 
interact with D03, D04, and D05 are shown in green and those that might interact with D07, 
D08, D09 and D10 are shown in yellow. Defining any specific binding pattern related to 
FLMDM2 or MDM2RING E3 ligase activities proved difficult. Previous work has indicated 
that MDM2 is a highly flexible protein, consisting of several functional motifs and flexible 
linkers (Nicholson & Hupp, 2010). The flexibility of MDM2 highlights that MDM2 
functions are regulated allosterically by several distinct MDM2-binding partners, for 
example, p53, ATP, RNA repressor, or the MDMX C-terminus mimetics in this work, 
binding to distinct motifs within MDM2 and allosterically regulating its conformation and 
function. This might also explain why the MDMX C-terminal mimetics (D-series) have 
different effects on FLMDM2 and MDM2RING E3 ligase activities. 




























Figure 6-9: Potential interactions between MDM2RING and selected compounds. This table 
lists of MDM2 residues located within 4 Å distance around each D-series compound. FLMDM2 
E3 ligase inhibitors, D03, D04, and D05, are highlighted in green; MDM2RING E3 ligase 
inhibitors, D07, D08, D09, and D10 are highlighted in yellow; other compounds were coloured in 
cyan.  
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Although we have not yet clarified why D-series compounds have different effects on 
FLMDM2 and MDM2RING, with respect to development of potential anti-cancer therapies, 
it is encouraging that D-series compounds can indeed inhibit MDM2 E3 ligase activity. 
There is still a great deal of work required to optimise those selected compounds; however, 
results demonstrate that our virtual screening strategy can be used as a promising primary 
screening system to search for compounds that can inhibit FLMDM2 or MDM2RING E3 
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6.4 A model for the structure of the UbcH5a-MDM2RING complex 
In the ubiquitination pathway, numerous reports have shown that E3-E2 binding is essential 
for the transfer of ubiquitin to the E3 substrate or E3 itself (autoubiquitination), including the 
following targets UbcH7-E6AP, UbcH7-cCb1, UbcH5b-cIAP2, UbcH5-CHIP, Uve1a-
UbcH13-CHIP (Huang et al., 1999; Mace et al., 2008; Xu et al., 2008; Zhange et al., 2005; 
Zheng et al., 2000). This raises an interesting question: what might the consequence be if a 
small molecule disrupts the E2-E3 interaction? It is presumed that ubiquitination does not 
proceed without the E2-E3 interaction. Because the MDM2 RING domain interacts with E2 
proteins, such as UbcH5a, and facilitates transfer of the ubiquitin molecule from E2 to the 
substrate of MDM2, e.g. p53 or itself. In the next two sections, our aim is to find by virtual 
screening small molecules to interrupt the interaction of UbcH5a (E2) and MDM2 (E3). Two 
main target sites were studied: the E2-binding site of MDM2 and the E3-binding site of 
UbcH5a.   
 
 Building a model of the UbcH5a-MDM2 complex 
The first step is to build a good model of the UbcH5a-MDM2 complex. To date, there is no 
known crystal structure of an UbcH5a-MDM2 complex. As an alternative approach, we 
decided to build a model of the UbcH5a-MDM2 complex based upon other known crystal 
structure of the cIAP2-UbcH5b complex (PDB: 3EB6) (Mace et al., 2008) to use as our 
reference. Although the structures of other E3s with their cognate E2s are also known, the 
overall structure and amino acid sequences of cIAP2 has higher degree of similarity to 
MDM2 than the other available structures. Firstly, cIAP2, Baculoviral IAP repeat-containing 
protein 3, is also a RING-type E3 protein. Secondly, other RING-type E3 proteins, such as 
BRCA1-BARD1 or Ring1b-Bmil, dimerise when they interact with sections of α-helix but 
not β-sheets as seen with MDM2 or cIAP2 (Figure 6-10A). MDM2 and cIAP2 RING 
domains are both located at the C-terminus of the proteins, whereas BRCA1-BARD1 and 
Ring1b-Bmil RING domains are found at the N-terminus. Moreover, based on the amino 
acid sequences (Figure 6-10B), cIAP2 shares 35% identity with MDM2. Sequence 
alignments of the RING domains of various E3 proteins were analysed using MyHints, a 
database which includes a tool for analyzing protein sequences (Pagni et al., 2007). 
Furthermore, the phylogram also suggested that cIAP2 has a closer evolutionary relationship 
to MDM2 than any other characterised proteins (Figure 6-10C). The phylogram was 
generated using the ClustalW program, and is a branching diagram that graphically indicate 
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the evolutionary relationship among the species based upon the similarities and differences 
seen in the amino acid sequences (Figure 6-10C). Another key reason for selecting the 
reference structure used is that the cIAP2 cognate E2 protein is UbcH5b, a homolog of 
UbcH5a. The similarity of UbcH5b to UbcH5a is 99% and the identity is 89% (Figure 6-11). 


























Figure 6-10: Comparison of E3 heterodimer/homodimer and the E2-E3 complex. (A) 
Overlay of the MDM2– MDMX heterodimer with Ring1b-Bmi1 heterodimer and BRCA1-
BARD1 heterodimer. The structure of cIAP2 homodimer has higher similarity to MDM2-
MDMX and both dimerise through their C-terminal β-sheet. Four zinc ions seen in these 
homodimers/heterodimers are shown in gray. BRAC1, Ring1, and MDM2 are coloured yellow, 
and BARD1, Bmi1 and MDMX are coloured cyan. (B) Sequence alignment of the RING domain 
of E3 proteins prepared using the MyHints. Yellow bars below the sequences represent highly 
conserved residues. (C) Phylogram of the RING domains of E3 proteins, the distance represents 
their evolutionary relationship.  
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Figure 6-11: Comparison of UbcH5a and UbcH5b. (A) Sequence alignment and (B) 
superposition of the two structures.  
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To build a model structure of the UbcH5b-MDM2 complex, the MDM2 molecule from the 
MDM2/MDMX complex (PDB: 2VJE) was superimposed onto the cIPA2 molecule of the 
UbcH5b-cIAP2 complex (PDB: 3EB6) (Figure 6-12). In this work, we used the TopMatch 
program, which is a suite of computational tools for the alignment and superposition of 
protein structures (http://topmatch.services.came.sbg.ac.at/) (Sippl & Wiederstein, 2008; 
Sippl, 2008). We also superpositioned the MDM2/MDMX heterodimer onto other E2-E3 
structures, such as CHIP-Ubc13 or cCbl-UbcH7. In addition, previous work has described 
that while the RING domains of E3 proteins are very different in their amino acid sequences, 
they have a conserved functional structure.  These superposition results revealed that the 
RING domain of MDM2 overlaid well with all the RING domains of these E2-E3 proteins 
(Figure 6-12). The overlay with cIAP2-UbcH5a was particularly close (r.m.s.d. of 1.3 Å over 
the 121 Core Cα atoms). MDM2 also has this conserved functional structure for interaction 
with E2 proteins:  the α helix in MDM2 or in other E3 proteins play a critical role in the 
interaction with the N-terminal fragments of E2 proteins (Figure 6-12).   
UbcH7-cCbl  (PDB: 1FBV) UbcH13-CHIP (PDB: 2C2V)
UbcH5-cIAP2 (PDB: 3EB6)
 
Figure 6-12: Schematic representation of the superposition of MDM2-MDMX heterodimers 
onto other E2-E3 complexes. (A) UbcH7-cCbl (PDB: 1FBV); (B) Ubc13-CHIP (PDB: 2C2V); 
(C) UbcH5b-cIAP2 (PDB: 3EB6). MDM2-MDMX heterodimer is shown in cyan, other E3 
proteins are shown in grey, E2 proteins are shown in lime green and zinc ions are depicted as 
yellow spheres. 
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 A more detailed view of a new model of the UbcH5a-MDM2 complex 
After the model of the UbcH5b-MDM2 complex was generated, closer inspection of the 
complex showed that there were no clashes with UbcH5b. Crystal structures of the RING 
domain of MDM2, cIAP2, UbcH5b are shown in cyan, yellow and green, respectively 
(Figure 6-13A). Both E3s have similar ββαβ structures (Figure 6-13B). Analysis of the 
sequence alignment reveals that MDM2 has additional residues 448GC449 and 
471RNKP474 when compared with the sequence of cIAP2 (Figure 6-13C &D). The model 
suggests residues 448GC449 extend the β1 of MDM2 and result in a different orientation of 
the following loop (452HGKT455), located between the β1 and β2 (red circle, Figure 6-13A 
& B). The loop of MDM2 is orientated away from the surface of UbcH5b. This region is also 
the ATP-binding site, suggesting that orientation of the loop could be correlated to ATP-
binding. Furthermore, the MDM2-UbcH5b model showed that residues in UbcH5b, D59 and 
F62, were located within 4Å distance around the MDM2 471RNKP474 motif. This suggests 
that this motif could be critical to interactions with UbcH5b or UbcH5a. Overall, the model 










Figure 6-13: A new model of UbcH5b-MDM2. (A) An MDM2 molecule (PDB: 2VJE) is 
superimposed onto the cIAP2 molecule of UbcH5a-cIPA2 (PDB: 3EB6). MDM2 is shown in 
cyan, cIPA2 is shown in yellow, and UbcH5b is presented in green surface. The interactive 
regions of the E2-E3 binding site are the N-loop and the α-β3 loop (shown as arrow). (B) 
Superimposition of the structure of MDM2RING onto the structure of cIAP2. Red circle 
highlights the different orientation of the loop 452HGKT456 of MDM2, when compared to that 
of cIAP2. (C) Sequence alignment of MDM2 and cIAP2. Starred residues illustrate additional 
interaction seen in MDM2. Magenta bars highlight the ATP binding site (GCIVHGKT) and the 
RNKP motif. (D) Close up view of the orientation of the loop (452HGKT454, yellow) and the 
motif (471RNKP474, magenta) of MDM2 to the UbcH5a surface. Residues in blue surface are 
D59 and F62 in UbcH5a, may interact with the RNKP motif of MDM2.  
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6.5 Drug target site (2): the UbcH5a-binding site of MDM2 
In this section, the aim was to find small molecules that could bind to the UbcH5a binding 
site of MDM2 and disrupt the E2-E3 interaction. The virtual screening strategy adopted 
included the following steps: (1) define and characterise the target site, the UbcH5a-binding 
site of MDM2, (2) create a docking template using UFSRAT, (3) simulate the putative 
binding interaction using Autodock, and (4) evaluate the effect of small molecules on the E3 







       
Target site:












Figure 6-14: Graphical representation of the aims of the project and the virtual screening 
strategy employed. The UbcH5a-binding site in MDM2 is characterised and defined. Small 
molecules including the U series (shown in magenta) are hypothesised to bind to the UbcH5a-
binding site of MDM2 (cyan) as above.  
 
 
6.5.1 Define the target site in the UbcH5a-binding interface of MDM2 
A model of the UbcH5b-MDM2 complex was built; residues in the interface between the 
two proteins are likely to be involved in the interaction and therefore it is necessary to 
carefully define these residues. Since there is no crystal structure available, the putative E2-
binding residues in MDM2 were predicted based on the known structures of cIAP2-UbcH5b. 
On the basis of the cIAP2-UbcH5b crystal structure, several residues of cIAP2 involved in 
the interaction with UbcH5b are highlighted in Figure 6-15A: Glu553, Val559, Met561, 
Asn562, Leu585, Pro589, and Arg592. The interface residues in MDM2 are Ala434, Val439, 
Ile440, Gln442, Leu468, Pro476, Val477 and Arg479 (Figure 6-15A). Consistent with our 
putative E2-binding residues, previous mutagenesis data show that I440, L468, P476 and 
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R479 MDM2 mutants abolished MDM2 E3 activity, V439 reduced E3 activity (Linke et al., 
2008). Previous work also indicates that there is a conserved shallow groove shared by these 
E2-E3 complexes, including cIPA2-UbcH5b, c-Cbl-UbcH7, and CHIP-Ubc13 (Mace et al., 
2008). This E2-binding groove is surrounded by a small hydrophobic region at the centre of 
the E2-binding site, with an acidic region toward the N-terminal end and an arginine residue 
on the C-terminal side (Mace et al., 2008; Zhang et al., 2005; Zheng et al., 2000). To 
determine whether our putative UbcH5a-binding site has a similar groove in MDM2RING, 
residues that might interact with UbcH5b were highlighted on the surface of MDM2 RING 
(Figure 6-15B). The selected MDM2 residues have similar characteristics to those of the E2-
binding residues in cIPA2, and are also very similar to those seen in c-Cbl and CHIP. The 
corresponding E2-binding site in MDM2 also includes a hydrophobic centre, a conserved 
arginine residue (R479), and an acidic group. The E2-binding site within those E3 proteins 
has distinct contacts around the major E2-binding site and those additional contacts may 
determine the specificity of the E2-E3 interaction. Overall, the target site of the UbcH5b-

















































Figure 6-15: Conserved features of the E2-binding groove on E3 proteins. (A) Schematic 
representation showing the known UbcH5b-binding residues in cIAP2 (yellow sticks) and the 
equivalent residues in MDM2 (in cyan residues) orientate to the E2 surface (in green). (B) Close-
up view of the corresponding E2-binding residues of MDM2 to cIAP2. (C) There is a shallow 
groove on each E3 protein: a hydrophobic centre (white), acidic region (red), and a conserved 
Arg residue (blue). cIPA2 and MDM2 are shown coloured in light yellow and light orange 
surface representation, respectively. Residues of E3 ligases involved in the E2-binding 
interaction are shown as sticks.  
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6.5.2 Virtual screening results of the UbcH5a-binding site of MDM2 
Because our aim is to find small molecules to bind to the E2-binding site of MDM2, an 
appropriate template for our virtual screening system will be residues of the MDM2-binding 
partner, UbcH5a. Although our model was the MDM2/UbcH5b complex, UbcH5a has high 
sequence identity with UbcH5b and both are MDM2 cognate E2 proteins. Therefore, 
residues of UbcH5b involved in the E2-E3 interaction are suitable candidates to define a 
template for drug design. To define which residues in UbcH5b are most appropriate to act as 
our template, the cIAP2-UbcH5b structure and data from previous work carried out in the 
group were used as references. Until now, there is only one structure of the UbcH5b-RING 
type E3 complex, the UbcH5b-cIAP2 (Mace et al., 2008). Residues of UbcH5b, Met1, Lys4, 
Arg5, Lys8, Glu9, Asp12, Arg15, Pro61, Phe62, Gln92, Ser94, Pro95, Ala96 and Thr98 
confer cIAP2-binding (Mace et al., 2008). The UbcH5c-BRCA1 interaction studied by NMR 
and chemical shift analysis indicated that Arg5, Lys8 and Ala96 in UbcH5c are required for 
binding of BRCA1 (Christensen et al., 2007). Based on previous studies, we decided to 
utilise the same residues of UbcH5b, which interact with cIAP2, as our template candidates. 
Presumably, those equivalent residues are likely to be involved in interaction with MDM2. 
In Figure 6-16, we presented the interface of MDM2-UbcH5b, and also showed the putative 
MDM2-binding residues in UbcH5b. Most candidate residues were in the groove 
(hydrophobic patch) and some were outside of the hydrophobic groove and those residues 








Figure 6-16: Residues potentially involved in the interaction between MDM2 and UbcH5b. 
(A) Schematic representation shows the residues responsible for the UbcH5b-MDM2 interactions. 
UbcH5b and MDM2 are shown as green and cyan surface, respectively. Residues of MDM2 and 
UbcH5b in the interaction surface are shown in sticks and coloured white and yellow. (B) A flow 
chart of the virtual screening strategy used to find UbcH5b-mimetic small molecules, U-series 
compounds (in magenta), in the UbcH5b-binding site of MDM2. Atom types are also depicted 
(C=white or yellow or magenta, O=red, and N=blue). 
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Residues in E2 proteins mostly interact with residues in the groove of E3 proteins. For 
example, in the complex of cCbl-UbcH7, Phe62, Phe62, Pro97 and Ala98 of UbcH7 interact 
with most residues in the cCbl groove regions, Ile383, Cys404, Ser407, Trp408, Pro417, Phe 
418 and Arg420 (Zheng et al., 2000). In the Ubc13-CHIP U box, there is a similar binding 
pattern, Arg7, Lys10, Met64, Ser96, Pro97, and Ala99 of Ubc13 interact with a hydrophobic 
groove in CHIP, such as Phe238, Ile236 and Pro270 (Zhang et al., 2005). This data 
suggested that residues in UbcH5b which are around the E2-binding area of MDM2 may 
provide the major binding interactions with MDM2. The MDM2-binding residues of interest 
in UbcH5b were non-continuous; therefore an alternative approach was used to determine 
the template. The template for UFSRAT shown in dots in Figure 6-16B was generated based 
on the distributions of the atoms of Met1, Pro61, Phe62, Ser94, Pro95 and Ala96 of UbcH5b. 
The final template was located in the centre of the hydrophobic groove. There are some 
charged MDM2 residues around that might provide some additional binding. Since the target 
site, the UbcH5a-binding site of MDM2, and the template for UFSRAT simulation have 
been determined, virtual screening could be used to search for UbcH5b-mimetic antagonists 
of MDM2.  
 
1000 small molecules from the EDULISS database were chosen following a UFSRAT run 
based on their UbcH5b-mimetic conformations (step 4, Figure 6-16B). Next, Autodock 
simulations were used to predict the putative binding mode, energy, and affinities. Following 
this second round of screening, 200 compounds were selected and ranked by their putative 
binding affinities to MDM2 (step 5, Figure 6-16B). Estimated binding affinities of those 
compounds ranged from 117.8 nM to 94.5 μM, with binding energies of from -9.5 kcal/mol 
to -5.5 kcal/mol. The mimetic compounds with the optimum binding mode to the target 
(Figure 6-17), good solubility and low toxicity were selected. The top hit molecules were 
manually inspected based on the putative binding model, binding affinity and the solubility, 
nine were selected and purchased from Spec. Co. (Table 6-2) Effects of those UbcH5b-
mimetic antagonists, or U-series compounds were evaluated by in vitro ubiquitination 
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Figure 6-17: The estimated binding modes of small molecules bound to the UbcH5a-binding 
site of MDM2 were shown. Small molecules (U-series, U01 ~ U09) are shown in magenta sticks 
and the template candidate for virtual screening (yellow sticks). MDM2 is coloured in cyan. The 
residues located around the UbcH5a-binding site of MDM2 are coloured based on the atomic 
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Table 6-2: Characteristics of the U-series compounds. The chemical structures of these U-
series compounds are shown in the table. All of those compounds are purchased from Spec Co. 
Molecular weight (M.W.), LogP are also shown. Estimated △G and estimated binding affinity of 








U01 -9.5 111.8 nM 4.9 487.0
U02 -8.4 674.1 nM 4.3 523.6
U03 -7.0 7.1 μM 2.9 508.0
U04 -7.0 7.0 μM 4.2 523.5
U05 -6.7 13.2 μM 3.9 598.7
U06 -6.5 18.3 μM 4.1 507.6
U07 -6.0 39.6 μM 4.4 415.5
U08* -5.9 52.3 μM 3.7 383.4
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6.5.3  Evaluation of UbcH5a-mimetics on MDM2 E3 activity 
Effects of the UbcH5b mimetic antagonists (U-series compounds) on MDM2 E3 ligase 
activity were evaluated by an in vitro ubiquitination assay. In this work, two MDM2 proteins 
were used: FLMDM2 and MDM2RING. Different effects were seen with these compounds 
on FLMDM2 and MDM2RING (Figure 6-18). In these experiments, 500 μM compound was 
incubated with FLMDM2 or MDM2RING for 10 minutes, and the other components 
required for in vitro ubiquitination were added (ubiquitin, E1, UbcH5a, p53). The reaction 
time for in vitro ubiquitination was 10 minutes and then 2X loading dye was added to stop 
the reaction. The ubiquitination levels of p53 were detected by an anti-p53 antibody, D01, as 
discussed earlier in Chapter 3. Initially, our results showed that 500 μM U05 activated 
FLMDM2 E3 ligase activity significantly, for example, more ubiquitin was attached to p53, 
(Figure 6-18A, work carried out by Dr. Susanne Patterson). U02, U4, and U06 slightly 
inhibited FLMDM2 E3 activity. However, subsequent experiments could not replicate this 
result. In subsequent experiments, U05 had lost its activity, and no strong ladders of 
ubiquitinated-p53 were observed on the gel (Figure 6-17B). It is likely that U05 is unstable 
or the activity was caused by an impurity in the initial batch of compound. 





(Courtesy of Dr. Susanne Patterson)  




Figure 6-18: Evaluation of U-series compounds to FLMDM2 E3 activity. (A) 500 μM U-
series compounds are tested in this work. U05 is found to activate FLMDM2 E3 activity. This 
experiment was carried out by Dr. Susanne Patterson. (B) U05 lost its activation effect MDM2 
E3 activity after several weeks.   
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  The potential  interaction between U05 and MDM2RING 
On the basis of the model of the U05-MDM2 complex, the distances of those MDM2 
residues Val439, Ile440, Gln442, Leu468, Arg471, Lys473, Pro474, Cys475, Pro476 and 
Arg479 were within 4Å of the U05 molecule. Those MDM2 residues were consistent with 
our proposed E2-binding residues. Especially, the atoms of U05 may form H-bonds with the 
Ile440 carboxyl-amide or carboxyl-oxygen (Figure 6-19A). It is consistent with the report 
that the equivalent residue in cIAP2 is Val558 which forms an H-bond with Arg5 of UbcH5b 
(Mace et al., 2008), suggesting that the interaction of U05 and MDM2 is likely to form an H-
bond. To test this assumption, more U05-mimetics (Figure 6-19B) were tested. 
 
The chemical name of U05 is ethyl 5-(1, 3-benzodioxol-5-yl)-2-{[5-(4-methyl-1-
piperazinyl)-2-furyl] ethylene}-3-oxo-7-phenyl-2, 3-dihydro-5H-[1, 3] diazole [3, 2-a] 
pyramid- dine-6-carboxylate. Experiments in the Ball group tested the effects of U05 
mimetic compounds on MDM2 (Figure 6-19), and the U05 mimetic compounds (HP-series 
compounds) were solubilised in DMSO, and immediately tested by in vitro ubiquitination 
experiments to determine any effects on FLMDM2. These U05-like compounds activated 
FLMDM2 E3 ligase activity (Figure 6-18B), behaving in a similar fashion to U05. However, 
the activating ability diminished in subsequent repeats of the experiments. New U05 
compound was purchased, and tested. The result is similar to previous experiments, 
revealing that U05 or U05-mimetics lose their activation ability possibly due to the 
instability of U05 and U05-mimetic compounds. Reasons behind the activation of MDM2 E3 
activity by U05 or U05-mimetic compounds are still unclear. The MDM2 E3 activity may be 
activated by one specific chemical that might be essential for the synthesis of these group 
compounds. Another possible explanation is that these compounds might activate MDM2 E3 
activity by an allosteric mechanism. For example, U05 attaches to FLMDM2 inducing a 
conformational change in FLMDM2, accelerating the rate of transfer of ubiquitin from 
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Figure 6-19: Evaluation of U05 and U05 mimetic compounds (HP series) on FLMDM2 E3 
activity. (A) Schematic representation shows a putative interaction between U05 and MDM2 
Ile440. Distances between these putative H-bonds are highlighted in red dashed lines. The 
MDM2 is shown as a surface in cyan, U05 was magenta stick. (B) The effects of U05 and U05 
mimetic compounds are tested on FLMDM2 E3 activity. (C) Chemical structures of U05 and 
U05 mimetic compounds. The core structure within all compounds was highlighted (in red 
dashed circle) on U05. 
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 U04 and U06 activate MDM2RING E3 ligase activity  
Different effects of UbcH5b-mimietics on MDM2RING E3 ligase activities were observed. 
500 μM U04 and U06 activated MDM2RING E3 activity significantly and several 
ubiquitinated p53 ladders were observed (Figure 6-20A). U04 and U06 produce different 
effects on FLMDM2 (inhibition) and MDM2RING (activation). Other compounds, such as 
U01, U02, U03, U05, U07 and U08 slightly inhibited MDM2RING E3 activity. The 
chemical formula of U04 is 5-[4-(benzyloxy)-phenyl]-4-(2,3-dihydro-1,4-benzodioxin-6-
ylcarbonyl) -1- (2-furylmethyl)-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one, and the chemical 
formula of U06 is 4-(2,3-dihydro-1,4- benzodioxin- 6- ylcarbonyl)-3-hydroxy-5-[4- 
(pentyloxy)phenyl]-1- (tetra-hydro-2- furanyl-methyl)-1,5-dihydro-2H-pyrrol-2. Surprisingly, 
both of them have similar structures but their estimated binding modes were dissimilar 
(Figure 6-20B). MDM2 residues within 4Å of U04 were Val439, I440, Cys441, Cys464, 
Lys467, Arg471 and Lys473, whereas within U06 they were Val439, Ile440, Gln442, 
Cys464, Lys467, Leu468, Arg471, Lys473, Pro474 and P476. A close examination showed 
that of those two putative complexes there were two possible H-bonds in the U04 and 
MDM2 Lys467 and Lys473 complex; one H-bond in U06 and MDM2 Lys473 complex 
(Figure 6-20B). There is one conserved MDM2 residue, Lys473, which might form an H-










Figure 6-20: Effects of the U-series compounds on MDM2RING. (A)  500 mM compounds 
are tested by in vitro ubiquitination to evaluate their effects on MDM2RING-mediated 
ubiquitination of p53. U04 and U06 significantly activate MDM2RING E3 ligase activity. (B) 
Putative interactions in the U04-MDM2 complex and the U06-MDM2 complex. The H-bonds are 
highlighted in red dash and the distances are shown. Chemical structures of U04 and U06 are also 
shown.    
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 A potential mechanism for  U04 and U06-mediated activation of MDM2RING E3 
activity 
Because Lys473 is located in the α-β3 loop, U04/U06 might interact with Lys473 and the 
formation of the new H-bond might contribute to the conformational change seen in the C-
terminus, β3, moving it from the buried C8-binding site to the surface of UbcH5a. Moreover, 
previous thermal denaturation experiments (section 5.6.1) had shown that peptide 9 
(MDMX-analog peptide), destabilizes binding of UbcH5a. A number of reports suggest that 
MDM2RING C-terminal domains are responsible for MDM2-mediated ubiquitination. 
Taken together, we propose a model (Figure 6-21) that UbcH5a or UbcH5a-mimetic 
compounds (U04 and U06) interact with MDM2RING, affecting the conformation of 
MDM2RING to expose the C-terminal residues (C-tail) removing it from the C8-binding site 
and allowing it to interact with UbcH5a. This new conformation allows an increase in the 
rate of transfer of ubiquitins from UbcH5a to the MDM2 substrate, p53. To determine the 
binding mode of U04 and U06 with MDM2 RING, we also carried out crystallisation trials. 


















I. U04/U06 interacts with 
MDM2RING, inducing the 
conformational change in the 
MDM2 C-tail to be re-
oriented to the surface 
II. Exposed MDM2 C-tail 
accelerate the release rate of 




















Figure 6-21: Model for UbcH5a-mimetic, U04/U06, mediated activation of MDM2 E3 
activity. Our data suggest that UbcH5a or UbcH5a mimetic binds to the E2-binding site of 
MDM2RING domain may induce the conformational change in the MDM2 C-tail from the C8-
binding site to the surface, interacting with UbcH5a (cis-regulation, upper panel; trans-regulation, 
lower panel) and accelerating the poly-ubiquitination of p53. 
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 Different effects of U04 and U06 on FLMDM2 and MDM2RING E3 activity 
Results show that U04 and U06 contributed differently to the E3 activity of FLMDM2 
(Figure 6-19) and MDM2RING (Figure 6-20). We assumed that a remote domain in 
FLMDM2 is also involved in controlling MDM2 E3 ligase activity. Several reports have 
mentioned a possible mechanism suggesting remote domains in a protein can regulate the E3 
ligase activity (such as IAP protein or CHIP proteins) (Mace et al., 2008; Zhang et al., 2005). 
IAP antagonist has different levels of autoubiquitination when compared to BIR3-CARD-
RING protein and RING alone, showing that those differences may be due to IAP antagonist 
binding to BIR domains resulting in conformational change affecting its E3 activity (Mace et 
al., 2008). Moreover, CHIP U-box forms a symmetrical complex with Ubc13, but in the 
absence of Ubc13, the TPR domain of CHIP occludes the E2-binding site and becomes an 
asymmetrical dimer (Zhang et al., 2005). 
 
Therefore, it is likely that our FLMDM2 may also occlude the UbcH5a-binding site. UbcH5a 
is a larger protein and it is possible that UbcH5a binds to another domain within FLMDM2 
to induce the conformational change, exposing the E2-binding site. However, small 
molecules, such as U04/U06, might not provide enough interactions to induce the 
conformational change of FLMDM2. This idea is supported by the data showing that 
U04/U06 did not activate FLMDM2 E3 activity (Figure 6-19). In contrast, for the 
MDM2RING protein, U04/U06 might be able directly to interact with the MDM2RING E2-
binding site (Figure 6-21); the evidence comes from the data that U04/U06 activates MDM2 
E3 activity (Figure 6-20). Nevertheless, more work is required to investigate and fully 
understand the mechanism of the E2-E3 interaction, and clarify how remote domains in a 
protein regulate the E3 ligase activity.  
 
In summary, MDM2 E3 activators were found using our virtual screening system. For future 
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6.6 Drug target site (3): the MDM2-binding site of UbcH5a  
In this section, the aim is to search for small molecules that can bind to the MDM2-binding 
site on UbcH5a (Figure 6-22). The virtual screening strategy includes defining the target site 
in UbcH5a, generation of a candidate template using LIDAEUS, and estimation of the 
docking mode using AutoDock simulation, and finally assaying the effects of those small 




















Figure 6-22: Project aim and the virtual screening strategy: small molecules binding to the 
MDM2-binding site in UbcH5a. Small molecules (purple), M-series, presumably bound to the 
MDM2-binding site in UbcH5a (green), disrupting the interaction with MDM2 (cyan). The flow 
chart illustrates the virtual screening process.  
 
6.6.1 Define the MDM2-binding site in UbcH5b 
As in previous work, a new model of UbcH5b-MDM2 was used for virtual screening. 
UbcH5a has 99% similarity and shares almost 89 % identity with UbcH5b (Figure 6-11), 
showing that UbcH5b is an appropriate drug target model in our UbcH5a-MDM2 study. To 
design ligands that disrupt the UbcH5a-MDM2 interaction, the structure of UbcH5b-cIAP2 
and other relevant data were used as references to define residues important in the interaction 
(Mace et al., 2008; Zhange et al., 2005). Structures of the UbcH5b-cIAP2 complex and our 
new model of the UbcH5b-MDM2 complex showed that the N-terminal region of UbcH5b 
from each complex is involved in E3-binding (Figure 6-23). Previous structural studies 
showed that the cIAP2-binding residues in UbcH5a were located in α1 helix (Lys4, Arg5, 
Lys8, Glu9), in the loop of β3-β4 (residues Pro61, and Phe62), and the loop between the 310 
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helix and α2 helix (Gln92, Ser94, Pro95, Ala96, and Thr98) (Figure 6-23A) (Mace et al., 
2008). Our initial concept was to define the MDM2-binding site in UbcH5b to enable our 
virtual screening to search for potential ligands. However, on the basis of the crystal 
structure of UbcH5b-cIAP2 or UbcH5b-MDM2, the residues responsible for interaction with 
cIAP2 in the UbcH5b surface are extensive and shallow (Figure 6-23B), revealing that this 
initial target site was not ideal for designing inhibitors of protein-ligand interactions. 
Therefore, we decided to search for another potential target site in UbcH5b. Detailed 
analysis of the crystal structure of UbcH5b-MDM2 showed there was  cavity near the 
MDM2-binding surface (Figure 6-23B), which was surrounded by residues Arg5, Glu9, 
Asp12, Leu13, Thr98, Pro95, Ala96, Ile99 and Ser100 (Figure 6-23C). Numerous reports in 
literature have discussed the significance of cavities in proteins, providing a critical binding 
site for protein-protein interactions or protein-ligand interactions (Vassilev et al., 2004). One 
promising example is the cavity in the MDM2 N-terminal hydrophobic domain that interacts 












Figure 6-23: Schematic representations of residues involved in the UbcH5b-cIAP2 or 
UbcH5b-MDM2 interactions. (A) Residues of UbcH5b (white), cIAP2 (yellow) or MDM2 
(cyan) in the E2-E3 interactions are shown in sticks. Cys85 in UbcH5b, an active site for the 
attachment of ubiquitin is depicted in orange spheres. (B) Upper panel shows the UbcH5b-
MDM2 interactions and the interface in UbcH5a were highlighted in white surface representation. 
Red dashed lines highlight our new target site, which contains a cavity. Residues around the 
cavity are labelled and the site points for the template candidate used for screening generated 
using LIDAEUS, based on the chemical features of key residues in the new target site. Different 
colours represent distinct properties: red dots - hydrogen acceptor, blue dots - hydrogen donor 
and white dots - hydrophobic atoms. 
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6.6.2 Virtual screening data: the E2-binding site of UbcH5a 
After the new target site in UbcH5b was selected and characterised, the next step was to set 
up an initial screening run. The program, LIDAEUS was used to create putative site points as 
the template. As shown in Figure 6-23C, characteristics of those site points were assigned as 
hydrogen acceptors (red dots) or donors (blue dots), respectively, based on the surrounding 
residues of the target cavity. In our model, hydrogen donor (blue) site points were created to 
interact with the oxygen atoms of Glu9, Asp12, on the right-hand site in new target site and 
Ala96, Leu97, Thr98 and Ile99 resides in left-hand site. Hydrogen acceptor (red) site points 
were created for the interaction with UbcH5b residue Arg5. Some hydrophobic molecules 
(shown in white dots) were assigned to provide additional interaction abilities. Presumably, 
those site points might make electrostatic or hydrophobic interactions with residues in 
UbcH5b. 
 
Using a combination of EDULISS and LIDAEUS, 1000 small molecules, possessing similar 
electrostatic chemical properties as the template (dots, Figure 6-23C) were selected from the 
5 million compounds in the database. These, 1,000 compounds were subjected to a second 
round of screening by Autodock (Figure 6-24). Following AutoDock, 200 potential small 
molecules were ranked by binding affinity. Using a combination of the results of the 
estimated binding affinity, binding mode, toxicity and solubility to rank molecules, 10 
compounds, the M-series, were purchased to test effects on the target, UbcH5a. Chemical 
structures of these 10 small molecules (all from Spec. Co.) and their binding energy with the 
target were shown in Table 6-3. Estimated △G values of those compounds were -8.3 ~ -7.2 
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Figure 6-24: Modelled structures of 10 selected ligands with the target site of UbcH5b. The 
models are built on the basis of AutoDock simulation and structures are rendered by PyMol. 
UbcH5b is presented in green surface form. 10 selected ligands (M01 ~ M10) are shown in green 
sticks. The dots generated using LIDAEUS (As template reference) shown here represent 
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Table 6-3: Characteristics of the M-series compounds. Chemical structures of those M-
series compounds are shown in the table. All of those compounds are purchased from Spec Co. 
Molecular weight (M.W.), and LogP are also shown. Estimated △G and estimated binding 












M01* -8.3 900 nM 2.5 346.4 5 2
M02 -7.6 2.9 μM 2.7 412.4 7 1
M03 -7.5 4.0 μM 3.2 508.1 5 1
M04 -7.4 3.5 μM 3.2 372.5 3 1
M05 -7.4 4.1 μM 3.6 447.6 3 0
M06 -7.3 4.8 μM 2.6 336.4 2 1
M07 -7.2 5.0 μM 3.5 399.5 3 2
M08* -8.3 900 nM 2.3 304.4 5 2
M09* -7.3 4.7 μM 3.3 429.4 5 1
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6.6.3 in vitro ubiquitination studies: effects of the M-series compounds on 
the UbcH5a-cognate E3 interaction 
UbcH5b or UbcH5a interact with E3 ligases, such as MDM2, CHIP or cIAP2, and interfere 
with E3-mediated ubiquitination. These M-series compounds (M01~M10) could potentially 
bind to the E3-binding interface of UbcH5b and interrupt the interaction between UbcH5a 
and E3 ligase, abolishing E3-mediated ubiquitination. Previous reports have shown that each 
E2 protein can interact with many E3 ligases. The E3-binding sites in E2 proteins are quite 
similar, but there should be other determinants for specific E3 recognition. Therefore, in 
these experiments, two E3 ligases, CHIP (U-type E3) and MDM2 (RING-type) were used to 
verify the specificities of those M-series compounds to distinct E3 proteins. CHIP is a U-
type E3 ligase and MDM2 is a RING-type E3 ligase. Compounds were tested at a 
concentration of 500 mM using MDM2-mediated ubiquitination or CHIP-mediated 
ubiquitination. Results showed that a number of compounds inhibited MDM2-mediated 
ubiquitination, including M01, M02, M08, and especially M09 and M10 (Figure 6-25A). 
Another experiment with CHIP-mediated ubiquitination showed that M01 produced some 












Figure 6-25: The inhibitory abilities of 10 compounds (M-series) are tested using in vitro 
ubiquitination with two types of E3 ligases. (A) RING type E3 ligase, MDM2-mediated 
ubiquitination and (B) U type E3 ligase, CHIP- mediated ubiquitination. 
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 TDA studies: M09 interacts with UbcH5a 
[The thermal denaturation assay (TDA) was described in greater detail in Chapter 3] 
The TDA results showed that M09 induced a significant positive shift in the Tm of UbcH5a, 
from 58℃ to 79℃ (red line, Figure 6-26). After addition of 25 μM M09 to 2.5 μM UbcH5a, 
there were two peaks in the Tm panel: one Tm peak was similar to that of apo-UbcH5a at 
58℃, with a second peak at 79℃ (Figure 6-26A). The 2.5 μM UbcH5a-250 μM M09 
complex produced one peak at 58℃, following with the second peak at 82℃ (Figure 6-26B). 
This large effect on Tm provides evidence that M09 binds UbcH5a.  
 

















































































2.5μM UbcH5a+ 25μM M09
 
 
Figure 6-26: The unfolding transition curves of UbcH5a with M09. Apo-UbcH5a, M08-
UbcH5a and M09-UbcH5a are, respectively, in red, blue and green lines. (A) with 25 μM 
compound, and (B) with 250 μM compound. 
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 Potential interactions between M09 and UbcH5a  
Gels showed that M09 could inhibit both CHIP- and MDM2-mediated ubiquitination (Figure 6-
25). Moreover, based on previous thermal denaturation assay data (Figure 6-26), M09 seemed to 
affect the stability of UbcH5a. The putative binding mode of the M09-UbcH5b complex showed 
that UbcH5b residues, Met01, Lys04, Arg05, Lys8, Glu09, Asn12, Leu13, Pro61, Thr98, Ser100 
and Lys101 were  located within 4Å distance around the M09 molecule (Figure 6-27), and six 
putative H-bonds were formed to UbcH5b residues Arg5, Leu13, Thr98 and Ser100. Greater 
understanding of the interaction between M09 and UbcH5a is required to improve specificity 
against different E2-E3 interactions. Crystallisation and HSQC NMR experiments were carried 
out. However, M09 was insoluble at higher concentrations and precluded structural studies of the 







            
 
Figure 6-27: Potential interaction between M09 and UbcH5a. Six possible H-bonds in the 
M09-UbcH5b complex are highlighted in red dashed lines. The chemical structure of M09 is 
shown. UbcH5b is shown in green surface form. UbcH5b residues interacting with M09 are 
highlighted in white surface, M09 as magenta sticks. Atom types characterisation were coloured 
(C=white & magenta, O=red, N=blue). 
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6.7 Summary 
To summarise, using VS, several small molecules have been found to affect MDM2-
mediated ubiquitination (Figure 6-28). Several simulation programs were used for VS, 
including EDULISS (chemical database), UFSRAT (structural similarity simulation), 
LIDAEUS (rigid body docking), STP (potential binding site detection) and AutoDock (to 
predict putative binding modes). Those MDM2 E3 inhibitors/activators were chosen from 
millions of available chemicals. D03, D04, D05 inhibited FLMDM2 E3 activity and D06, 
D08, D09 and D10 inhibited MDM2RING E3 activity. U05 and U05-like seemed to activate 
FLMDM2 E3 activity, but the U05 series compound is unstable with time. Furthermore, U04 
and its analog U06 both activated MDM2RING E3 activity. M09 inhibited MDM2 and 


















































Figure 6-28: Overall MDM2 E3 antagonists/ agonists. 
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7 Summary and future work 
This thesis has described biochemical and biophysical studies of MDM2-ligand interactions, 
aiming to inhibit ubiquitination of p53 as a potential cancer therapy. Several approaches 
were taken, including structural studies, in silico screening for drug development, and 
enzymatic assays to provide insight into the following areas:  
1.  Biochemical and biophysical characterisations of MDM2RING (residues 386-491), 
MDM2RING△C (residues 386-478) and UbcH5a (Chapter 2, 3 and 4) 
2.   Studies of peptide 9, a potent MDM2 inhibitor (Chapter 5) 
3.  Small molecules inhibitors/activators of MDM2 E3 activity were selected using virtual 
screening (Chapter 6). 
 
7.1 Biochemical and biophysical characterisations of MDM2RING, 
MDM2RING△C and UbcH5a 
MDM2 is a major regulator of the level of p53 in the cell during transrepression and 
ubiquitination. A huge number of studies have investigated the interaction between the 
hydrophobic domain of MDM2 and p53, several molecules have been designed to interrupt 
the interaction and rescue p53 function. However, studies of MDM2-mediated ubiquitination 
of p53 are limited. Additionally, UbcH5a, one of MDM2 cognate E2s, is essential for 
MDM2-mediated ubiquitination. Therefore, the structure of MDM2-UbcH5a could provide 
insight into the E2-E3 mechanism and also act as a drug target for the development of small 
molecule inhibitors.   
 
7.1.1 Major findings and conclusions 
● Recombinant proteins: MDM2RING (residues 386-491), MDM2RING△C (residues 386-
478) and UbcH5a (residue 1-148) were successfully cloned, expressed and purified 
(section 2.4 & 2.5) and molecular weights were confirmed by MALDI-TOF MS (section 
2.6). 
●  in vitro ubiquitination data presented showed that MDM2RING and MDM2RING△C are 
E3 active ubiquitinating p53, suggesting a potential p53-binding motif in the N-terminal 
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fragment preceding the RING domain. A model was proposed to explain the mechanism 
of FLMDM2- and MDM2RING-mediated ubiquitination of p53 (section 3.1). 
●  MDM2RING tends to become higher order structured oligomers at high concentration 
(section 3.2). Negative staining TEM provides evidence that MDM2RING forms large 
(>660 kDa) regular donut-like structure (section 4.2) 
●  The thermal denaturation assay (TDA) was used to detect the folding state of our 
constructs.  
○ The thermal denaturation assay demonstrated that our purified MDM2RING is a metal-
binding protein. Experiments carried out in the presence of EDTA showed that EDTA 
chelates metals out of MDM2RING, inducing protein unfolding (section 3.3.1).  
    ○ The thermal denaturation assay provides evidence that ATP binds to and stabilises 
MDM2RING, improving the Tm value from 47.6 ℃ to 62 ℃ (section 3.3).  
    ○ UbcH5a is a folded protein and its Tm is 55.4℃ . Moreover, in the presence of 
MDM2RING, the Tm shifts to 53.4℃, revealing MDM2RING binds to and destabilizes 
UbcH5a (section 3.3).  
●   Circular Dichroism analysis of UbcH5a revealed that the protein is composed of 31.4% 
α-helix and 19.3% β-sheets, consistent with the published crystal structure (PDB: 2C4P) 
(section 3.4). 
●  Structural studies of the MDM2-UbcH5a complex.  
   ○ After extensive crystallisation trials, only microcrystals were found (section 4.1).  
   ○ 1D-NMR demonstrated that both MDM2RING and UbcH5a are folded following 
expression and purification (section 4.3.3).  
 ○ 15N-UbcH5a provides a properly dispersed HSQC-NMR spectrum. Also 65% assignment 
was achieved using available NMR data (NMR code: 6584) (section 4.3).  
   ○ In the presence of MDM2RING△C, residues involved in the UbcH5a-binding were 
observed (section 4.3.3). Some are located in the known E2-E3 binding interfaces, and 
others are allosterically regulated in the ubiquitin-binding backside of UbcH5a.  
 
7.1.2 Future work 
●  Further studies to optimise crystallisation are required to obtain useful crystals of the 
MDM2-UbcH5a complex. Such crystals could provide detailed information about the 
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complex for further drug development. Additional constructs are required to increase the 
likelihood of obtaining a stable E2-E3 complex providing a good target for crystallisation.   
●   It will be of interest to investigate our hypothesis that there is a new p53-binding site 
(residues 386-400) essential for FLMDM2- and MDM2RING- mediated ubiquitination. 
Further work is necessary to fully characterise the interaction of short MDM2RING 
peptides with p53. For example, in vitro ubiquitination assays can be used to test whether 
several MDM2RING deletion mutants ubiquitinate p53. MDM2RING peptides are 
synthesised and test their binding ability with p53 using the ELISA or pull-down 
methods.    
 
7.2 Studies of peptide 9, a potent MDM2 inhibitor 
Peptide 9, the twelve C-terminal amino acids of MDMX, was selected by K. Ball’s group, 
showing that it binds to FLMDM2. Similar results were obtained using pull-down methods. 
Peptide 9 was presumed to bind to the C8-binding site of MDM2RING domain. To further 
study how peptide 9 interacts with FLMDM2, and MDM2RING, a number of biophysical 
methods were used, for example, intrinsic tryptophan fluorescence, thermal denaturation 
assay, fluorescence anisotropy, and electrospray ionisation mass spectrometry. In addition, 
some reports have been described that the MDMX or MDM2 C-terminal fragments might be 
involved in E2-binding; therefore, peptide 9 was also tested with respect to its binding to 
UbcH5a.   
 
7.2.1 Major findings and conclusions 
●  in vitro ubiquitination data revealed that peptide 9 can inhibit FLMDM2 and 
MDM2RINIG (residues 386-491), suggesting that peptide 9 binds to MDM2RING 
(section 5.1). 
●  Intrinsic tryptophan data shows that peptide 9 binds to FLMDM2, resulting in an increase 
in the fluorescence intensity. Furthermore, peptide 9-binding inducing the blue shift 
demonstrates that the peptide 9-binding reoriented tryptophan into a non-polar 
environment (section 5.2).   
●  The study of buried surface area (BSA) of the complex can predict the potential binding 
ability and the numbers of H-bonds, providing additional evidence in support of successful 
protein-ligand. 
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○ BSA data suggest that the MDMX C-terminus makes additional H-bonds to 
MDM2RING compared to MDM2-terminal fragments (section 5.3 & section 6.3). The 
two C-terminal amino acids (I490 and A491) are critical for the formation of the three 
additional H-bonds. This result suggests why a peptide missing these residues lost its 
inhibitory effect on MDM2 E3 activity (section 5.3).   
● Fluorescence anisotropy data showed that peptide 9 binds to MDM2RING and 
MDM2RING△C. The Kd values of peptide 9 to MDM2RING and MDM2RING△C 
were 355.6 ±113.6 nM and 314.3 ± 157.9 nM, respectively (section 5.4).  
●  Thermal denaturation assay showed a significantly negative Tm shift for UbcH5a in the 
presence of peptide 9, from 58 ℃to 54℃ (section 5.6.1) . Furthermore, the fluorescence 
anisotropy assay showed the Kd value of the FITC-N’ labeled peptide 9 to UbcH5a is 
101.4 ±70.7 nM (section 5.6.2). The data provide evidence that peptide 9 binds to 
UbcH5a and destabilises the protein.  
● 1H-15N HSQC NMR data demonstrate that peptide 9 dissociate the UbcH5a-
MDM2RING△C complex (section 5.6.4).   
●  Electrospray ionisation mass spectrometry is used to monitor the folding state of a protein, 
and also provide information of a potential protein-ligand complex. For example, 
whether peptide 9 is complexed with MDM2RING△C or UbcH5a.  
○ ESI-MS data showed that monomeric-MDM2RING△C was predominant, which also 
reflects that the interaction of dimeric MDM2RING△C (observed in the SEC method) 
is likely hydrophobic and not electrostatic (section 5.5).  
○  In the presence of peptide 9, there were new peaks generated, PPL6, PPL7 and PPL8. 
The calculated molecular weight following deconvolution of the data suggested that 
the complex consists of peptide 9 interacting with two MDM2RING△C molecules 
(section 5.5). 
○ A characteristic bell shaped charge state curve was observed in the ESI-MS profile of 
UbcH5a, providing evidence that UbcH5a is a folded protein (section 5.6). 
○  In the presence of peptide 9, many peaks were generated in the ESI-MS profile of 
UbcH5a. According to the calculated molecular weight, the new species was the 
UbcH5a-peptide 9 complex, providing evidence that there was interaction between 
UbcH5a and peptide 9 (section 5.6.3).    
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7.2.3 Future work 
● On the basis of the ESI-MS profile, we proposed a hypothesis that peptide 9 promotes the 
dimerisation of MDM2RING△C. To further confirm the hypothesis, ITC or SPR 
experiments could provide information on the binding ratio of peptide 9 to 
MDM2RING△C. However, ITC requires large amounts of both peptides and proteins, 
and as peptide 9 tends to be insoluble at a high concentration, SPR (Surface Plasma 
Resonance) would be a more appropriate technique.  
● Thermal denaturation, fluorescence anisotropy and ESI-MS data demonstrated that peptide 
9 interacts with UbcH5a. To further detect how peptide 9 effects the conformational 
change of UbcH5a, intrinsic tryptophan fluorescence will provide insight into the 
mechanism of peptide 9 induced conformational change of UbcH5a.  
● Several biophysical experiments provide evidence that peptide 9 binds to MDM2RING, 
MDM2RING△C and UbcH5a. However, NMR data did not show significant changes on 
chemical shifts of the cross-peaks. Instead, dramatic reductions in signal intensity, and 
some visible aggregates were observed. Therefore, to study the peptide 9-binding site 
within MDM2RING or UbcH5a, mutagenesis experiments combined with other 
biophysical experiments could provide additional information to identify residues key to 
the interaction. 
 
7.3 Small molecules against MDM2 E3 activity were selected using 
virtual screening 
Transrepression and ubiquitination are two major MDM2-mediated regulation mechanisms 
of the p53 level in cells. Several small molecules have been found to inhibit transrepression, 
for example, Nutlin, through inhibition of the interaction between p53 and the MDM2 
hydrophobic domain. However, only a few small molecules have been found that are 
inhibitory to MDM2 E3 ligase activity. Since MDM2 RING domain possesses an E3 ligase 
for ubiquitination and it has been widely noted that dimerisation of MDM2 and the E2-E3 
interaction are essential for ubiquitination. Therefore, in the present work, small molecules 
inhibitors were selected using virtual screening approaches (consisting of EDULISS, 
UFSRAT, LIDAEUS and AutoDock programs) with the aim of disrupting these interactions.  
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7.3.1 Project aims 
●  To find small molecules that bind to the C8-binding site of MDM2RING-MDM2RING 
●  To find small molecules that bind to the E2-binding site of MDM2RING 
●  To find small molecules that bind to the E3-binding site of UbcH5a 
 
7.3.2 Major findings and conclusions 
●  To screen for small molecules-binding to the C8-binding site, the eight C-terminal amino 
acids from MDMX were used as a drug template. After virtual screening, using rounds of 
EDULISS, LIDAEUS and AutoDock, 10 compounds (D-series) were purchased and 
tested their effectiveness on FLMDM2- and MDM2RING-mediated ubiquitination. 
○  D03, D04 and D05 completely inhibit FLMDM2 but not MDM2RING, whilst D07, 
D08, D09 and D10 inhibit MDM2RING but not FLMDM2. The data suggested that 
those D-series compounds contributed to conformational changes in FLMDM2 and 
MDM2RING; therefore resulting in distinct inhibitory effects (section 6.3). 
○  D07, D08, D09 and D10 block the MDM2RING-mediated poly-ubiquitination on p53. 
Only monoubiquitinated-p53 was observed (section 6.3), suggesting that those 
compounds might induce MDM2RING to become monomeric. 
●  On the basis of the known crystal structure of the cIAP2-UbcH5a complex, a new model 
of the MDM2RING-UbcH5a complex was built, showing that no clash between these 
two proteins and that the modelled complex was a reliable drug target (section 6.4).  
●  U-series compounds were designed using the EDULISS, LIDAEUS and AutoDock 
methods to bind to the E2-binding site of MDM2RING.  
○  U05 was found to activate FLMDM2-mediated ubiquitination of p53; however, it lost 
activity over time. Similar results were found with U05-mimetics also being 
activatory to FLMDM2-mediated ubiquitination. This activity was also lost over time. 
This suggested that U05 and U05-mimetics did have effects on FLMDM2 E3 activity, 
but over time the molecules became unstable (section 6.5). 
○  U04 and U06 activated MDM2RING-mediated ubiquitination of p53, but had no 
effects on FLMDM E3 activity. Those differences could be due to the distinct 
conformational changes on FLMDM2 and MDM2RING (section 6.5). 
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○  Taken together with findings that UbcH5a interacts with peptide 9, we propose a 
model that U04/U06 binds to the E2-binding site of MDM2 and induces the exposure 
of the C-terminus of MDM2 (peptide 9 analog) onto the surface of MDM2RING, 
facilitating the UbcH5a-MDM2 C-terminus interaction. Moreover, the thermal 
denaturation data showed that peptide 9 destabilise UbcH5a, suggesting that the C-
terminus of MDM2 could induce conformational flexibility of UbcH5a releasing the 
Ub from UbcH5a to the substrate, p53 (section 6.5).   
●  Virtual screening was used to design compounds (M-series) to bind to the E3-binding site 
of UbcH5a. M09 was found to inhibit CHIP- and MDM2-mediated ubiquitination, 
suggesting the M09 binds to UbcH5a and inhibits the E2-E3 interaction. The thermal 
denaturation data showed that M09-binding increases the stability of UbcH5a (Section 
6.6).  
 
7.3.3 Future work 
●  D03, D04 and D05 can inhibit FLMDM2-mediated ubiquitination, but the binding affinity 
is as yet unknown. Therefore, for any future work, measurement of the binding affinity is 
essential to provide information on the efficiency of those compounds. Moreover, those 
compounds are able to be used as a starting point for the second round of virtual 
screening to provide better inhibitors.   
●  We proposed a hypothesis that MDM2RING C-terminus is important to the release of 
ubiquitin from UbcH5a to the substrate, p53. It was assumed that U04/U06 induces 
conformational changes in the MDM2 C-terminus, resulting in greater surface exposure 
to facilitate the MDM2 C-terminus to interact with UbcH5a, enhancing ubiquitin loading 
onto the substrate. To further confirm the hypothesis, MDM2RING△C should be tested. 
Presumably, there is no difference in MDM2RING△C-mediated ubiquitination of p53 in 
the presence or absence of U04/U06. 
●  M09 can inhibit CHIP- and MDM2-mediated ubiquitination with low-specificity and low 
levels of  inhibition to both E3 activities. Using M09 as a starting point for second round 
of virtual screening should enable an increase in specificity.  
● All those small molecules have been tested in crystallisation trials with MDM2RING or 
UbcH5a. However, no crystals suitable for X-ray diffraction studies were grown. The 
crystal structure of the protein-ligand complex would provide detailed information about 
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the binding pattern and would increase the success rate of small molecule selection using 
virtual screening. Therefore, new constructs could be made to repeat these trials.  
● Lead optimisation of selected small molecules (inhibitors/activators) is required using 
similarity or quantitative structure-activity relationship (QSAR) to increase their 
effectiveness against MDM2 E3 ligase activity. The further aim of the project is to solve 
the 3-dimensional structure of the newly discovered MDM2-UbcH5a complex, complexes 
of MDM2 with small molecules, and complexes of UbcH5a with small molecules, in order 
to provide detail information on the interaction between the druggable target and the small 
molecule (inhibitors/activators).  
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